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SUMMARY 
 
     Gastric and oesophageal cancers were responsible for more than one million deaths in 2002. 
Although global incidence of gastric cancer is decreasing, this malignancy is still the fourth most 
common cause of cancer worldwide. The incidence of oesophageal adenocarcinoma is rising rapidly, 
three-fold in the last two decades. The incidence of adenocarcinoma of gastric cardia is stable.   
          In the pathogenesis of both gastric and oesophageal adenocarcinomas, the state of the gastric 
mucosa and its secretory function plays a central role. Non-cardia adenocarcinoma develops in 
subjects with H.pylori associated atrophic gastritis and hypochlorhydria. Little is known about the gastric 
phenotype in patients with adenocarcinoma of the cardia and gastroesophageal junction.   
     Another important but poorly understood risk factor for upper GI adenocarcinoma is male gender. 
     In the first study we aimed to investigate the association between the pattern of H.pylori gastritis 
and gastric secretory function in 255 H.pylori-infected patients with dyspepsia showing normal 
endoscopy. Our findings showed that maximal acid output correlates inversely with severity of corpus 
gastritis, corpus atrophy, and positively related to male gender and serum pepsinogen I. 
    In the second study we compared cancers at the cardia and non-cardia subsites with respect to 
pre-morbid gastric mucosal atrophy and acid secretion.   In a nested case-control study comprising 
101,601 men and women enrolled in the Norwegian JANUS cohort, 230 cases of gastric cancer were 
identified. 173 cases including 144 non-cardia and 44 cardia cancer were enrolled to study. Three 
controls were matched to each case. Serum pepsinogen I, pepsinogen II,  anti-H.pylori IgG antibody 
and gastrin were measured using serums which had been collected a median of 11.9 years before 
cancer diagnosis radioimmunoassay method.     
          Non-cardia cancer was positively associated with H.pylori and gastric atrophy. The diffuse and 
intestinal histological subtypes of non-cardia cancer were of similar proportions and both showed a 
positive association with H.pylori and atrophy. Cardia cancer was negatively associated with H.pylori, 
but H.pylori positive cardia cancer showed a positive association with gastric atrophy. The predominant 
histological subtype of cardia cancer was intestinal and it was not associated with gastric atrophy   XV
compared to the diffuse subtype. Cardia cancer in atrophic patients had an intestinal: diffuse ratio 
similar to non-cardia cancer, whereas cardia cancers in persons without atrophy were predominantly 
intestinal.  
     These findings indicate two aetiologies of cardia cancer, one associated with H.pylori  atrophic 
gastritis, resembling non-cardia cancer, and the other associated with non-atrophic gastric mucosa, 
resembling oesophageal adenocarcinoma.  Serological markers of gastric atrophy may provide the key 
to determining gastric versus oesophageal origin of cardia cancer. 
     In the third study we extended our investigation of the aetiology of cardia cancer by examining the 
association of both serological evidences of gastric atrophy and gastroesophageal reflux disease 
(GORD) symptoms with adenocarcinoma of the oesophagus, cardia and non-cardia regions of the 
stomach. This has been performed for the different histological subtypes of the cancer. We have also 
included H.pylori status and smoking history which are other well established risk factors for upper GI 
cancer.  This has been undertaken in a population in Northwest Iran with a high incidence of upper 
gastrointestinal cancer
.  Serum pepsinogen I/II was used as a marker of atrophic gastritis and 
categorised to five quintiles. History of GORD symptoms, smoking and H.pylori infection was 
incorporated in logistic regression analysis. Lauren classification was used to subtype gastric and 
oesophageal adenocarcinoma. 
     Non-cardia cancer was associated with atrophic gastritis but not with GORD symptoms; 55% of 
these cancers were intestinal subtype. Oesophageal adenocarcinoma was associated with GORD 
symptoms, but not with atrophic gastritis; 84% were intestinal subtype.  Cardia cancer was positively 
associated with both severe gastric atrophy and with frequent GORD symptoms though the latter was 
only apparent in the non-atrophic subgroup and in the intestinal subtype. The association of cardia 
cancer with atrophy was stronger for the diffuse versus intestinal subtype and this was the converse of 
the association observed with non-cardia cancer.  
     These findings indicate two distinct aetiologies of cardia cancer, one arising from severe atrophic 
gastritis and being of intestinal or diffuse subtype similar to non-cardia cancer, and one related to 
GORD and intestinal in subtype, similar to oesophageal adenocarcinoma.  Gastric atrophy, GORD   XVI
symptoms and histological subtype may distinguish between gastric versus oesophageal origin of 
cardia cancer. 
     In the fourth study we investigated the relationship between gender and upper gastrointestinal 
adenocarcinoma.  Male gender is a well-established risk factor for oesophageal adenocarcinoma. Male 
predominance of gastric cancer is related to the histological subtype of the tumour being more marked 
in the intestinal versus diffuse histological subtype. In addition, global data suggests that the male 
predominance of upper gastrointestinal cancer is related to the anatomical location, being higher for 
proximal and lower for distal tumours. However, the proportion of the intestinal histological subtype 
differs according to anatomical site and it is unclear whether it is the anatomical site or the histological 
subtype which is associated with the gender phenomenon.  We have conducted a population-based 
study to investigate this.   
     The study was based upon 3270 gastric and oesophageal cancers recorded in West of Scotland 
Cancer Registry between 1998 and 2002.  The Lauren subtype of adenocarcinoma was determined by 
reviewing 1204 reports and 3241 slides in a sample of 812 cases. Logistic regression models were 
used to estimate relationship between male predominance and histological subtype, tumour location 
and age. 
     We found that the crude incidence rate of intestinal subtype was higher in males (23.86/ 10
5/ year) 
versus females (9.00/ 10
5/ year), giving M/F of 2.65.  M/F ratio of intestinal subtype cancer was 3.41 at 
age <50, reached a peak of 7.86 at age 50-59, and then showed a progressive decrease throughout the 
life. In contrast, the incidence rate of diffuse subtype adenocarcinoma was similar in both sexes (5.58 
vs. 5.20 /10
5/ year) yielding M/F of 1.07. Multivariate analyses including histological subtype, tumour 
location and age indicated that the male predominance was related to the histological type rather than 
anatomical location. Intestinal type tumour showed similar male predominance of incidence irrespective 
of its anatomical location (OR, 95% CI: 2.6, 1.78 – 3.9).  Further analysis of the age-specific incidence 
curves indicated that the male predominance of intestinal subtype was due to a 17.2-year delay of 
development of this cancer in females. 
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1. 1. Structure of Oxyntic Mucosa 
 
      The largest surface area of stomach is covered by oxyntic mucosa. The luminal 
surface of the oxyntic mucosa
  contains numerous orifices that lead to tubular 
invaginations
 called foveolae or pits, at the bottom of which open one or
 more glands. The 
pit is depicted in continuity with a single gland composed of isthmus, neck, and base, but 
the pit could be in continuity with two or more glands (Fig. 1).  The pit is lined by pit cells. 
Six types of epithelial cells are distributed along the
  pit and gland regions 
(1-4). The 
principle cell type of gland is the oxyntic cell, or 
parietal cell, which secretes hydrochloric acid 
and scattered through the gland. The second 
numerous cell type is the pepsinogen-secreting 
chief cell
 that lines the base.  Two remaining of 
these cells are mucus
  secreting, namely, the 
surface mucous cell (MSC) or pit cell that
 lines 
the pit and the mucous neck cell (MNC) that 
lines the neck (Fig.1). Other cell lining the 
branched tubular glands includes D cell, which 
synthesize and secretes somatostatin 
(5). 
Enterochromaffin-like cells (ECL) are located in 
the lamina properia of the gastric gland and 
synthesize and secrete histamine 
(6). 
 
Fig 1.1: A typical gastric gland in 
oxyntic mucosa  
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1.2. Function of the Oxyntic Mucosa 
     1.2.1. Acid Secretegogaues and Inhibitors 
     Three main stimulating natural mediators are Histamine, Gastrin and Acetylcholine. 
Histamine is produced by decarboxylation of L-histidine. Most
 histamine in the body is 
stored in mast cells and basophil leukocytes,
 although some is found also in eosinophils 
and platelets. In
 the gastric mucosa, histamine occurs mainly in ECL cells and
 mast cells. 
The role of mast cell histamine probably reflects
 the pathophysiological role of mast cells 
in immune reactions.
 The ECL cells are rich in histidine decarboxylase
 (HDC) and are 
actively producing and releasing histamine 
(7-10). Among different type of histamine 
receptors, H2 receptors are main type, responsible for acid secretory function of 
histamine. 
 
     Gastrin is the key hormonal inducer of acid secretion which is released from endocrine 
G cells in the gastric antrum. Gastrin can be secreted in response to eating a meal; 
circulating gastrin stimulates acid secretion by binding to CCKB receptors on parietal cell 
and Enterochromaffin-like cells in the corpus of the stomach. Thus gastrin stimulation of 
acid secretion from parietal cell includes direct activation 
(11) as well as indirect stimulation 
via release of the potent acid secretagogue histamine from ECL cells 
(12-14). 
Cholecystokinin type B (CCKB) is the responsible receptor for gastric effect 
(15). 
 
     Acetylcholine  is  a  general  neurotransimter mainly secreted by parasympathetic 
nervous system. Acetylcholine released from vagus nerves stimulate gastric acid 
secretion via the muscarinic receptor type 3 (M3) on the parietal cell 
(16, 17). Cholinergic 
system can also control the acid secretion by stimulating of the histamine release 
indirectly 
(18). 
 
     There are numerous peptides and chemicals are thought to have direct and indirect 
inhibitory effects on gastric acid secretion, including somatostatin, Cholecystokinin, 
adrenomodulin, calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-Chapter 1: Gastric Secretion In Health 
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activating peptide (PACAP), antral natriuretic peptide (ANP), pancreatic polypeptide (PP), 
secretin, polypeptide YY, entroglucagon, serotonin, vasoactive intestinal peptide (VIP) and 
prostaglandins 
(19-21). The most potent physiological inhibitor of oxyntic cells and G cells is 
14- or 28- amino acid somatostatin, which is released by the D cell present in close 
proximity of the G cells in the antrum and of the oxyntic cells in fundus to inhibit these 
cells by paracrine mechanisms. It is released by the action of H+ on the receptors of the D 
cells and since its major effect is the inhibition of gastrin release and gastric acid 
secretion, it may be considered as a typical feedback controller of gastric secretion 
(22). Its 
inhibitory effect is also mediated by the inhibition of histamine release from ECL cells 
through activation of specific membrane receptors called SSTR2 
(23). Calcitonin gene 
related peptide (CGRP) is present mainly at the sensory nerve ends in the oxyntic and 
antral gland area 
(24, 25) and plays a role in the axonal inhibition of gastric acid secretion. 
Secretin, produced in duodenum and jejunum may affect acid secretion by direct action on 
parietal cells and also indirectly through prostaglandins 
(26). Two other family members of 
secretin, VIP and PACAP, are present in enteric neurons. VIP may have an indirect action 
through release of somastatin 
(21). PACAP inhibits histamine release from the ECL cells 
and somatostatin from the D cells 
(27), leading to the inhibition of acid secretion 
(28, 29). 
 
1. 2. 2. Bicarbonate and its regulation 
     The earliest medical literature about bicarbonate (HCO3
-) refers to 1892 by the Danish 
physiologist Schierbeck 
(30) followed by Pavlov, who proposed that “alkaline mucus lining 
the gastric mucosa” neutralized luminal acid 
(31). Secretion of HCO3
-  into the surface 
mucus layer provides a first line of mucosal protection against acid in the stomach. 
Alkaline secretion by the stomach has been demonstrated in humans and laboratory 
animals. Bicarbonate secretion by frog 
(32) and mammalian 
(33, 34) fundic and antral 
mucosae mounted in an in vitro chamber was inhibited by anoxia, cyanide, or 2:4 
dinitrophenol, indicating its dependence on tissue metabolism. Secretion in vitro was 
stimulated by cyclic GMP, but not cyclic AMP and cholinergic stimuli, which increased Chapter 1: Gastric Secretion In Health 
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gastric alkaline secretion in vitro 
(35) and in vivo 
(36, 37) while elevating mucosal cyclic GMP 
concentrations in the canine fundus and antrum 
(38). The gastric surface epithelial cells 
contained high concentration of cyclic GMP diestrase 
(39), and the antral mucosa was 
composed mainly of this cell type. Furthermore, gastric antral and gastric fundic alkaline 
secretions display very similar properties, including almost identical sensitivity to 
stimulants and inhibitors 
(40, 41). The overall conclusion of these studies strongly suggests 
that metabolic dependent secretion of bicarbonate is a property of the gastric surface 
epithelial cells 
(42). 
 
 
1.3. Regulation of Acid Secretion 
     1.3.1. The parietal cell and its receptors 
     The earliest concept as to how the stomach handls food was enunciated by 
Hippocrates in the 5
th century BC. His idea was that the stomach cooked food. It was not 
until more than 2000 years later, in the 18
th century, that the French physicist Reamur 
suggested that the stomach digests the dissolves food 
(42). Prout discovered gastric 
hydrochloric acid in 1823, and Beaumont initiated physiology by studying the regulation of 
acid secretion in a man with gastric cutaneous fistula in 1826 
(43). This event was followed 
by the identification of oxyntic gland parietal cell as natural secretors of gastric acid by 
Heidenhain and Golgi in 1875 and 1893, respectively 
(44).  
     In healthy adults, 1 billion parietal cells can be found within the acid secreting mucosa 
in the body and fundus of the stomach. Forty million parietal cells secrete 1 mEq acid per 
hour resulting in a maximal acid output (MAO) of 20-26 mEq/hr in healthy humans 
(45). 
Hydrochloric acid is produced by the H
+, K
+-ATPase enzymes in parietal cells. The 
enzyme transports hydrogen ion into the parietal cell canaliculus in exchange for 
potassium ion. In the resting parietal, cell the H
+, K
+-ATPase is inactive and present 
largely in tubular vesicles in the cytoplasm of the cell. Stimulation of the parietal cell 
occurs via the acetylcholine (M3), gastrin (CCKB) and /or histamine (H2) receptors on the Chapter 1: Gastric Secretion In Health 
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basolateral membrane via second messengers. This causes the movement of H
+, K
+-
ATPase to the apical membrane of the cell, where it can exchange H+ for K+. Chloride 
ions enter the secretory canaliculi from the cytoplasm by a passive transport mechanism, 
resulting in the secretion of HCL 
(46-48). 
 
1.3.2. Gastric Acid Secretion Pathways; Cephalic Phase 
     Central stimulation of the vagus nerve by thought, sight, smell, taste and swallowing of 
food results in acid secretion 
(49-51). Early studies suggested that vagal activity during the 
cephalic phase induces acid secretion directly by stimulation of fundus, and indirectly by 
stimulation of antrum 
(52). Proximal vagotomy decreases the acid response to sham 
feeding in humans 
(53). The acid response to vagal stimulation is controlled by cholinergic 
system because small doses of atropine eliminates the acid response to intravenous 
insulin and 2-deoxyglucose which are both chemical stimulants of vagus 
(54). 
 
          Gastrin plays a physiological role in the cephalic phase acid secretion in humans. 
Modified sham feeding causes small but significant rises in serum gastrin 
concentrations
(55). However, circulating gastrin responses cannot fully explain the entire 
cephalic phase acid response to modified sham feeding. Combined cephalic and gastric 
stimulation in humans enhances acid secretion without a significant rise in circulating 
gastrin over that produced by gastric phase stimulation alone 
(56). The preceding 
experiments indicated that during the cephalic phase of secretion, vagus nerve stimulation 
causes both stimulation and inhibition of gastrin release. Vagal cholinergic muscarinic 
stimulation of the fundus increases acid secretion but inhibits gastrin release. Vagal 
cholinergic muscarinic and non-cholinergic stimulation of the antrum increases the gastrin 
release. The net effect of inhibitory and stimulatory vagal pathways during the cephalic 
phase is a modest increase in circulating gastrin 
(57). Based on of Konturek and 
colleagues’ recent studies vagal stimulation by various techniques including classic sham-
feeding as well as that induced by insulin hypoglycaemia, the highest response to vagal Chapter 1: Gastric Secretion In Health 
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stimulation does not exceed 50% of that attained with exogenous stimulus such as 
histamine or gastrin applied in a dose inducing maximal gastric acid secretory 
response
(58).  
 
     There are a few centrally acting inhibitory pathways of gastric acid secretion during 
cephalic phase. In animal models, injection of calcitonin, CGRP 
(59), nourotensin 
(60), 
bombesin 
(61), interleukin 1 
(62), corticotrophin-releasing factor (CRF) 
(63), neuropeptide Y 
(64) and prostaglandins 
(65) to different parts of central nervous system has been shown to 
inhibit gastric acid secretion 
(62, 64, 65). Most of the pathways through which central acting 
molecules exert acid inhibition involve vagal and sympathetic nervous system.  The 
hypothalamus also appears to be an important site of action of many peptide inhibitors pf 
acid secretion. IL-1 and bombesin are examples of gastric acid secretion inhibitors which 
affect hypothalamus 
(62, 66). Peptide YY (PYY), which is structurally and functionally related 
to neuropeptide Y and released postprandially from the ileum and colon, displays a potent 
inhibition of gastric acid secretion during cephalic and gastric phases 
(67). 
 
 
 1.3.3. Gastric Acid Secretion Pathways; Gastric Phase 
     During gastric phase of acid secretion, gastrin plays central regulatory role. Two major 
pathways of gastrin-related gastric phase are mechanical distension and chemical 
stimulation by luminal nutrients.  
     Distension of stomach produces approximately 20% of maximal acid output in humans 
(68). Stimulated gastrin and capsaicin-sensitive vagal afferent pathways are two main 
mechanisms involved in distension-related gastric acid secretion. Marked distension of the 
stomach induces a rapid rise of gastrin, and this rise is not inhibited by low pH of antrum 
(69). The elevated gastrin is only modest and cannot fully account for the total acid 
response to the distension. A capsaicin-sensitive vagal afferent pathway accounts for 40% 
of the total acid response to gastric distension, which may or may not involve gastrin 
(70). Chapter 1: Gastric Secretion In Health 
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Experiments with anesthetized males suggest that vagus nerves mediate acid secretion 
by mechanical and chemical stimulation, and that gastrin mediates acid secretion partly by 
chemical stimulation but not by mechanical stimulation 
(71). 
          The strongest stimulants of gastric acid secretion during gastric phase are luminal 
nutrients. Peptides, amino acids, carbohydrates and fats stimulate acid secretion 2-4 
times above that caused by mechanical stimulation 
(72). Some components of coffee 
(73), 
wine 
(74) and the carbohydrate metabolites of fermented beer 
(75) also stimulate acid 
secretion. 
     The  most  essential  regulator  of  acid secretion in gastric phase is gastrin which 
accounts for most of the acid response to graded increase in intra gastric concentration of 
peptone 
(68). Gastrin was discovered by Edkins in 1905 
(76). In the 1960's Gregory and his 
colleagues purified gastrin from antral mucosal extract and from a tumour of Zollinger-
Ellison syndrome (gastrinoma) and revealed the chemical structure of gastrins 
(77, 78). The 
predominant form of gastrin in the antral mucosa and the circulating blood is 17-amino 
acid gastrin and 34-amino acid peptide with identical C-terminal sequence including Trp-
Met-Asp-72 Phe-NH2, which by itself has similar acid stimulatory activity to the whole 
gastrin molecule. In the beginning of the 1970's, Yalow and Berson 
(79, 80) detected another 
form of gastrin composed of larger molecule and named it, "big big gastrin". 
 
     Besides the classic routes of activation through acetyl choline, gastrin, and histamine, 
a number of metabolic factors (including serum calcium and protein) or amino acid-rich 
diets influence gastric acid secretion via only partly characterized pathways. After the 
identification of Calcium Sensing Receptors (CaSR) in gastric tissue and its localization at 
the basolateral membrane of parietal cells 
(77), Dufner et al demonstrated the presence of 
a functional CaSR in the human stomach and showed that this receptor may modulate the 
activity of acid-secreting H_-K_- ATPase in parietal cells 
(78). Stimulation of CaSR with 
divalent cations or the potent agonist Gd(3+) leads to the activation of the H(+)/K(+)-
ATPase and subsequently to gastric acid secretion. Remy et al showed that in the human Chapter 1: Gastric Secretion In Health 
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gastric parietal cell, the CaSR is coupled to pertussis toxin sensitive heterotrimeric G-
Proteins and requires calcium to enhance the activity of the proton-pump 
(79). 
   
       
1.3.4. Gastric Acid Secretion Pathways; Intestinal Phase 
     The intestinal phase of gastric acid secretion contributes a small percentage (only 5%) 
of total acid response to meal. When a meal reaches the proximal part of the duodenum, 
this phase of gastric secretion occurs. In the 1940's, Gregory and Ivy 
(80) proved the 
humoral nature of this phase. Inhibition of gastric secretion by presence of acid in 
duodenum has been showed by studies dated back to one century ago 
(81). This 
phenomenon was further investigated by Konturek and Grossman 
(82) in 1965. They found 
that the upper duodenum is involved in the inhibition of gastric secretion and that the 
excision of consecutive parts of duodenum leads to a gradual increase in acid production 
by the stomach. A total excision of the duodenum completely eliminates the inhibitory 
effect of acid in the intestines on gastric secretion. Subsequently, Konturek and Johnson 
explained this mechanism by inhibitory intramural and vago-vagal duodenogastric reflexes 
(83). 
      The mucosa of proximal small intestine contains significant amounts of gastrin, but 
only modest increases in circulating gastrin were measured during intestinal perfusion 
with peptone 
(84). There is another factor, so called entero-oxyntin, secreted by small 
intestine mucosa that enhances the response to exogenous gastrin 
(85). The gastrin 
potentiating the effect of the entero-oxyntin may be the most important contribution of the 
intestinal phase of secretion to the total acid response to a meal.  
     During the intestinal phase, absorbed amino acids also stimulate gastric acid secretion. 
Luminal amino acids appear to stimulate gastric acid secretion through a gastrin 
dependent pathway, whereas the effect exerted by the absorbed amino acids is mainly 
gastrin-independent 
(86). Chapter 1: Gastric Secretion In Health 
 
 
10
     In  contrast  to  many  different  mechanisms involved in stimulation of gastric acid 
secretion during intestinal phase, inhibition of acid secretion is elicited mainly by three 
factors: intra-luminal fat, acid and hyperosmolar liquids 
(87). Intra-luminal fat presumably 
causes the release of numerous peptide and chemical inhibitors of acid secretion such as 
secretin, somatostatin, peptide YY, nourotensin, VIP, GIP and enteroglucagon, but the 
inhibitory mechanism of none of them has been completely determined.  Circulating 
secretin concentration increases in response to oleic acid perfusion of the upper small 
intestine 
(88) and by acidification of the duodenal lumen 
(89, 90). The release of secretin by 
duodenal acidification pathway is mediated by a secretin releasing peptide (SRP). The 
release and action of SRP are neurally mediated depending on vagal afferent pathways 
(91). In addition to direct effect of secretion on acid secretion, it can reduce acid secretion 
by increasing of somatostatin, PGE-2 and finally stimulation of secretion of PACAP-27 
(92).  
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     1.4.1. Discovery of pepsins and other gastric proteinases 
     Studies on gastric digestion during 1820-1840 led to the discovery of pepsin by 
Schwann as the agent which, in the presence of stomach acid, causes the dissolution of 
nutrients such as meat or coagulated egg white 
(93). Soon afterward it was shown that 
these protein nutrients were cleaved by pepsin to diffusible products named peptones. 
Efforts to isolate and purify pepsin were spurred by its widespread adoption for the 
treatment of digestive disorders, and highly active preparations were available by the end 
of the nineteenth century. In 1930, Northrop crystallized swine pepsin. The availability of 
this purified pepsin during the 1930s led to the discovery of the first synthetic peptide 
substrates for pepsin, thus providing needed evidence for the peptide structure of native 
proteins, a matter of debate at that time. In 1941, the effect of crystalised pepsin on anti-
pneumococcal antibody was studied by Petermann et al 
(94). After 1945, with the 
introduction of new separation methods, notably chromatography and electrophoresis, 
and the availability of specific proteinases, the amino acid sequences of many proteins, 
including pepsin and its precursor pepsinogen, were determined. In 1952, Janowitz and 
Hollander measured basal pepsin secretion from gastric content of healthy and peptic 
ulcer patients. After 1975, the three-dimensional structures of pepsin and many of its 
relatives were determined by means of x-ray diffraction techniques, greatly extending our 
insight into the mechanism of the catalytic action of these enzymes 
(95). 
 
      1.4.2. Classification and Function of Pepsins 
     The gastric proteinases have been divided into three main groups: 1) pepsins, 
including pepsin A and pepsin C, 2) chymosin, and 3) cathepsin E. Chymosin is the 
predominant enzyme secreted by neonates while adults’ stomachs secret primarily pepsin 
A and pepsin C 
(96). Chymosin is particularly effective in digesting milk proteins and this 
property accounts for its long standing use in the production of cheese as well as 
providing a rational for its predominance in neonates. A recently updated classification 
and nomenclature has been introduced by Gritti et al based on International Union of Chapter 1: Gastric Secretion In Health 
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Biochemists (IUB) rules 
(97), (Table 1.1). Gastric pepsins A and C originally were 
differentiated on the basis of electrophoretic mobility 
(97) and immunoreactivity. Salmoff et 
al identified seven isozymes, or isozymogens in the case of proenzymes, in human gastric 
mucosa, which were designated as pepsinogens 1-7 according to decreasing 
electronegativity. Based on immunoreactivity, pepsinogen 1-5 were classified as 
pepsinogen A (or pepsinogen I) while pepsinogen 6 and 7 correspond to pepsinogen C (or 
pepsinogen II). Recent studies have confirmed and extended the distinction between 
pepsin A and pepsin C by localising the genes encoding these enzymes to different 
chromosomes in man. Thus pepsin A genes are found on chromosome 11 
(98) while 
pepsin C is localised to chromosome 6 
(99).  
 
     In general gastric zymogens have two main roles in humans: 1) facilitating digestion of 
food proteins and 2) providing an antibacterial barrier. The gastric zymogens, including 
pepsinogen I and pepsinogen II, each contain a prosegment that serves to stabilize the 
inactive form and prevent entry of the substrate to the active site. Upon ingestion of food, 
each of the zymogens is released into the gastric lumen and undergoes conversion into 
active enzyme in the acidic gastric juice. This activation reaction is initiated by the 
disruption of electrostatic interactions between the prosegment and the active enzyme 
moiety at acidic pH values. The conversion of the zymogen into its active form is a 
complex process, involving a series of conformational changes and bond cleavage steps 
that lead to the unveiling of the active site and ultimately the removal and dissociation of 
the prosegment from the active centre of the enzyme 
(100).  
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Table 1.1: Aspartic proteinases and cod numbers designated on the basis of IUB’s 
Enzyme Nomenclature rules. (Modified from Gritti et al [127]) 
Common Name  Alternative Names  IUB Code 
     Gastric proteinases 
Pepsin A  Pepsin I, corresponding to zymogen PGA  EC 3.4.23.1 
Pepsin B  Cathepsin E, slow-moving proteinase  EC 3.4.23.2 
Pepsin C  Pepsin II, fastricsin, corresponding to zymogen 
PGC 
EC.3.4.23.3 
Chymosin   EC.3.4.23.4 
Cathepsin D    EC.3.4.23.5 
     Other proteinases 
Microbial aspartic proteinases (from fungi and HIV-1)    EC.3.4.23.6 
Renin   EC.3.4.23.15 
 
 
     Although it has been long believed that an optimal pH of around 2 allows pepsin to 
operate in its natural acidic environment, and at neutral pH the protein is denatured, 
recently, an inactive pepsin conformation has been identified that accumulates at mildly 
acidic pH. Campos et al showed that pepsin adopts, in the 6.5-4.0 pH interval, a native-
like, although catalytically inactive, conformation 
(101). 
 
The gastric lumen represents a bactericidal barrier, whose major components are an 
acidic pH and pepsin. In a recent study, pepsin has been shown to affect the motility of 
the bacteria, one of its most important virulence factors. It showed that the antibacterial 
effect of pepsin occurs in two phases: rapid loss of motility and subsequent destruction. In 
another study, investigators used the rapid pepsin-induced bacterial immobilization as a 
marker of antibacterial efficiency. The proteolytic activity of different pepsins was 
normalized to values between 2 and 200 U/ml in the hemoglobin degradation test of 
Anson, performed at pH 2 and 5. They found that pepsin C completely inactivates H. Chapter 1: Gastric Secretion In Health 
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pylori at proteolytic activities of 2 (pH 5) and 20 (pH 2) U/ml. In contrast, the activities of 
pepsin A and chymosin required to affect Helicobacter motility were ten times higher 
(102). 
In another study, the susceptibility of Escherichia coli and Helicobacter pylori to pH and 
the effect of pepsin-mediated proteolysis were investigated. Survival of bacteria was 
diminished at pHs of less than 3.5, whereas killing required a pH of less than 2.5. Pre-
incubation with pig pepsin at 0.5, 1.0 and 2.0 mg ml-1 at pH 3.5 reduced viable counts by 
100% for E. coli 690 and E. coli K-12 after 100 min incubation. With H. pylori, the viable 
counts decreased to 50% of the control after 20 min incubation in 1 mg pepsin ml-1 at pH 
2.5, 3.0 and 3.5. The gastric juices showed bactericidal activity at pH 3.5, and the rate of 
killing was juice dependent, with complete death of E. coli 690 occurring between 5 and 
40 min post-incubation. Thus, killing of E. coli and H. pylori occurs optimally at pHs of less 
than 2.5. At pH 3.5, little effect is observed, whereas addition of pepsin alone or in gastric 
juice causes a marked increase in bacterial susceptibility, suggesting an important role for 
proteolysis in the killing of bacteria 
(103). 
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     1.4.3.1. Stimulation of Pepsinogen Secretion 
 
     1.4.3.1.1. Cholinergic System 
     Acetylcholine and cholinergic analogues have been shown to be potent stimuli for 
pepsinogen secretion. The secretion of pepsin can be stimulated directly by vagus nerves 
stimulatory signals or indirectly by one or more following mechanisms: insulin-induced 
hypoglycaemia, 2- deoxyglucose, alcohol, sham feeding, hyperventilation, vago-vagal 
reflexes resulting from the distension of the stomach, psychic stimuli and by depression of 
the cerebral function. All these stimuli are ineffective after vagotomy and can be blocked 
by administration of suitable doses of atropine 
(104). Results from earlier studies have been 
demonstrated that acetylcholine and cholinergic agents increase pepsinogen secretion 
through both M1 and M2 muscarinic receptors. The blockade of pepsinogen secretion by 
different anticholinergic agents suggested a stronger role of M1 compared to M2 
receptors. This has been well shown by experiments demonstrating that pirenzepine is a 
powerful inhibitor of pepsinogen secretion through the M1 receptor. On the contrary, M2 
sub-type receptors can be selectively stimulated only in isolated parietal cells and gastric 
mucosa membranes 
(105, 106). Recent studies using antagonists suggested that the M3 
receptor subtype plays a prominent role in mediating pepsinogen secretion, but in situ 
hybridization indicated expression of M1 receptor in rat chief cells. Xie et al developed a 
murine secretory model of transgenic mice to investigate the regulation of pepsinogen 
secretion. Their results indicate that, in gastric chief cells, a mixture of M1 and M3 
receptors mediates cholinergic stimulation of pepsinogen secretion and that no other 
muscarinic receptor subtypes are involved in this activity 
(107). 
 
          The results of studies by Blandizzi et al indicate that the activation of muscarinic 
receptors by vagally released acetylcholine is not sufficient b y  i t s e l f  t o  s t i m u l a t e  
pepsinogen secretion and that a facilitatory action mediated by acid secretion is Chapter 1: Gastric Secretion In Health 
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necessary to allow an increment of peptic output in response to vagal cholinergic stimuli. It 
is suggested that such facilitatory input is driven to chief cells by local intramural reflexes 
that involve capsaicin-insensitive intrinsic nerves 
(108).  
 
     1.4.3.1.2. Adrenergic System 
      In isolated glands, the β-adrenergic agonist, isoproterenol, is able to stimulate 
pepsinogen secretion 
(109). As this stimulation is inhibited by propranolol but not by 
atropine or H2 blockers, it seems to be a direct effect. Since isoproterenol is unable to 
stimulate acid secretion from the parietal cells, it seems possible that pepsinogen 
secretion triggered by isoproterenol infusion is specific. Further experiments on the gastric 
gland have shown that the β2-selective antagonist ICI-118551 is 100- times more potent 
than a β1-selective antagonist betaxolol for inhibition of pepsinogen secretion 
(110-112).  
 
1.4.3.1.3. Cholecystokinin 
     Octapeptide cholecystokinin (CCK-8) and other related peptides were found to induce 
pepsinogen secretion in gastric glands 
(113). CCK-8 appears to have a direct effect on the 
chief cells. This stimulation is inhibited by the cGMP analogue, and it seems that the 
potency of this stimulation depends on the presence of a sulphated tyrosine residue in the 
molecule. Central administration of CCK-8s stimulates pepsinogen secretion through the 
activation of peripheral CCKa and CCKb receptors. Also it was observed that CCK-8s 
stimulus is mainly mediated by CCKa receptors subtype 
(114, 115). According to the findings 
of Blandizzi et al, under in vivo conditions, the stimulant actions of CCK-like peptides on 
pepsinogen secretion are mediated, at least in part, by an increase in NO generation 
(116). 
Further work of the same team emphasized that increase in pepsinogen output evoked by 
centrally applied cholecystokinin-8S does not depend on interaction with central nervous 
sites. Following central or parenteral injection of cholecystokinin-8S, the increase in peptic 
secretion would result from activation of both peripheral CCKa and CCKb receptors 
presumably located at the level of gastric mucosa 
(117). Chapter 1: Gastric Secretion In Health 
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1.4.3.1.4. Gastrin 
     Gastrin and pentagastrin stimulate pepsinogen secretion in intact animals, but no 
direct stimulation of the chief cells has been demonstrated and so far there is no evidence 
for a direct physiological secretion 
(118, 119).  
 
 1.4.3.1.5. Histamine 
     There are controversial findings about histamine related pepsinogen secretion. In 
different in vitru models, histamine is reported to have no effect on pepsinogen secretion 
(120, 121) or a small stimulatory effect 
(122). Histamine can either induce or, in high doses, 
inhibit pepsinogen secretion 
(118, 123). Therefore, it was suggested that these responses are 
mediated by H2 receptors and that the acidification of the gastric lumen can stimulate 
histamine secretion which, in its turn, by activating a local cholinergic reflex, can stimulate 
pepsinogen secretion 
(124-126). On the other hand, in vitro studies on isolated gastric glands 
suggest that acid and pepsinogen secretion are regulated independently, although in vivo 
the two processes seem to react to the same stimuli. These results indicate that histamine 
cannot be considered a direct physiological regulator of pepsinogen secretion by the chief 
cells. 
 
1.4.3.1.6. Other Peptides and Macromolecules 
     Secretin: Secretin has been reported to stimulate pepsinogen secretions in vivo, but 
results of in vitro studies showed no clear stimulatory effect of secretin on pepsinogen 
secretion 
(127-129).  
     Vasoactive Intestinal Peptide (VIP):  VIP has been reported to stimulate pepsinogen 
secretion through the same receptor mechanism as secretin 
(129-131). 
     Bombesin: Bombesin also has been shown to stimulate pepsinogen secretion through 
direct action on gland cells and indirectly by modulating gastrin release 
(119, 109, 132).  Chapter 1: Gastric Secretion In Health 
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     Epidermal  Growth  Factor  (EGF): Although epidermal growth factor (EGF) inhibits 
gastric acid secretion, it stimulates pepsinogen secretion by activating eicosanoid 
generation, tyrosine kinases, MAP kinases, Ca2+, NO, and guanosine 3',5'-cyclic 
monophosphate 
(133). The EGF dose dependently increases basal pepsinogen secretion 
and a mitogenic concentration (0.1 nM) of EGF induces submaximal stimulation. Similar 
effects have been observed with transforming growth factor alpha. EGF effects on 
pepsinogen secretion are in addition to that induced by CCK-8 and db-cAMP stimulated 
pepsinogen secretion. EGF-induced pepsinogen secretion is completely inhibited by a 
human immunospecific EGF receptor antibody and reduced by both genistein and 
tyrphostin-25, two different tyrosine kinase inhibitors 
(134).  
     Protease Activated Receptors: Protease-activated receptor-2 (PAR-2) is abundantly 
expressed in gastric mucosal chief cells, facilitating pepsinogen secretion. According to 
Kawao et al, PAR-1, a thrombin receptor, like PAR-2, might function to facilitate 
pepsinogen secretion, suggesting a role of the thrombin-PAR-1-pathway in the stomach 
(135). Another study indicates that the activation of PAR-2 causes a Ca2+-ERK-dependent 
stimulation of pepsinogen secretion 
(136).  
     Na-K-2Cl cotransporter-1 (NKCC):  NKCC has been detected at exceptionally high 
levels in the gastric mucosa of several species, prompting speculation that it plays 
important roles in gastric secretion. NKCC contributes to secretions of Na+, K+, Cl-, fluid, 
and pepsinogen by the gastric mucosa through a process that is electrogenic in character 
and independent of acid secretion. The probable source of the NKCC-dependent non 
acidic electrogenic fluid secretion is the parietal cell. The observed dependence of 
pepsinogen secretion on NKCC supports the concept that a non acidic secretory stream 
elaborated from parietal cells facilitates flushing of the proenzyme from the gastric gland 
lumen 
(137). 
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2.1. Introduction 
      The key role of gastric acid secretion in benign and malignant disease of upper 
gastrointestinal tract has been known since late 19
th century. Alterations of acid secretion 
in the form of hypersecretion and hyposecretion has been a challenging field for many 
scientists and clinicians who were interested to provide the best evidence to understand 
pathophysiological pathways of peptic ulcer disease and gastric cancer. 
 
     The  gastric  acid  hypersecretion  in patients with duodenal ulcer has been studied 
adequately before H.pylori era 
(1-8). Also, the development of gastric ulcer has been shown 
to appear more common in subjects with less acid secretion 
(9, 10). Impaired mucosal 
defence against bile and acid and duodeno-gastric reflux of bile were suggested as main 
pathological background of gastric ulcer 
(11, 12). Traditionally, severe hypochlorhydria or 
achlorhydria has been known as a characteristic feature of gastric cancer. Achlorhydria, 
determined by the augmented histamine test, is the functional expression of the most 
severe atrophic gastritis and is followed by a 3 to 6 fold increased risk of gastric cancer 
(13, 
14). 
 
     The Introduction of H.pylori by Marshall and Warren in 1984 
(15) was a remarkable 
evolution in the understanding of upper gastrointestinal pathophysiology. H.pylori-induced 
superficial gastritis was introduced as an essential and triggering factor in duodenal and 
gastric ulcers. The recovery of normal acid secretion following eradication therapy 
revealed strong association between H.pylori infection and gastric alterations of gastric 
acid secretion in duodenal ulcer. Successful healing of gastric ulcers after H.pylori 
eradication also showed its critical role in the pathogenesis of peptic ulcer disease. 
Moreover, due to accumulated evidence on the critical role of H.pylori in the development 
of gastric cancer, IARC introduced it as the first degree carcinogen for gastric cancer on 
1994 
(16). Chapter 2: Gastric Secretion in Disease 
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     A short overview of historical and current evidence on the gastric secretory state in 
general and acid secretion in particular, seems to represent acid as central core of 
pathophysiology of gastroesophageal malignancies. In this chapter, I will review the 
alterations of gastric acid secretion in peptic ulcer disease in the first instance. Secondly, 
the alterations of acid and pepsinogens in gastric cancer and its precancerous lesions will 
be discussed. Finally, the results of our own study on predictors of maximal acid output in 
H.pylori infected patients will be presented. 
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2.2. Alterations of Gastric Acid Secretion in Duodenal Ulcer Disease 
 
     Duodenal ulcer is one of the common upper gastrointestinal diseases in humans. 
Except for a minor percentage of cases, almost all of the subjects who develop duodenal 
ulceration have H.pylori infection 
(17, 18).  Eradicating the infection usually cures the ulcer 
disease 
(19).  There is now substantial evidence that the infection causes the duodenal 
ulceration by stimulating increased gastrin release and increased acid secretion (
20-22).   
     In duodenal ulcer patients, the H.pylori gastritis is mainly confined to the antral mucosa 
with little inflammation of the acid secreting body mucosa. The inflammation of the antral 
mucosa results in increased gastrin release and this is apparent, both under basal 
conditions and following stimulation by food or by gastrin releasing peptide 
(23-25).  
Eradication of the infection results in a fall in serum gastrin with the values returning to 
normal within 2 to 14 days of commencing anti-H.pylori therapy
 (26, 27). 
     The  hypergastrinaemia  associated  with  H.pylori infection in duodenal ulcer patients 
appears to be due to the inflammation depleting antral somatostatin concentrations and 
thus disrupting the acid-mediated inhibitory control of gastrin release 
(28-31). In the healthy 
stomach, high acid concentrations in the gastric lumen stimulate the release of 
somatostatin by the antral D cells, and this inhibits gastrin release by the G cells, thus 
providing a negative feedback control to prevent excessive gastric acid secretion.  This 
control mechanism is disrupted by H.pylori infection.  The mechanism by which the 
infection depletes the somatostatin concentration is unclear. It may be related to the 
ammonia produced by H.pylori elevating antral pH and thus removing the physiological 
trophic effect that gastric acid exerts on the antral D cells
  (25).  An observation by De 
Francesco et al suggests that lymphocyte density in the antral mucosa could play a role in 
the increased gastrin production occurring in patients with H.pylori-induced duodenal ulcer 
(32). It is possible that H.pylori antral gastritis might affect G and D cell function by the 
stimulation of low production non-specific cytokines 
(33, 34).  Other in vitro studies have Chapter 2: Gastric Secretion in Disease 
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shown that certain cytokines affect gastrin somatostatin release, though it is difficult to 
know whether this can be extrapolated to the in vivo situation 
(35).   
       
     The important point about the increased gastrin release stimulated by H.pylori infection 
in duodenal ulcer patients is that it leads to increased acid secretion 
(36, 37).  Such subjects 
have increased basal acid output and increased maximal acid output stimulated by 
gastrin-releasing peptide.  The excess basal acid output of these patients can be mainly 
attributed to the H.pylori-induced hypergastrinaemia as eradicating the infection results in 
the normalization of acid secretion and the disappearance of the hypergastrinaemia 
(23, 24, 
35, 38).   
  
     There are some dark areas regarding H.pylori infection and altered acid secretion in 
patients with duodenal ulcer versus healthy or non-ulcer dyspeptics. Increased acid 
secretion is a characteristic of duodenal ulcer patients and not seen in the great majority 
of subjects infected with H.pylori without duodenal ulcer.  Gillen et al investigated the 
physiological explanation for the fact that H.pylori infection results in increased acid 
secretion in duodenal ulcer patients but not in non-ulcer subjects 
(39).  The degree of 
increase in serum gastrin concentration was similar in H.pylori-infected duodenal ulcer 
patients and in H.pylori-infected non-ulcer subjects.  However, the two groups varied 
markedly in their acid response to the increased gastrin.  The duodenal ulcer patients 
showed a normal or increased acid response to gastrin. This phenomenon is more likely 
due to the fact that they have a high parietal cell mass, together with the fact that the 
sensitivity of their parietal cells to gastrin stimulation is normal. This explanation was 
supported partly by Jacobson et al 
(40). In contrast, H.pylori infected non-ulcer subjects do 
not have an increased parietal cell mass, and, in addition, their parietal cells are 
abnormally insensitive to gastrin stimulation.  The difference in parietal cell mass between 
these two groups may be a genetic factor.  The impaired sensitivity to gastrin 
characteristic of the non-ulcer subjects is due to the fact that in these subjects the H.pylori Chapter 2: Gastric Secretion in Disease 
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gastritis involves the body mucosa and impairs its function, whereas in the duodenal ulcer 
subjects, the acid secreting mucosa is not affected by the H.pylori gastritis and its 
function, therefore, is unimpaired.  The reason why the inflammation involves the body 
mucosa in non-ulcer subjects may be due to the fact that they have a lower genetically 
determined parietal cell mass as a high acid output protects the oxyntic mucosa from 
H.pylori gastritis. 
      
     In summary, several different observations support the hypothesis that the disruption of 
normal physiological control of gastric acid secretion by H.pylori infection develops 
duodenal ulcer by producing an increased duodenal acid load.  Eradication of H.pylori 
infection normalises acid secretion and this is associated with resolution of the ulcer 
disease.  It should be emphasised that this hypothesis applies only to duodenal ulcer 
disease which is the main complication of the infection.  H.pylori infection can also result 
in gastric ulceration and this complication is likely to be related to the bacterium directly 
damaging the gastric mucosa. 
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2.3. Alterations in Gastric Function Predisposing to Gastric Cancer 
 
     Historically, achlorhydria was one of the characteristic features of gastric cancer, which 
was explained by the presence of severe atrophic gastritis in the mucousa adjacent to the 
tumour. The carcinogenic process, starting from superficial chronic gastritis, progress to 
atrophic gastritis, intestinal metaplasia and finally glandular dysplasia and cancer, was 
well described by Correa in pre H.pylori era 
(41). Soon after H.pylori was recognized as the 
cause of chronic gastritis, it became apparent that the epidemiological paradigms that 
linked atrophic gastritis and gastric cancer could be applied to H.pylori infection 
(42-44). How 
these inflammatory and precancerous steps progress to cancer and their risk factors are 
not our main topic in this chapter, only alterations in gastric acid secretion will be 
discussed here. 
     In contrast to patients with duodenal ulcer, chronic H.pylori infection results in marked 
hypochlorhydria or achlorhydria in a subgroup of subjects, including whom with 
asymptomatic infection, non-ulcer dyspeptics, and patients with gastric cancer
  (45).  In 
these subjects, the inflammation predominantly involves the body mucosa and this 
markedly impairs the ability of the parietal cells to secrete acid.  The majority of these 
subjects also have evidence of atrophy of the antral and/or body mucosa and this 
contributes to the hypochlorhydria.  Eradication of the infection results in various degrees 
of recovery of gastric acid secretion 
(46).  In subjects with little or no evidence of atrophy, 
eradication of the infection may result in the complete recovery of normal levels of acid 
secretion.   Regression of gastric atrophy and intestinal metaplasia following H.pylori 
eradication has been shown in experimental animal models 
(47-49). In several human 
studies, gastric atrophy and intestinal metaplasia did not progress 
(50, 51) and even 
regressed after H.pylori eradication 
(52-55).  
     The reason why this subgroup of subjects develops a corpus predominant gastritis and 
low acid secretion is less clear.  However, it may be related to a pre-morbid low acid Chapter 2: Gastric Secretion in Disease 
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output which would allow the gastritis to develop in the body mucosa
  (56).  As other 
explanation, it may be related to antigenic mimicry between the parietal cells and the 
organism with the immune response impairing the function of the parietal cells which 
would then lead to the development of body gastritis 
(57).  Alternatively, it may be related to 
dietary factors such as high salt intake or low Vitamin C intake which will predispose 
patients to the atrophy of the antrum or body mucosa.  Atrophy of either region (mostly 
that of the body) will impair the ability of the stomach to secrete acid and this will again 
allow the gastritis to become established in the body mucosa and further inhibit acid 
secretion.  
  
2.3.1. Factors influencing progression to gastric cancer 
     There has been considerable interest in the factors associated with particular 
histological and physiological phenotype induced in the stomach by H.pylori  infection.  
Studies have been focused on three groups of potential influencing factors, namely (I) 
different strains of H.pylori infection, (II) environmental co-factors, and (III) host genetic 
factors:  
          I) Patients infected with the more virulent CagA positive strain, have more intense 
inflammatory infiltrate both in their antral and body mucousa of the stomach 
(58).  CagA 
positive infection is also associated with an increased prevalence of atrophy 
(59).  
However, the distribution of the inflammation between the antral and body region of the 
stomach and the associated disturbance in gastric secretion is unrelated to the strain of 
the infection 
(58).  Infection with the more virulent CagA positive strain of H.pylori infection 
thus increases the risk of developing either gastric cancer or duodenal ulcer disease but 
the infection does not in itself determine which of these two outcomes more likely are 
(60).  
 
     II) Many environmental factors have been known to be associated with increased risk 
of gastric cancer.  Recent studies have confirmed that H.pylori-infected subjects with a 
low intake of fruit and vitamin C have an increased risk of developing gastric cancer Chapter 2: Gastric Secretion in Disease 
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compared to subjects with H.pylori infection and a high intake of fruit and vitamin C 
(61, 62).  
In addition, tobacco smoking is a risk factor for gastric cancer 
(63, 64). H.pylori infected 
subjects who smoke have a three-fold increased risk of developing gastric cancer 
compared to H.pylori-infected subjects who do not smoke 
(61).  Both the diet deficient in 
antioxidants and the free radicals in cigarette smoke are likely to promote the 
development of atrophic gastritis in H.pylori infected subjects. High intake of salt also has 
been shown to be able to increase risk of gastric cancer in H.pylori infected population, 
particularly in high risk area such as Japan 
(65, 66). According to Lee et al, subjects with 
H.pylori infection and a high salty preference had a 10-fold higher risk of early gastric 
cancer than subjects without H.pylori infection and with a low salty preference 
(62).   
Recently, it has been shown that concurrent helminthic infection modulates the response 
to Helicobacter felis in mice and reduces the risk of developing atrophy 
(67).  This appears 
to be due to down-regulation of the TH1 cytokine response.  This observation might 
explain the relatively low incidence of gastric cancer in African countries, despite the high 
prevalence of H.pylori infection.  
 
     III) The role of host genetic factors in determining the response to H.pylori infection and 
subsequent outcome has received considerable attention over the last decade.  Our 
colleagues recently studied 100 first-degree relatives of patients with non-cardia gastric 
cancer and compared them with 100 control subjects with family history of gastric cancer 
(68).  The H.pylori status, mucosal histology and gastric secretory function of each subject 
were determined. These studies showed that there is a very high incidence of gastritis, 
atrophy and hypochlorhydria in H.pylori-infected subjects with a family history of gastric 
cancer.  In contrast, prevalence of this phenotype was very rare in the subjects with a 
family history of gastric cancer but with no evidence of H.pylori infection and in H.pylori- 
uninfected subjects with the or without a history of gastric cancer.  This observation was 
consistent with interaction between the infection and a host genetic factor, resulting in a 
histological and physiological phenotype known to lead to gastric cancer. Chapter 2: Gastric Secretion in Disease 
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    The above findings raised many questions regarding the presence of a potential host 
genetic factor which could interact with the infection and result in gastric cancer.  The 
interleukin-1 gene was the first candidate.  It is known that if the infection induces 
increased production of interleukin-1 by the gastric mucosa and that this cytokine is a 
powerful inhibitor of acid secretion, it could therefore induce hypochlorhydria in response 
to the infection 
(69, 70). The group found that the pro-inflammatory genotypes were twelve 
times more common in H.pylori-infected subjects with hypochlorhydria and achlorhydria 
than in infected subjects without this phenotype.  In further studies they were able to show 
that subjects with the pro-inflammatory interleukin-1 genotype had an increased risk of 
going on to develop gastric cancer 
(71). In other side, it is also known that the pattern of 
gastritis is influenced by gastric acid secretory status.  For example, long-term 
suppression of gastric acid secretion by proton pump inhibitors will transform an antral 
predominant non-atrophic gastritis to a body predominant gastritis and will also accelerate 
the development of atrophy 
(72).  Consequently, the reduction in acid secretion induced by 
the increased interleukin-1 production will also lead to pangastritis or body predominant 
gastritis and atrophy.   
           
2.3.2. Hypochlorhydria or Atrophic Gastritis? 
     It is now well established that the subjects in whom H.pylori infection induces corpus-
predominant gastritis have the greatest risk of gastric cancer 
(73).  There are also a 
number of observations indicating that the low acid secretion itself may be an important 
factor in the carcinogenic process.  These are discussed below: 
I) For many years it has been recognised that gastric cancer develops against a 
background of chronic hypochlorhydria 
(13, 74). 
II) Epidemiological studies have indicated that H.pylori-infected duodenal ulcer patients 
have a very low risk of gastric cancer 
(75).  These subjects have dense colonisation of their 
antral mucosa with the bacterium and the associated severe antral gastritis.  The fact that 
they do not develop gastric cancer indicates that the infection and inflammation Chapter 2: Gastric Secretion in Disease 
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themselves are not sufficient to induce cancer and that other factors must be involved.  
The duodenal ulcer patients as discussed above are characterised by high acid output, 
and this may protect them from processes involved in carcinogenesis. 
III) El-Omar et al tested the hypothesis that H.pylori-induced hypochlorhydria is associated 
with an increased risk of gastric cancer by studying acid secretion in first degree relatives 
of patients with cancer of the mid or distal stomach 
(76).  In that study they discovered that 
50% of first degree relatives of gastric cancer patients with H.pylori infection had gastric 
acid hyposecretion compared with only 5% of H.pylori infected subjects without family 
history of gastric cancer.   This indicates that there is a close association between the 
risks of gastric cancer and the development of gastric acid hypochlorhydria in response to 
H.pylori infection. 
IV) Hansen et al in a collaboration with our team have also tested the hypothesis that 
gastric acid hyposecretion predisposes patients to the cancer in a large Norwegian cohort 
study in which serum samples were stored prior to development of the cancer 
(77).  
Subjects with H.pylori infection had an overall 3-fold increased risk of developing gastric 
cancer of the mid or distal stomach.  The study was further analysed by measuring serum 
gastrin concentrations in the stored serum as a surrogate marker of H.pylori-induced 
hypochlorhydria.  This indicated that subjects with a high serum gastrin level indicative of 
hypochlorhydria and H.pylori infection had a seven-fold increased risk of developing 
cancer compared to subjects with the infection and a normal gastrin level. 
     The original Correa hypothesis for gastric cancer proposed that subjects with gastritis 
developed atrophy and that the atrophy resulted in hypochlorhydria 
(41). At present, there 
is no doubt about relationship between atrophic gastritis and gastric cancer 
(76-81). In other 
side, there is a close association between atrophic gastritis and hypochlorhydria.  As a 
consequence, it is unclear whether it is the atrophy itself that predisposes patients to 
cancer or whether it is the acid hyposecretion present in patients with atrophy that 
predisposes them to gastric cancer. The hypochlorhydria is then a key factor in the 
carcinogenic process in that it allows colonisation of the gastric lumen with bacteria able Chapter 2: Gastric Secretion in Disease 
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to synthesise carcinogenic nitrosamines which would induce progressive damage to the 
gastric mucosa, leading to more severe atrophy, dysplasia and carcinoma.  Sobala et al 
showed that subjects with H.pylori-induced hypochlorhydria have in addition to bacterial 
colonisation, also increased intragastric nitrite 
(82) concentration and profound depletion of 
gastric juice ascorbic acid 
(82, 83) which will also facilitate the formation of nitrosamines 
(84). 
 
     According  to  El-Omar  et  al,  H.pylori gastritis can cause chronic hypochlorhydria or 
achlorhydria in the absence of atrophy 
(45).  It is therefore possible that it is the 
hypochlorhydria that predisposes patients not only to the development of cancer but also 
to development of the atrophy as a result of epithelial damage by nitrosamines formed in 
the neutral stomach. 
     Recent  support  for this concept that H.pylori-induced hypochlorhydria may lead to 
atrophy comes from the observations in which H.pylori-infected subjects have been 
treated with proton pump inhibitory therapy 
(85). These studies have indicated that H.pylori-
infected subjects with hypochlorhydria who have undergone proton pump inhibitory 
therapy develop corpus atrophy, which is not seen in H.pylori-infected subjects who were 
not treated with these drugs and whose intragastric pH, therefore, remains acidic.  This 
again supports the concept that hypochlorhydria is a key factor in determining the 
development of atrophy in response to H.pylori infection. 
      
2.3.3. Summary and Conclusion 
    Gastric acid secretion represents a key role in the most benign and malignant upper 
gastrointestinal disorders.  H.pylori infection as the most common bacterial infection 
worldwide exerts variable effects on gastric acid secretion. In some subjects it stimulates 
increased acid secretion, and this appears to be the key mechanism by which it results in 
duodenal ulcer disease.  In other subjects, it results in profound inhibition of gastric acid 
secretion, and this is associated with an increased risk of gastric cancer.  It can be seen 
that the development of gastric cancer is a complex, multistage and multifactorial process.  Chapter 2: Gastric Secretion in Disease 
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The various stages involve the progression from H.pylori superficial gastritis to atrophic 
gastritis with intestinal metaplasia and hypochlorhydria and then further progression to the 
development of dysplasia and cancer.  Numerous co-factors are involved in promoting or 
inhibiting this progression. There is increasing evidence that the hypochlorhydria per se 
may interact with the H.pylori gastritis in such a way as to facilitate carcinogenesis.   
Finally, it should be mentioned that in the majority of subjects, H.pylori infection results in 
no overall change in gastric acid secretion and these subjects rarely develop a clinical 
disease. 
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Gastric Histology, Serological Markers and Age as Predictors of Gastric 
Acid Secretion in H.pylori Infected Subjects 
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2.4.1. INTRODUCTION 
 
 
     There is a close association between the level of gastric acid secretion and the type of 
disease affecting the upper gastrointestinal tract.  Duodenal ulceration occurs in subjects 
with high acid secretion 
(86-90), gastro-oesophageal reflux disease and its complications in 
subjects with normal 
(91) or high levels of acid secretion 
(92-94), gastric ulceration in subjects 
with moderately reduced secretion 
(95) and gastric cancer in patients with profoundly 
reduced or absent acid secretion 
(96-99).  
     The level of acid secretion is thought to play a role in the aetiology of these common 
upper gastrointestinal diseases. Increased gastric acid secretion and duodenal acid load 
predispose to duodenal ulceration as demonstrated by the Zollinger-Ellison syndrome 
(100, 
101). Absence of gastric acid secretion is thought to predispose to gastric cancer by 
allowing colonization of the stomach by carcinogen synthesizing bacteria and also by the 
reflex hypergastrinaemia stimulating cell proliferation 
(102-104). The role of acid in the 
aetiology of gastro-oesophageal reflux disease is demonstrated by the therapeutic 
efficacy of acid inhibitory medication.  
     There has been a marked change in the pattern of upper gastrointestinal disease in the 
western world over the past century.  The incidence of gastric cancer has progressively 
fallen 
(105-107), that of duodenal ulceration risen and then fallen and the incidence of reflux 
disease and its malignant complications has increased 
(107, 108). These changes in the 
incidence of the disease are thought to be due in part to a rise in gastric acid secretion.  
There are also marked geographical variations in incidence of upper gastrointestinal 
disease.  Reflux disease and its complications are more common in the western versus 
eastern world and the opposite trend is seen for gastric cancer.  Again, these variations 
are thought to be related in part to regional variations in levels of gastric acid secretion.   Chapter 2: Gastric Secretion in Disease 
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     A major factor known to influence gastric acid secretion is Helicobacter pylori infection 
which colonises the gastric mucosa of more than 50% of the world’s populations.  The 
effect of the infection on acid secretion is related to the pattern of gastritis which it induces 
in the stomach.  Previous studies have examined acid secretion and H.pylori gastritis in 
specific diseases e.g. duodenal ulceration, gastric ulceration and gastric cancer 
(109-111). In 
the present study, we have examined the relationship between the pattern of H.pylori 
gastritis and gastric acid secretion in a large number of subjects without specific upper 
gastrointestinal disease.  For various reasons, acid secretion is now rarely measured and 
we have therefore also assessed the ability to predict the level of acid secretion from 
gastric histology and serological markers.   
 
          The aim of this study is assessment of the value of gastric histology, serological 
markers and other characteristics of patients as predictors of gastric acid secretion in 
H.pylori infected subjects. 
 
 
 
 
2.4.2. METHODS AND MATERIALS 
 
2.4.2.1. Study Population 
The study involved 255 H.pylori-positive dyspeptic patients with normal upper 
gastrointestinal endoscopy (i.e., no evidence of mucosal ulcerations, erosions, or 
neoplastic changes) who had undergone acid secretory studies in our unit over the past 
10 years. Subjects were not included if they had taken proton pump inhibitor therapy in 
the past year or H2 blocker therapy within the previous 3 weeks.  Their H.pylori infection 
was confirmed by positive results in at least one of two methods, C
14 urea breath test and Chapter 2: Gastric Secretion in Disease 
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gastric histology.  123 (48.2%) of them were male and 132 (51.8 %) were female. Mean 
age was 43.4 years with standard deviation of 13.2 and range of 18 to 84 years. Patients’ 
median (± interquartile range) height, weight and BMI were 167 (± 16) cm, 70 (± 19) Kg 
and 25 (± 5) Kg/m2, respectively. 
 
2.4.2.2. Histologic Assessment 
     Endoscopic biopsies of both the antrum and body region of the stomach were available 
in 175 of the patients. The age and sex distributions of this group were not statistically 
different from rest of cases. The processed biopsies were stained with hematoxylin-eosin 
and  H.pylori  –specific Cresyl fast violet stain.  All slides were assessed by a single 
pathologist for H.pylori density as well as type and severity of gastritis. The histological 
criteria applied to the evaluation of gastritis were based on the Updated Sydney 
Classification of Gastritis as follows 
(112): Gastritis: Presence of inflammatory cells of any 
type in the lamina propria. Grade of inflammation: Severity of infiltration of lymphocytes 
and plasma cells. Activity of inflammation: Presence of neutrophils in the inflammatory 
infiltrate. The sum of the grade and activity was expressed as combined inflammatory 
score (CIS) for each participant with maximum possible score of 6 
(113). Mucosal atrophy 
was defined as the separation of the mucosal glands and a decrease in the thickness of 
mucosa, greater in severity than that seen in the inflammation of the lamina propria and 
usually associated with an increase in the stromal matrix. Intestinal metaplasia: Presence 
of goblet cells with or without other cellular elements of intestinal mucosal and glandular 
epithelium.  
 
2.4.2.3. Acid Output Measurement: 
After a 12-hour fast, an orogastric tube (Anderson Inc., New York, NY) was swallowed, 
and its position in the dependent part of the stomach was checked using the water 
recovery test 
(114). Intermittent suction was then applied using an intermittent suction unit 
(Omeda, Columbia, MD) that applies suction for 20 seconds in each 32-second cycle. An Chapter 2: Gastric Secretion in Disease 
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intravenous infusion of Pentagastrin (Peptavlon; ICI, Cheshire, England) was started at a 
rate of 0.6 µg.kg-1.h-1 to stimulate maximal acid secretion. Gastric juice was collected for 
1 hour in 15- minute aliquots. 
The volume of each 15-minute gastric juice collection was recorded, and its hydrogen ion 
concentration was measured by titration with 0.1 mol/L NaOH to pH 7 using an autotitrator 
(Radiometer ETS 822; Copenhagen, Denmark). The acid output per 15-minute period was 
then calculated by multiplying the volume by the hydrogen ion concentration. Maximal 
acid output in response to Pentagastrin (MAO) was calculated by taking the mean of two 
highest consecutive 15-minute collections and expressed as millimoles per hour. 
 
2.4.2.4. Serologic Assay 
     Blood was obtained from each patient during the visit to the endoscopy unit. Separated 
serum samples were stored at -70°C until analyzed. Serum pepsinogen I (PG I) and 
pepsinogen II (PG II) were assayed with enzyme immuno-sorbant assay (ELISA) methods 
using monoclonal antibodies to pepsinogen I and II (BIOHIT diagnostics, Biohit LTD, UK). 
Serum gastrin-17 was measured using ELISA kit from the same supplier. All procedures 
were done according to the manufacture’s instructions and results of PG I and PG II 
reported in µg/L and pmol/L for gastrin-17. PG I/II ratio was calculated and reported in 
fraction. H.pylori cag-A antibodies were determined using a polyclonal EIA method, as 
previously described 
(115). 
 
2.4.2.5. Statistical Analysis   
     Except for MAO values, all other variables had relatively non symmetric distribution, so 
a non-parametric test of Spearman’s-rho was used for bivarate correlations. All results 
were presented with two-sided significance level. Partial correlation analysis with zero-
orders was used to estimate possible confounders. For testing the differences of mean 
MAO in different levels of gastritis and atrophy we used oneway ANOVA and post hoc Chapter 2: Gastric Secretion in Disease 
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Dunnett test, if appropriate. Mann- Whitney U test was used for comparing age of male 
and female patients. 
     Stepwise  linear  regression  was  applied for determining histologic and serologic 
predictors of MAO. Body atrophy score, antral atrophy score, serum PG I, serum PG I/II 
ratio, serum gastrin, age, H.pylori density of antrum, body, or H.pylori in one of two sites, 
and body combined inflammatory score were selected as independent variables and MAO 
as the dependent variable. The main criteria for the probability of F to enter and F to 
remove of independent variables were <=0.05 and >=0.10, respectively. In addition to 
standardized coefficients, co-llinearity statistics were presented for each of variables. For 
most statistical analysis we used SPSS v12.0 software.  
 
2.4.2.6. Ethical Approval 
This study was approved by the western infirmary ethics committee.   
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2.4.3. RESULTS 
 
2.4.3.1. Acid output and H.pylori related gastritis 
     The density of H.pylori colonization of the antral mucosa was positively associated with 
the acid output with a correlation coefficient of (CC) 0.31 (p<0.01), but the H.pylori density 
of the body was not correlated significantly with the acid secretion (CC= -0.11, p=0.19). 
Recalculation of this relationship using mean score of H.pylori density at any site showed 
a positive correlation with acid output (CC=0.17, p<0.05). 
     Chronic inflammation of the antrum was positively associated (cc=0.27, p<0.01) with 
acid output, while there was a more potent negative association between the chronic 
inflammation of the body mucosa and acid output (cc= -0.41, p<0.01) (fig 2.1). Active 
inflammation in the antrum did not show any significant relationship with the acid output 
but in the body it showed a negative correlation (CC= -0.28 and p<0.01) with the acid 
output. Combined (i.e. active plus chronic) inflammatory scores of the antrum showed a 
positive correlation with the acid output, reaching a peak of 29.3mmol/hr at histological 
score 4.  However, from score 4 to 6 we found slight decrease in the acid output with  the 
lowest value of 24.2mmol/hr at score 6.  Combined inflammatory score of the body after a 
peak of 33.7mmol/hr at score 2 showed persistent downward trend with minimal acid 
output of 9.5 at score 6.  Statistical tests with ANOVA showed significant difference 
between mean the acid output among patients with different combined inflammation 
scores (F=6.9, p<0.5).  Also significant inverse correlation of body combined inflammation 
with acid output was apparent (CC= -0.50 and p<0.01) (fig 2.2).  
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     Two  other  indices,  body/antral  chronic inflammation ratio and body/antral combined 
inflammation ratio, were tested for their relationship with the acid output. Both of them 
showed significant inverse correlation with the acid output, with -0.49 (p<0.01). As shown 
in Fig 2.3, the body / antrum ratio of active inflammation had a similar inverse correlation 
with the acid output but with a relatively weak significance (CC= -0.17, p=0.07 and F=3.0, 
p= 0.05). 
     The density of H.pylori per each score of combined inflammation also was evaluated 
regarding relationship with the acid output. Those indices at both antral and body sites 
were positively correlated with the acid output with correlation coefficients of 0.29 (p<0.01) 
and 0.38 (p<0.01), respectively. 
 
2.4.3.2. Acid output and gastric atrophy 
     Antral-confined atrophy was detected in 19 (12.6%) and atrophy limited to body in 27 
(17.9%).  Only 11 patients (7.3%) had multifocal atrophy.  Mean (± sd) acid output in non 
atrophic patients was 29.1 (±12.2) mmol/hr.  In patients with antral atrophy only, the acid 
output was 19.5 (±11.1), in subjects with body atrophy only and multifocal atrophy, the 
acid output was reduced at 11.9 (±7.2) and 11.5 (±10.1)mmol/hr, respectively.  Using 
oneway ANOVA, there were significant differences between groups regarding acid output 
(F=22.0, p<0.01).  Dunnett t test showed that acid output in each of the groups with 
atrophy was statistical different compared with non-atrophic group (all p<0.05) (Fig 2.4).   
     As presented in Fig 2.5, both antral and body atrophy scores had significant inverse 
correlation with acid output. The CC for antral atrophy was -0.30 (p<0.01) and for body 
atrophy it was -0.59 (p<0.01). The ratio of body/antral atrophy also showed prominent 
reverse relationship with acid output from 27.4 mmol/hr with ratio <1 to 10.1 mmol/hr with 
ratio equal or greater than one (Fig 2.6). 
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     Zero-order partial correlation showed that the relationship between body atrophy and 
acid output could be exaggerated with age and body combined inflammation. After 
controlling the age, the correlation co-efficient dropped form -0.54 to -0.48 (11% 
decrease). Controlling body combined inflammation also decreased the correlation of 
body atrophy score and acid output from -0.54 to -0.40 (26% fall). By controlling both 
variables, the correlation co-efficient dropped from -0.54 to -0.47 (31%). 
Intestinal metaplasia at both antral and body sites had negative relationship with acid 
output with cc= 0.23 (p<0.01) and cc= 0.20 (p<0.05), respectively. 
 
2.4.3.3. Acid output and PG I, PG I/II ratio, gastrin-17  
     The median serum PG I and PGII levels of all participants were 146.9 µg/L 
(Interquartile range 97.0) and 9.6 µg/L (Interquartile range 8.0), respectively. Calculated 
median PG I/II ratio was 15.1 (Interquartile range 11.0). Serum PG I was correlated 
positively with the acid output at CC= 0.38 (p<0.01). There was no relationship between 
the acid output and serum PG II, but the ratio of PG I/II had a positive CC=0.30(p<0.01) 
with the acid output (Figs 2.7 and 2.8). 
Median serum gastrin-17 of enrolled patients was 2.2 pmol/L. There was significant 
correlation between the acid output and serum gastrin-17.  
 
2.4.3.4. Cag-A serology; relationship with acid output and gastric histology 
   In 177 patents who had enough serum for anti Cag A serology, the mean acid output 
was similar in patients with positive versus negative Cag-A serology with 28.3 (±11.2) and 
26.7 (±12.3) mmol/hr, respectively. However re-observation of the correlation between anti 
Cag A antibody titre and inflammatory histologic parameters revealed its significant 
relationship with antral active inflammation [cc= 0.35, p value<0.01], body active 
inflammation [cc=0.33, p value<0.01] and body chronic inflammation [cc=0.24, p 
value<0.05]. There was no strong and significant relationship between anti Cag A 
antibody and atrophic or metaplastic  changes in gastric mucosa. 0
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2.4.3.5. Other factors associated with acid output 
     Age had inverse relationship with acid output (CC: -0.44 and p<0.01) (Fig 2.9). 
Calculation of relationship between acid output and age in male and female separately, 
revealed slightly greater inverse relationship among males than females (-0.41 vs. -0.38).  
     Regarding  gender,  male  patients  had  mean acid output 28.5(±13.2) mmol/hr and 
females 21.4 (±10.4) mmol/hr. Statistically, the difference with independent t test was 
significant (p<0.01). It should be mentioned that female patients were slightly older than 
males (median age 44 vs. 40, Mann-Whitney U test: p<0.05). Two other variables, body 
combined inflammatory score and body atrophy were evaluated in the both sexes, and we 
found no significant difference between males and females. 
     Smokers, who smoked 3 or more cigarettes per day had mean acid output=29.9(± 9.1) 
mmol/hr compared with non-smokers who had mean acid output of 26.5 (±12.6) mmol/hr. 
The difference between the two groups was at borderline significance (p= 0.05). The 
major histological changes such as antral combined inflammation, body combined 
inflammation and body atrophy were not statistically different between smoker and non 
smoker groups, but serum level of PG I  was significantly higher in smokers than non-
smokers [250.8 (Interquartile range:117) Vs. ( 190.5 (Interquartile range: 138) p<0.05]. 
     The height of patients showed a positive significant correlation with acid output, with 
CC= 0.43 and P<0.01. Weight also had positive but less potent relationship (CC=0.26, 
p<0.01) with acid output but BMI did not show any significant relationship (CC=0.02, 
p=0.84). Gender subgroups were not different regarding relationship of acid output and 
these variables. 
 
2.4.3.6. Best predictors of acid output 
     In order to determine the best predictors of acid output, all variables which had obvious 
and significant linear relationship with acid, were selected. Body atrophy score, antral 
atrophy score, serum PG I, serum PG I/II ratio, serum gastrin, age, H.pylori density of Chapter 2: Gastric Secretion in Disease 
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antrum, body, or H.pylori in one of two sites, and body combined inflammatory score were 
entered as independent variables and acid output as dependent variable. The stepwise 
model produced four models. In the final model, according to standardized coefficients, 
body combined inflammation with Beta of -0.34, body atrophy (Beta= -0.30), serum PG I 
(Beta= 0.26) and age (Beta= -0.26) were the most independent predictors of acid output. 
All other variables were excluded from model according to enter and remove criteria. The 
R and R square in the final model were 0.79 and 0.62 respectively (table 2.1).  
 
 
Table 2.1: Summary of stepwise linear regression analysis for predictors of 
maximal acid output 
Predictors Unstandardized 
Coefficients 
Standardized
Coefficients 
P 
value 
Co-linearity 
Statistics 
  B SE  Beta   Tolerance 
% ♣ 
VIF 
¶ 
Intercept   42.38  7.00    0.00    
Body Combined 
Inflammation  -2.56 0.79  -0.34  0.00 67  1.50 
Body Atrophy  -5.44  1.94  -0.30  0.01 63  1.60 
Age -0.33  0.11  -0.26  0.00 97  1.04 
Serum PG I  0.04  0.01  0.26  0.01 86  1.16 
 
Dependent variable: Maximal acid output 
R= 0.79, R square= 0.62,  Standard error of the estimate= 8.43 
♣ Tolerance is the percentage of the variance in a given predictor that cannot be 
explained by other predictors. 
 
¶ A variance inflation factor greater than 2 is usually considered problematic regarding 
co-linearity by other predictors.  
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Fig 2.7: Relationship of serum pepsinogen I with maximal acid output
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2.4.4. DISCUSSION 
 
     H.pylori infection produces a wide variety of pattern of gastritis 
(116-125). The pattern of 
gastritis varies in the extent to which it involves the antrum versus body region of the 
stomach and in the extent to which it produces acute inflammation, chronic inflammation, 
intestinal metaplasia and atrophy.  Our current study indicates that these different patterns 
of gastritis are associated with different levels of gastric acid secretion. 
     The antrum and body region of the stomach both play an important role in regulating 
gastric acid secretion. The antral mucosa contains the G cells, which release the gastrin.  
This hormone is released in response to ingestion of protein-containing foodstuffs and it 
stimulates the oxyntic mucosa to secrete acid 
(126). The hormone acts on the gastrin 
receptors on the ECL cells of the oxyntic mucosa causing them to release histamine, 
which acts in a paracrine fashion, binding to the H2 receptors on the parietal cells and 
thereby stimulating to secrete acid 
(127-129). Gastrin also exerts a trophic influence of the 
ECL cells and parietal cells of the oxyntic mucosa 
(130-131). 
     H.pylori gastritis influences the function of the antral mucosa, stimulating increased 
release of gastrin by the G cells 
(132-136). It is unclear whether this is due to the influence of 
inflammatory cytokines 
(137-139) or due to the ammonia produced by the bacterium’s urease 
activity raising antral surface pH and thus blocking the physiological inhibition of gastrin 
release by luminal acid 
(140). H.pylori antral gastritis will thus tend to increase gastric acid 
secretion by increasing gastrin release.  If the infection produces atrophy of the antral 
mucosa, the rise in gastrin will be moderated due to loss of G cells 
(141-143). As gastrin is 
released by ingestion of food, the main influence of the antrum is in meal-stimulating acid 
secretion which is technically difficult to measure.  We assessed acid secretion in 
response to stimulation by exogenous gastrin, which acts directly on the oxyntic mucosa.  Chapter 2: Gastric Secretion in Disease 
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Our study will therefore not have detected changes in meal stimulated acid secretion due 
to disturbances in antral function. 
     The current study demonstrates the strong correlation between H.pylori body gastritis 
and reduced gastric acid secretion. Both inflammation and atrophy of the body mucosa 
were strongly associated with reduced gastric acid secretion.  The effect of the atrophy is 
clearly explained by loss of acid secreting parietal cells.  The inflammation of the body 
mucosa is thought to produce functional inhibition of acid secretion.  We, and others, have 
shown that eradicating H.pylori in patients with low acid secretion produces recovery of 
secretion, which is associated with resolution of the body gastritis without any change in 
atrophy 
(143, 144). The mechanism by which H.pylori-induced inflammation impairs the 
function of the oxyntic mucosa is not clear.  However, the infection stimulates production 
of interleukin-1 beta, which is a powerful inhibitor of acid secretion, blocking the release of 
histamine from the ECL cells and also inhibiting the function of the parietal cells 
(145, 146). 
The current study clearly shows that atrophy and inflammation are both independently 
associated with low acid secretion.  
     We were able to investigate the relationship of maximal acid output and anti Cag A 
antibody.  While there was a significant correlation between the severities of antral and 
corpus active inflammation and anti Cag A antibody, the mean acid output was similar in 
patients with positive versus negative Cag A serology. A more intense inflammatory 
infiltrate both in gastric antral and body mucosae has been shown previously 
(58).  Cag A 
positive infection is also associated with an increased prevalence of atrophy 
(59). However, 
the distribution of the inflammation between the antral and body region of the stomach 
and the associated disturbance in gastric secretion is unrelated to the strain of the 
infection 
(58). Infection with the more virulent Cag A positive strain of H.pylori infection thus 
increases the risk of developing either gastric cancer or duodenal ulcer disease but the 
infection does not in itself determine which of these two outcomes are more likely 
(60).   
     The  serum  concentrations of pepsinogens are indicators of gastric atrophy and 
consequently of gastric secretory function.  Pepsinogen I originate from gastric fundic Chapter 2: Gastric Secretion in Disease 
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glands 
(147) whereas pepsinogen II is secreted by glands of the body, and antral region of 
the stomach as well as proximal duodenum 
(148). We found pepsinogen I the most useful 
predictor of the disturbance of acid secretion in our H.pylori infected subjects.  This is 
consistent with our histological studies confirming that atrophy of the body mucosa was 
the most powerful predictor of low acid secretion as pepsinogen I is a strong predictor of 
body atrophy.  
     We were also able to examine the influence of a variety of demographic characteristics 
of the patients on acid secretion. Our data showed that smokers who smoked 3 or more 
cigarettes per day had greater acid secretion compared to non-smokers. There was no 
significant relationship between cigarette smoking and major histological factors but our 
data revealed higher level of PG I among smokers. Chronic smoking is associated with 
higher gastric acid secretion in both ulcer and non-ulcer subjects 
(149-152). In addition there 
is a significant positive association between the number of cigarette smoked and the 
magnitude of acid secretion 
(153). Nicotine administrated intravenously stimulates acid 
secretion in man 
(154). Chronic cigarette smoking stimulates the vagus and activates the 
parietal cells to enhance acid output 
(153). Increased serum PG I in smokers was another 
finding of our study which could be related to their higher acid secretion with parallel 
increased chief cell secretory capacity 
(150). 
     Our data indicate a marked decline in acid secretion with increasing age in both male 
and female H.pylori infected subjects. The median acid output in 20 year-olds was 35 
mmol/h and fell to 15 mmol/h in 70 year olds. This negative association between acid 
secretion and age in H.pylori infected subjects has been previously observed 
(155). In 
contrast, acid output has been reported to remain steady or increase with age in H.pylori 
uninfected subjects 
(156). The lower acid secretion in the older H.pylori infected subjects 
can be explained partly (but not fully) by more severe body gastritis and higher prevalence 
of atrophy 
(155, 157, 159). It is unclear to what extent the higher prevalence of low acid 
secretion and higher prevalence of body gastritis and atrophy in older subjects is due to 
increasing age or a cohort effect where those born at an earlier time have increased Chapter 2: Gastric Secretion in Disease 
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predisposition to develop these abnormalities. In some patients with severe body atrophy, 
autoimmune gastritis may be an aetiologic factor for hypochlorhydria in advanced age. 
That may results as a consequence of interaction between H.pylori infection and host 
response to the organism's antigens, and to gastric auto-antigens including gastric H
+/K
+ 
ATPase 
(160). 
          Our study showed that male patients have greater acid output than females. This 
finding is consistent with previous work 
(158, 161) but its biologic explanation has not been 
clearly defined. In females, smaller gastric surface area and corresponding smaller 
parietal cell mass or lower parietal cell reactivity or both may be responsible 
(161, 162). The 
height of our patients positively correlated with acid output, and this effect was similar in 
both sexes, suggesting body surface could explain more acid secretion in males. Iijima et 
al reported that in H.pylori infected subjects, there was a more marked fall in acid output 
with increasing age in males versus females 
(155).  This is consistent with our current 
finding. 
     Due to the number and variety of factors affecting acid secretion and the potential for 
interaction between them, we performed stepwise linear regression analysis.  This 
indicates four independent factors: 1) body inflammation, 2) body atrophy, 3) serum 
pepsinogen I and 4) age are powerful predictors of acid secretion. Combination of these 
factors had strong relationship with acid output and could be used for prediction of acid 
output in individual patients. 
     It should be emphasized that this study shows the association between the patterns of 
gastritis and gastric acid secretion but does not in itself indicate the nature of the 
association. Previous studies have shown that eradication of H.pylori  infection causes 
recovery of gastric acid secretion in patients with body predominant atrophic gastritis 
thereby providing evidence that this histological pattern of gastritis can cause inhibition in 
acid secretion 
(143, 144, 164, 165). However, it is important to recognise also that acid secretion 
may affect the pattern of gastritis.  This is demonstrated by the fact that inhibition of acid 
secretion by proton pump inhibitors causes the pattern of gastritis to change from an Chapter 2: Gastric Secretion in Disease 
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antral predominant gastritis to a body predominant gastritis and may also cause 
acceleration of the atrophic process 
(166, 167).   
     Irrespective of the complex nature of the association between the pattern of gastritis 
and acid secretion, our current study does provide data allowing the prediction of acid 
secretion based on gastric histology, serological markers and patient characteristics.  This 
may be useful in estimating levels of acid secretion in different populations as well as in 
individual patients. 
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     This chapter deals with the upper gastrointestinal tract adenocarcinoma comprising 
adenocarcinoma located in distal oesophagus and stomach. Although tumours of proximal 
part of duodenum are anatomically classified as upper gastrointestinal tract, this topic is not 
discussed in this overview because of rarity of its malignant tumours. 
     It should be mentioned that the term of gastric cancer in almost all of the medical literature 
refers to gastric adenocarcinoma, the most common histological type of gastric cancer. Also, 
anatomical classification of gastric cancer to proximal and distal commonly refers to tumours 
located at cardia and non-cardia regions of the stomach, unless alternative definitions 
provided.  
 
 
3.1. Epidemiology of Upper Gastrointestinal Adenocarcinoma 
 
 
3.1.1. Gastric Cancer  
 
     Gastric adenocarcinoma, the main histological type of gastric cancer was said to be the 
commonest primary cancer in the world in 1980, with almost 670,000 new cases in that year 
(1). By 1990, it was overtaken by carcinoma of the lung, partly because of the rising incidence 
of lung cancer, but also because gastric cancer is one of the tumours whose frequency is 
falling worldwide 
(1, 2).   
          According to GLOBOCAN 2002, there were an estimated 930,000 new incident and 
700,000 mortalities from gastric cancer worldwide 
(3). Overall age-standardised incidence 
rates were 22.0 and 10.3 per 100,000 per year in males and females, respectively, with 
corresponding mortality rates being 14.3 and 8.3 per 100,000 
(3). Gastric cancer was the third Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
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most common cause of male cancer after cancers of lung and prostate and the second most 
common cause of male cancer death (after lung cancer). It was the fifth most common cause 
of female cancer (after cancers of breast, cervix, large bowel and lung cancers and the fourth 
most common cause of female cancer death 
(3). 
     There are remarkable geographic and ethnic variations in gastric cancer incidence in the 
world and in its trends for each population through time. The lowest rates have been reported 
from North America, Western Europe and North Africa and the highest in East Asia, South 
America and Eastern Europe (Fig 3.1). According to most recent edition of Cancer Incidence 
in Five Continents (vol IX) 
(4), reporting incidence rates from population-based cancer 
registries worldwide, some Japanese populations with an age-standardised rate as high as 80, 
still have a very high risk of gastric cancer. The incidence rates of gastric cancer in Gharbiah 
of Egypt (ASR: 3.3 in males and 2.0 in females) and Mumbai of India (4.6 in males and 2.3 in 
females) are  clear examples of low risk areas of North Africa and South Asia, respectively. 
The wide variation of gastric cancer incidence rate shows more than 15-fold difference 
between lowest and highest risk populations.  
      One feature of gastric cancer however, that is consistently observed in all populations 
(reflected in a comparison of rates by gender in Figure 3.1) is the approximately doubling of 
the age-standardised risk in males compared to females. In general, female incidence rates at 
a given age are equivalent to male rates at an age 10-15 years younger. The consistency of 
this difference has never been adequately explained 
(5). The male predominance of gastric 
and also oesophageal adenocarcinoma appears to be related to the different time of onset 
rather than the different rate of cancer development, and this topic has been investigated 
deeply in chapter 6 of this thesis.  
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Fig 3.1. Incidence rates of gastric cancer per 100,000 person-years for selected cancer 
registries world wide by sex. Data are presented in format of age-standardised rate by 
world standard population of all sites and cardia site in separate bars. Source: Cancer 
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3.1.2. Gastric Cancer; Cardia versus Non-Cardia 
     Despite the small size of cardia relative to the remaining parts of stomach, cancer of this 
area represents distinct etio-pathological features. Until recent decades, almost all 
epidemiological findings related to gastric cancer considered as a single entity. In fact, in 
1991, a novel observation reported that the incidences of adenocarcinomas of the 
oesophagus and the gastric cardia were increasing more rapidly than those of any other 
cancers in the United States. The observation repeated the same result in an updated report 
(6,7). Although the reliability of these reports was challenged after a decade by Corley et al 
(8) 
who showed that at least a part of the phenomenon could be explained by sub-site 
misclassification, the reports attract an increasing number of studies focused on distinctive 
pathogenesis of cardia cancer.  
     Currently, according to global cancer data, less than 10% of all gastric cancers are located 
in cardia, but there are very wide variations in reported proportions from different cancer 
registries. While, the incidence of gastric cancer is low in North America and Western 
European countries (Fig 3.1), the regions have showed much larger proportion of cardia 
cancer compared to other populations. Based on the most recent data from IARC 
(4), cardia 
cancer accounts for more than 54% of male gastric cancer cases in Montana, USA and the 
overall reported figures of the other populations of the same country are more than 30%.   In 
Europe, Denmark (43%), Switzerland and UK (overall more than 30%) have largest recorded 
proportion of cardia cancer. In contrast, in East Asia, Central and South America which have 
been recorded as high risk areas for gastric cancer, the proportion of cardia cancer is almost 
always less than 10%.  
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      In spite of considerable worldwide variations in proportion of cardia sub-site to all gastric 
cancers, the actual incidence rate of cardia cancer appears to have less disparity throughout  
different populations. The highest registry-based report from Europe was from Scotland with 
WASR (standardized with world population) of 4.2 and 1.4 in males and females, respectively. 
The overall incidence rate (WASR) of Cardia cancer in North America is less than 3.0 in 
males and 0.7 in females. Interestingly, while contribution of cardia cancer to the incidence 
rate of gastric cancer in Japan is considerably lower than in North American and European 
populations, the actual incidence rate of cardia cancer is similar or even higher than the latter 
populations. The highest population-based incidence rate of gastric cardia cancer was 
reported from China (Nangang), being 13.3 and 5.7 in males and females, respectively 
(4). 
 
3.1.3. Oesophageal Adenocarcinoma 
     Oesophageal cancer, comprising all histologic types, is the eighth most common cancer 
worldwide, responsible for 462,000 new cases in 2002 (4.2% of the total), and sixth most 
common cause of death from cancer with 386,000 deaths (5.7% of the total) 
(9). Worldwide, 
most oesophageal cancers are squamous cell carcinomas, arising in the middle and lower 
third of the oesophagus. Recently, there appears to be an increase in western countries in 
relative and absolute numbers of adenocarcinomas of the lower third of the oesophagus 
(10). 
Before the mid 1970s, the incidence of adenocarcinoma of the oesophagus seems to have 
represented less than 5% of all oesophageal cancers. Thereafter, the incidence of 
adenocarcinoma of the oesophagus has increased rapidly in the USA 
(11-14) and in the most 
parts of Europe 
(15-17), and is still rising 
(18, 19). This increasing trend cannot be explained by 
changes in the classification of the tumours located near or in the gastro-oesophageal 
junction (the tumours classified as oesophageal instead of cardia) because the increasing 
incidence is evident both in adenocarcinoma of the oesophagus and adenocarcinoma of the 
gastric cardia. The reasons for the increasing incidence are still unknown 
(19).  Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
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3.2. Histologic Classification of Gastric Adenocarcinoma 
     As there are marked differences in structure and differentiation, not only between separate 
carcinomas, but also within individual tumours of gastric cancer, several histological 
classifications have been used in the practical and academic medicine. This section will 
introduce each classification briefly and will discuss the Lauren classification and its 
implications in aetiology and the pathogenesis of gastric adenocarcinoma. 
 
3.2.1. The Lauren Classification 
     Lauren introduced the classification system in 1965. According to the original definition, 
gastric adenocarcinoma can be divided into three categories: intestinal, diffuse and mixed 
types 
(20). In general, intestinal type tumours have a glandular pattern usually accompanied by 
papillary formations or solid components. The glandular epithelium consists of large 
pleomorphic cells with large hyperchromatic nuclei often with numerous mitoses. They are 
usually fairly well polarized columnar cells, sometimes with a prominent brush border and 
goblet cells. Mucin secretion is variable and can be seen focally in the cytoplasm of scattered 
cells or extracellulrly in the lamina of neoplastic glands. By contrast, diffuse type 
adenocarcinomas are predominantly composed of poorly cohesive and widely infiltrating 
small tumour cells with indistinct cytoplasm and regular, only faintly hyperchromatic though 
often pyknotic nuclei without many mitoses. Gland formation is unremarkable, except 
sometimes in the superficial part of the tumour. Mucin secretion is common and extensive 
throughout the tumour. Signet ring cells are common, and there may be extracellular mucin in 
the stroma . Connective tissue proliferation is more marked and inflammatory cell infiltration 
less prominent than in intestinal cancers 
(20, 21). Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
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     In general, the mean age of patients with intestinal type tumours is higher than those with 
diffuse type 
(22-26). There is also a considerable gender-based difference in the incidence and 
age of the onset of intestinal type cancer. While the incidence of diffuse type adenocarcinoma 
is equal in males and females, intestinal type shows a significant male predominance 
(25-28).  
     The overall proportion of intestinal type is higher than that of diffuse type gastric cancer in 
most populations 
(20, 24), but this proportion varies with anatomical location of the tumour. In 
cardia and the proximal part of stomach, a great majority of adenocarcinomas are intestinal 
type, but in non-cardia cancer, this predominance is less significant 
(23, 26, 29).  
     The different carcinogenesis pathways leading to intestinal or diffuse type adenocarcinoma 
have received much more attention. The intestinal subtype of gastric adenocarcinoma arises 
due to the progression of chronic superficial gastritis to atrophic gastritis to intestinal 
metaplasia to dysplasia and finally cancer 
(30). The strong relationship of intestinal type 
adenocarcinoma with each step of this cascade, H.pylori infection, atrophic gastritis and 
intestinal metaplasia has been documented 
(31-37). The diffuse type has a similar association 
with H.pylori infection 
(31-33), but it represents little relationship with severe atrophic gastritis 
and intestinal metaplasia 
(34-37). Diffuse type gastric cancer is also seen in inherited gastric 
cancer due to germline E-cadherin mutation 
(38, 39).  
 
3.2.2. World Health Organization (WHO) Classification 
     This system categorizes gastric adenocarcinoma into four categories, namely papillary, 
mucinous, tubular, and signet ring cell type. Papillary adenocarcinoma is composed of 
pointed or blunt finger like epithelial processes with fibrous core. This tumour usually makes a 
polypoid mass into the lumen of the stomach. Tubular adenocarcinoma consists of branching 
glands embedded in, or surrounded by, a fibrous stroma. Mucinous carcinoma contains large 
amounts of extracellular mucin in more than 50% of the tumour. In some cases, the cells from 
glands are lined by columnar mucus-secreting mucosa. In others there are disaggregated Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
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clusters of cells which appear to be floating in lakes of mucin. Signet ring cell carcinomas do 
not form tubules. They are composed largely of mucin-secreting signet ring cells but also 
contain cells with no mucin and cells with eosinophilic granular cytoplasm containing neutral 
mucin. Tumours composed predominantly of signet ring cells are more common in younger 
patients and in the distal stomach 
(21, 40, 41). All of the above types, with the exception of signet 
ring cell carcinoma, may be graded as well, moderately or poorly differentiated 
(21). In spite of 
excellent reproducibility of the WHO classification, it has poor prognostic value in clinical 
practice compared to other classification systems 
(42-44). 
 
3.2.3. Other Classifications 
Ming Classification: This classification was introduced by Ming in 1977. This divides 
tumours into an expanding type (67%) and an infiltrative type (33%). In the expanding type, 
the tumour cells are surrounded by small amounts of fibrous tissue with a variable 
inflammatory response. It is very often accompanied by intestinal metaplasia in the adjacent 
mucosa. This compares roughly to the intestinal type of Lauren classification. The infiltrative 
type is ill-defined and contains widely infiltrative tumour cells with poor inflammatory cell 
response. Accompanying intestinal metaplasia is less common 
(45). Again, descriptive features 
of this type are very similar to the diffuse type in the Lauren classification. Therefore, this 
system appears to have no significant advantages to the original Lauren classification nor did 
it show any prognostic value 
(46, 47).  
 
Mulligan and Rember Classification: This classifies gastric adenocarcinoma into mucus cell 
type, intestinal type and pylorocardiac gland type. It is only the latter variant that distinguishes 
this classification from that of Lauren and, as the name suggests, it occurs predominantly in 
the cardia or pylorus. Pylorocardia carcinomas are well-demarcated oxophytic tumours, 
frequently with surface ulceration. These tumours are commoner in men and are Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
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characterized microscopically by varying-sized glands lined by stratified or singly oriented 
cylindrical cells that often show striking vacuolation or clear cell change and stain brilliantly 
with the periodic acid-Schiff reaction 
(21, 48). 
 
The Goseki Classification: This classification was introduced by Japanese pathologist, 
Goseki in 1992. It attempts to encompass undifferentiated carcinoma as well as the more 
common types. It is based on tumour histology and includes four grades, based on tubular 
differentiation and intracellular mucin production. Group I consists of well differentiated 
tubules with poor intracellular mucin production; group II consists of well differentiated tubules 
and plentiful intracellular mucin; group III has poorly differentiated tubules and poor 
intracellular mucin; and group IV tumours are made up of poorly differentiated tubules and 
plentiful intracellular mucin 
(49). 
 
The Carneiro Classification: Carneiro proposed a new classification in 1997 that is again 
based on four histological types. These includes glandular and isolated cell carcinomas that 
are roughly equivalent to the intestinal and diffuse carcinomas of the Lauren classification, a 
solid variety composed of sheets, trabeculae or islands of undifferentiated cells with no 
glandular formation, and a mixed type that consists of a mixture of glandular and isolated cell 
types. Glandular tumours were commonest in the Portuguese population studied, followed by 
mixed, solid and isolated cell types in descending order 
(21, 50).  
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3.3. Risk Factors of Gastric and Oesophageal Adenocarcinoma 
 
 
Development of gastric cancer is result of a multistage process which starts with a superficial 
non-atrophic gastritis. Except in a small number of cases, the progression of H.pylori-induced 
chronic gastritis to adenocarcinoma is the main carcinogenic pathway. Many environmental, 
endogenous and microbial factors are involved in this multifactorial process. Oesophageal 
adenocarcinoma also develops against an inflammatory background mainly induced by the 
gastroesophageal reflux of acid and bile. In this section, I will review briefly the most common 
risk factors of the upper gastrointestinal adenocarcinomas of gastric cardia, non-cardia and 
oesophagus. 
 
3.3.1. Helicobacter pylori Infection 
 
     After the discovery of H.pylori by Marshall and Warren in 1984 
(51), findings of the most of 
investigations introduced the bacterium as the main cause of chronic gastritis and peptic ulcer 
disease. Until 1988 there was no direct evidence of the involvement of H.pylori in gastric 
cancer 
(52). Now the relationship between gastric cancer and H.pylori infection is one of the 
most investigated area in medical literature with more than 2500 scientific paper indexed by 
Index Medicus. 
     The  association  of  H.pylori with gastric cancer has been evaluated extensively and I 
believe that summarising all of the published studies in this limited space is impossible, so a 
review of a few meta- analysis results may cover most of the high quality investigations. 
Huang et al 
(53) identified 19 qualified studies and reported a summary odds ratio for gastric 
cancer in all sub-sites of 1.9 (95% CI: 1.32 – 2.78) 
(54-72). Cancer of gastric cardia showed a 
weaker relationship with H.pylori than those on non-cardia location (1.23 vs. 3.08; P=0.003). Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
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As expected, association of early gastric cancer with H.pylori was more prominent than 
advanced tumours (6.35 vs. 2.13; P=0.01). 
     At the same time, Eslick et al reviewed 42 studies including most of publications covered 
by previous meta-analysis and found an overall odds ratio of 2.04 (95% CI: 1.69-2.45). This 
study showed no difference between the location of tumour and the power of association 
(73). 
     Early gastric cancer is considered as an early stage in the development of gastric cancer, 
and it seems to be more a reliable model for the assessment of relationship between gastric 
cancer and H.pylori infection. In a new meta-analysis conducted by Wang et al 
(74), they 
summarised results of 15 studies on early gastric cancer and showed that the prevalence of 
H.pylori infection was significantly higher in patients with early gastric cancer (87.3%) than in 
non-neoplasm controls (61.4%) (OR 3.38, 95% CI: 2.15–5.33) 
(75-89). In six studies the 
prevalence of H.pylori infection in early gastric cancer was significantly higher than in 
advanced gastric cancer (OR 2.13, 95% CI: 1.75–2.59) 
(75, 77, 78, 80, 86, 87). No significant 
difference in the prevalence of H.pylori infection was seen between the patients with intestinal 
type and those with diffuses type early gastric cancer 
(75, 78, 79, 71, 75, 88, 90-92). 
 
3.3.1.1. H.pylori Virulence and Gastric Cancer 
Although about half of the world’s adult population is infected with H. pylori, only a small 
minority develop gastric cancer. The results of a sophisticated study by Uemura et al showed 
that only 2.9% of 1246 H.pylori–infected patients developed gastric cancer after a mean 
endoscopic follow-up period of 7.8 years 
(93). Variation in many environmental and host 
factors and their interactions can explain the different outcomes, and the H.pylori strain 
variability may play a role. Carriage of strains with the cag pathogenicity island, a large 
chromosomal region that encodes virulence genes, including the cag A gene, is associated 
with an increased risk of the development of peptic ulcer disease as well as gastric 
precancerous lesions and gastric adenocarcinoma 
(94-97). A meta analysis by Huang et al Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
 
64
showed that among H.pylori infected populations, infection with cag A-positive strain further 
increased the risk of gastric cancer by 1.64 fold overall and 2.01 fold for non-cardia cancer. 
Gastric cardia cancer was not affected 
(98). In Asian populations, there in no consistency in the 
results of studies, while some previous authors found no association 
(99, 100), newer reports 
showed an increased risk of gastric cancer 
(101, 102). In addition, vac A- and bab A-positive 
H.pylori strains are also associated with an increased gastric cancer risk 
(103-105).  
 
 
3.3.2. Atrophic Gastritis and Intestinal Metaplasia in Gastric non-Cancer 
 
     Gastric atrophy was first recognized in 1870 in the post mortem samples of a patient with 
pernicious anaemia 
(106). Atrophic gastritis has been defined as the loss of specialized 
glandular tissue, including loss of the oxyntic glands containing parietal cells in the gastric 
corpus 
(107).  Also, intestinal metaplasia which is often associated with atrophic gastritis is 
defined as the replacement of original gastric glands with straight tubular crypts lined by 
absorptive and goblet cells similar to the mucosa of small intestine (complete) or colon 
(incomplete) and accompanied by inflammatory infiltrates in the lamina propria 
(108). Chronic 
atrophic gastritis, as an intermediate step of the carcinogenesis cascade of gastric cancer has 
showed a strong relationship with gastric adenocarcinoma, particularly intestinal subtype 
(109-
112). H.pylori infection induces superficial non-atrophic gastritis which progresses to atrophic 
gastritis with loss of acid secretion and then intestinal metaplasia to dysplasia and cancer.  A 
variety of bacterial, host and environmental factors are known to contribute to the progress 
through these different pre-cancerous stages 
(113).  Traditionally, the relationship between 
atrophic gastritis and gastric cancer has been defined for non-cardia cancer, but our recent 
studies showed that even adenocarcinomas located at the cardia region may demonstrate a 
relationship with atrophic gastritis, particularly those with least relationship with 
gastroesophageal reflux disease 
(114, 115).  Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
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     There is a considerable correlation between the geographic distributions of atrophic 
gastritis and of gastric cancer. Many studies have showed high prevalence of atrophic 
gastritis in high risk area for gastric cancer; i.e. Japan with a histologic detection rate of 
atrophic gastritis in 53%, Estonia, in up to 64% of studied population, in Finland 27 - 44%, and 
in Columbia with 45% in comparable age groups 
(116-120). In contrast, results of investigations 
using the same histologic methods for the diagnosis of atrophic gastritis in populations with 
low risk of cancer revealed much lower prevalence of this precancerous change, e.g. 28% in 
Sweden and 22% in Australia 
(121, 122). Cancer risk rises exponentially with grade and the 
extent of atrophic gastritis, and is found approximately 45 to 90-fold in patients with severe 
atrophic gastritis compared with the cancer risk in subjects with healthy stomach 
(111, 123). 
     Atrophic gastritis is generally present as either a multifocal or a diffuse pattern in gastric 
mucosa and usually is followed by and/ or associated with the appearance of metaplastic 
glands. A form of mucous metaplasia that has been termed pseudopyloric metaplasia, also 
known as spasmolytic polypeptide-expressing metaplasia (SPEM), is more strongly 
associated with gastric cancer than intestinal metaplasia and might be the precursor to the 
cancerous lesion 
(124, 125). The increased risk of cancer following SPEM has also been 
documented in some mouse model studies 
(126, 127). 
     The loss of normal mucosal glands leads to a failure in normal secretory functions of the 
gastric mucosa. Atrophy in the corpus results in low output of acid, whereas atrophy in the 
antrum results in impairments in the output of gastrin-17. In atrophic gastritis, the feedback 
loop controlling acid and pepsin secretions via the gastrin link is broken, resulting in varying 
degrees of hypochlorhydria, or even achlorhydria, and in hypo- or hypergastrinaemia, 
depending upon whether the antrum is atrophic or not 
(111). The histological grade of atrophic 
gastritis and the accompanied chronic gastritis of corpus mucosa have a strong negative 
correlation with acid output, and also with serum/plasma levels of pepsinogen I (or PG I/II 
ratio) as discussed in the previous chapter. Advanced atrophic corpus gastritis and loss of the Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
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feedback inhibition of antral G cells by low intragastric acidity result in hypergastrinaemia, and 
the gastrin-17 levels in serum may even be some hundreds of pmols per litre in some 
subjects if the antrum is normal. The associated metaplastic glands also can not secrete acid 
or gastrin-17 
(111). With the progression of atrophy, the metaplastic glands and epithelium may 
appear more and more immature, which is shown as a shift from IM of the complete (‘‘small-
bowel type’’) type to IM of immature and incomplete types (‘‘colon type’’). This shift is 
considered to reflect an increasing risk of cancer in atrophic gastritis 
(128). The hypochlorhydria 
or achlorhydria in the stomach allows colonization of bacteria other than H.pylori, some of 
which may produce mutagenic and carcinogenic substances 
(119, 129). 
 
3.3.3. Atrophic gastritis and Intestinal Metaplasia in Cardia Cancer 
 
     Carditis and intestinal metaplasia of cardia are rather common findings in routine practice 
and also in populations with high risk of gastric cancer 
(130, 131). Gerson et al found that 25% of 
asymptomatic subjects undergoing screening programme had evidence of intestinal 
metaplasia at the gastrooesophageal junction 
(132). This can be explained by the fact that this 
anatomical region is subject to damaging effects of both H.pylori infection and gastro-
oesophageal reflux. This chronic damage contributes to the metaplastic formation and 
extension of apparent cardia mucosa and is also likely to be key factor in the development of 
neoplasia at this site 
(133). 
     Association of atrophic gastritis with cardia cancer is a new topic and has received less 
attention in medical literature. In general, atrophic gastritis has not been defined for cardia 
mucosa; therefore most reported associations of cardia cancer with atrophic gastritis measure 
the presence and /or severity of atrophy in all gastric mucosa other than cardia.  
     Unlike the well recognized association of atrophic gastritis with non-cardia cancer, atrophic 
gastritis has a divergent relationship with cardia cancer. In our study on patients with cardia 
cancer from Norway which will be presented in next chapter, we found a significant negative Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
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association between H.pylori infection and cardia cancer. However, we found that in subjects 
who were H.pylori seropositive, their risk of cardia cancer was markedly increased if they also 
had evidence of atrophic gastritis 
(134). In another study, the nature of association of two types 
of cardia cancer with atrophic gastritis and gastroesophageal reflux disease was examined on 
cardia cancer patients from Iran. Cardia cancer was positively associated with both severe 
gastric atrophy and with frequent GORD symptoms, though the latter association was only 
apparent in the non-atrophic subgroup and in the intestinal subtype. The association of cardia 
cancer with atrophy was stronger for the diffuse versus intestinal subtype, and this was the 
converse of the association observed with non-cardia cancer 
(115). These findings indicate two 
distinct aetiologies of cardia cancer, one arising from severe atrophic gastritis and being of 
intestinal or diffuse subtype similar to non-cardia cancer, and another related to GORD and 
intestinal in subtype, similar to oesophageal adenocarcinoma.   
 
3.3.4. Smoking and Gastro-oesophageal Adenocarcinoma 
     According to recent IARC Monograph on Tobacco Smoke and Involuntary Smoking the 
results from both cohort and case -control studies are consistent with a causal role of tobacco 
smoking in the development of gastric cancer 
(135). In a large population-based cohort of 
669570 Korean men 
(136), yielding 127 cardia and 2409 non cardia cancer, a moderate 
association was found between smoking and cardia (RR: 2.2; 95% CI: 1.4-3.5) and non-
cardia cancers (RR: 1.4; 95% CI:1.3-1.6). In another large study in USA 
(137), current smokers 
were at increased risk of cardia cancer (HR: 2.9, 95% CI:1.7- 4.7) and gastric non-cardia 
cancer (HR: 2.0, 95% CI:1.3 - 3.2). In a study by Sjodahl et al in Norway, the risk of gastric 
cancer was almost twice as high in daily smokers (HR: 1.9, CI 95%: 1.3 -2.7) as in never 
smokers. Attributable risk (AR) of gastric cancer was 18.4% 
(138). This was similar to the 
results of European prospective study (EPIC) 
(139), with an estimated 17.6% of the risk of Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
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gastric cancer attributable to smoking and somewhat higher than the worldwide estimated 
11% attributable risk derived from a 1997 meta-analysis of smoking and stomach cancer 
(140). 
     With  regard  to  anatomic  subsite  of  gastric cancer and smoking, there is considerable 
discrepancy in reported associations. While many studies found a significant increase in the 
risk of cardia cancer 
(141-146), other studies observed a significant increase in the risk of non-
cardia cancer 
(147-151). Results of a pooled analysis of two large prospective studies from 
Japan 
(152) and also our study on Iranian patients revealed no association of smoking with 
gastric cardia cancer 
(115). 
     There have been controversial results regarding the role of tobacco smoking as a risk 
factor for oesophageal adenocarcinoma.  While there is some evidence of the lack of 
significant association between oesophageal adenocarcinoma and smoking 
(115, 144, 153), other 
studies suggest weak to intermediate associations. A case-control study nested in General 
Practitioner Research Database in the UK by Lindblad et al showed a weak association (OR= 
1.5, 95% CI: 1.1 – 2.0) between current smoking and oesophageal adenocarcinoma 
(154). Two 
large population-based studies also revealed weak to moderate increased risk of 
oesophageal adenocarcinoma by smoking 
(143, 155). This result has been supported recently by 
two case–control studies with considerable association between oesophageal 
adenocarcinoma and current smoking 
(137, 156). 
 
 
3.3.5. Gastroesophageal Reflux Disease (GORD) 
 
3.3.5.1. GORD and Oesophageal Adenocarcinoma 
     Gastroesophageal reflux disease is the well-established risk factor of oesophageal 
adenocarcinoma. One of the best pieces of evidence of the association of GORD symptoms 
with oesophageal adenocarcinoma was introduced by Lagergren et al in 1999 
(157). They 
showed that among persons with recurrent symptoms of reflux, as compared with persons Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
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without such symptoms, the odds ratio was 7.7 (95% CI, 5.3 -11.4) for oesophageal 
adenocarcinoma. There was also significant positive correlation between the frequency, 
severity, and duration of reflux symptoms and the risk of cancer. Among persons with long-
standing and severe symptoms of reflux, the odds ratios was 43.5 (95% CI: 18.3 - 103.5) for 
oesophageal adenocarcinoma. This study was preceded by one study 
(158) and followed by 
many other studies supporting the strong association of reflux symptoms with increased risk 
of cancer 
(159-161). Two of these studies found that both frequent GORD symptoms and a 
history of hiatus hernia were associated with increased risk for oesophageal adenocarcinoma 
(159, 160). 
     Barrett’s oesophagus or columnar-lined metaplasia of oesophagus is a consequence of 
long-term GORD. Barrett’s oesophagus is a precancerous lesion of oesophageal 
adenocarcinoma 
(162). Although it is not completely established that Barrett’s oesophagus is 
an obligatory step in the development of cancer, there is common belief that it is an 
intermediate stage between GORD and adenocarcinoma 
(163). The cancer risk in patients with 
Barrett’s oesophagus is much higher than those without it. In a recent large prospective study, 
the incidence of oesophageal adenocarcinoma in patients with Barrett’s oesophagus who 
were under surveillance endoscopy was 1/220 patient–years follow up, equal to 0.45% per 
year 
(164). This rate is obviously higher than 0.023% correspondent expected rate in patients 
with GORD 
(161). In large sample-sized studies, the excess risk of oesophageal 
adenocarcinoma in patients with Barrett’s has been estimated to be 30 to 60-fold relative to 
the risk of the general population 
(165-168).   
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3.3.5.2. GORD and Cardia Cancer 
 
     Surprisingly the association of gastric cardia cancer with GORD appears to be a topic of 
review articles rather than original researches. Review of a few available studies showed that 
unlike the oesophageal adenocarcinoma which represents a strong relationship with GORD, 
in the case of cardia cancer, this relationship is less marked 
(157, 169, 170) or even null 
(171).   
    A proportion of adenocarcinomas arising at the cardia may have a similar aetiology and 
pathogenesis to oesophageal adenocarcinoma. This could arise if only the most distal part of 
the oesophageal squamous mucosa is subject to chronic exposure to gastric juice. In all of 
the above mentioned studies, the association of cardia cancer with GORD is much weaker 
than that between reflux and oesophageal adenocarcinoma. This would therefore suggest 
that only a relatively small proportion of cardia cancers might be attributed to gastro-
oesophageal reflux. However, recent studies have demonstrated that the most distal 
oesophageal mucosa is frequently exposed to acidic gastric juice in healthy volunteers 
without reflux symptoms 
(172). This phenomenon has been referred to as short-segment reflux 
and it appears to be due to the opening of the distal oesophageal sphincter allowing the 
gastric acid to reach the first millimetre or two of the oesophageal squamous mucosa but not 
allowing the acid to reflux past the sphincter into the main body of the oesophagus. The 
proportion of cardia cancers arising from this short-segment reflux may therefore be 
substantially higher than the association between these cancers and symptoms of reflux 
would suggest. In our study, which will be presented in chapter 5 of this thesis, we showed 
that cardia cancer was positively associated with both severe gastric atrophy [OR, 95% CI: 
3.92 (1.77 to 8.67)] and with frequent GORD symptoms [OR, 95% CI: 10.08 (2.29 to 44.36)] 
although the latter was only apparent in the non-atrophic subgroup and in the intestinal 
subtype. The association of cardia cancer with atrophy was stronger for the diffuse versus 
intestinal subtype, and this was the converse of the association observed with non-cardia Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
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cancer. These findings indicate two distinct aetiologies of cardia cancer, one arising from 
severe atrophic gastritis and being of intestinal or diffuse subtype similar to non-cardia cancer, 
and another related to GORD and intestinal in subtype, similar to oesophageal 
adenocarcinoma 
(115).  
 
 
3.3.5. Male Gender 
 
     A remarkable and unexplained characteristic of upper gastrointestinal adenocarcinoma is 
its male predominance.  The higher incidence of these cancers in males has been observed 
in all parts of the world 
(3). 
     The  male  predominance  of  gastric  cancer is related to the histological subtype of the 
tumour.  Gastric adenocarcinoma may be of the intestinal or diffuse histological subtype as 
described by Lauren 
(20). The gender phenomenon is more marked in gastric cancer of the 
intestinal versus diffuse histological subtype and this has been described well by Sipponen 
and colleagues 
(173).  
     Oesophageal  adenocarcinoma  also  demonstrates a marked male predominance and 
tends to present at a younger age in males 
(174).  
     Global  data  from  cancer  registries suggests that the male predominance of upper 
gastrointestinal cancer is related to the anatomical location, which is higher for 
adenocarcinoma of the oesophagus and lower for adenocarcinoma of the distal stomach 
(175). 
The male to female ratio of age-standardised incidence rates for oesophageal 
adenocarcinoma in Scotland is 4.5:1, for adenocarcinoma of the gastric cardia or gastro-
oesophageal junction is 3.5:1 and for non-cardia cancer it is 2.0:1 
(176). However, the 
proportion of the intestinal subtype differs according to the anatomical site and it was unclear 
whether it is the anatomical site, or the histological subtype which is associated with the male 
gender predominance. In chapter 6, we will present results of our population-based study 
conducted on a randomised sample of all incident adenocarcinoma of the gastric cardia, non-Chapter 3: Gastrointestinal Cancer, Epidemiology & Risk Factors 
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cardia and oesophagus, 1998-2002 of West of Scotland. Our findings indicate that the 
intestinal subtype has the greatest impact on the gender ratio, and this is unrelated to whether 
the carcinoma has developed in the oesophagus or distal stomach.  Our study also indicates 
that the gender phenomenon is due to the development of the intestinal subtype of cancer 
being delayed by 17 years in females.  
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4.1. INTRODUCTION 
 
 
     Several observations indicate that cancers of the cardia region of the stomach are 
etiologically different from those of the rest of the stomach.  Cancers of the mid and 
distal stomach (non-cardia cancers) show a strong positive association with H.pylori 
infection whereas cardia cancer has been reported to have negative, positive or no 
association with H.pylori infection
  (1).  The incidence time trends of cardia and non-
cardia cancer also differ with the latter falling while the former is remaining static or 
increasing
 (2-5).   
     Substantial advance has been made in our understanding of the aetiology of non-
cardia cancer and, in particular, of the role of H.pylori infection.  The highest risk of 
non-cardia cancer is in subjects in whom the infection has induced atrophic gastritis 
and low or absent acid secretion 
(6). Non-cardia cancer is considered to be the result 
of progression from H.pylori  superficial gastritis to atrophic gastritis and 
hypochlorhydria to dysplasia and finally to cancer 
(7). 
     The aetiology of cancer of the gastric cardia region remains poorly understood.  
One reason for this may be the anatomical complexity of the cardia.  Cardia mucosa Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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extends from the oxyntic mucosa of the body of the stomach to the squamous mucosa 
of the distal oesophagus.  It consists of columnar mucosa resembling that of the 
gastric antrum.  In neonates the cardia mucosa is only a few millimetres in length
 (8).  
In adults, the cardia mucosa may be larger and this expansion may occur by 
metaplasia of the adjacent mucosa into cardia-like mucosa 
(9-12).  Proximal extension 
of cardia mucosa can occur by metaplastic transformation of the squamous mucosa of 
the distal oesophagus – a phenomenon that may be induced by acidic gastro-
oesophageal reflux.  Distal extension of cardia mucosa may arise from atrophic 
gastritis of oxyntic mucosa with loss of specialized cells and most commonly induced 
by H.pylori infection 
(9, 13).  When patients present with adenocarcinoma involving the 
gastric cardia, it is usually impossible to determine
 whether the tumour has arisen 
from metaplasia of the distal oesophageal squamous epithelium, from metaplasia of 
gastric oxyntic mucosa or from original cardia mucosa. 
    In a large nested case-control study in the Norwegian population, we observed that 
H.pylori infection was associated with an increased risk of non-cardia cancer but with 
a reduced risk of cardia cancer 
(14).  The current study was undertaken to compare 
cancers at those two sites with respect to premorbid gastric mucosal atrophy and acid 
secretion.   
 
 
AIM 
     The aim of this study was to examine the relationship between the state of the 
gastric mucosa and the risk of subsequently developing cardia versus non-cardia 
gastric cancer. Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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4.2. MATERIALS AND METHODS 
 
4.2.1. Study Setting 
 
          This was a nested case-control study.  It comprised 101,601 men and women 
enrolled in the Norwegian JANUS
 (15) cohort as blood donors in Oslo 1973-1986, as 
participants in the Oslo Study of Cardiovascular Disease 1972-1973
(17), and as 
participants in the Norwegian Counties Study 1974-1978 carried out by the National 
Health Screening Service in the three counties Oppland, Sogn og Fjordane, and 
Finnmark
  (17,18).  All solid gastric cancers diagnosed among the cohort members 
through 1992 were identified in The Cancer Registry of Norway.  Cases were limited 
to individuals with available historical serum from whom primary tumour tissue could 
be verified as gastric adenocarcinoma with unequivocal non-cardia or cardia origin.  
Of 230 identified gastric cancer cases, fifty-seven were excluded from the study 
because of no remaining or wasted serum (7), no tissue (2) or metastatic tumour 
tissue only (10) available for histologic examination, histological type diagnosed or 
suspected to be other than adenocarcinoma (6), doubt about the stomach being the 
primary site of the tumour (2), gastric resection prior to cancer diagnosis (16), or 
disseminated tumour growth precluding determination of cardia/non-cardia subsite 
origin (14).  To each cancer case, controls were matched according to gender, date of 
birth (within 54 months, 97% within 12 months, median deviation 3 months), date of 
serum sampling (within 17 months, 99% within 12 months, median deviation 3 
months) , and serum source (blood donors, the Oslo Study of Cardiovascular 
Disease, or county within Norwegian Counties Study).  Three controls were matched 
to 162 cases, and two controls were matched to 11 cases.   
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4.2.2. Cancer Subsites and Subtypes 
          The gastric adenocarcinoma cases were subsite classified as tumours of the 
cardia, fundus, body, antrum, or pylorus in accordance with ICD-O2 
(19) after review of 
all clinical, biopsy, and resection reports submitted to the Cancer Registry.  When 
needed, endoscopy and radiology reports were consulted.  Cardia cancers were 
defined as tumours whose centre was judged to be within 2cm distal to the gastro-
oesophageal junction.  Adenocarcinomas largely or entirely located within the distal 
oesophagus were excluded.  All adenocarcinoma diagnoses were verified on new 
pathology slides of biopsy or resection specimens and subtype classified according to 
Laurén 
(20) as intestinal, diffuse, or other. The other subgroup closely corresponds to 
mixed in newer terminology 
(21). Five cases were subtype-unclassifiable due to 
insufficient biopsy size. 
      
4.2.3. Serologic Tests 
     Serum had been collected from each cohort member at start of follow-up and 
thereafter kept frozen at –25
oC. Time elapsed between last meal and serum sampling 
was categorised as <1hour, 1-2 hours, 2-4 hours, 4-8 hours, and >8 hours.  Serum 
anti-H.pylori  IgG antibody concentration (average of two readings) was measured 
using the Pyloriset
TM EIA-G  test kit (Orion Diagnostica, Espoo, Finland).  For 
detection of current or previous H.pylori infection (ever infection), we chose a cut-off of 
250 U/l, which is lower than the cut-off of 500 U/l recommended by the manufacturer 
for detection of current infection
 (14).  The results of the H.pylori serology have been 
previously published 
(14).  Serum gastrin concentration was measured using antibody 
R98 which detects both Gastrin 17 and Gastrin 34
(22).  Serum pepsinogen I and 
pepsinogen II concentrations were measured using radioimmunoassay kits (Sorin 
Biomedica Diagnostics, Saluggia, Italy).     Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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     We validated the ability of serum pepsinogen I to pepsinogen II ratio (PGI/II) to 
detect atrophy.  This was performed using stored serum from 175 H.pylori positive 
patients with non-ulcer dyspepsia who had undergone endoscopy with antral and 
body biopsies.  Atrophy of body and antrum was graded as absent, mild, moderate or 
severe according to updated Sydney classification of gastritis 
(23).  Low PG I/II was 
valuable in detecting atrophy involving the gastric body.  At cut off point = 2.5, 
sensitivity and specificity of PG I/II was 71% and 67%, respectively for body atrophy of 
any severity.  The area under the ROC curve was 0.84 (95% CI: 0.69-0.99) for body 
atrophy of any severity.  The median (± interquartile range) of PG I/II in patients with 
none, mild, moderate and severe atrophy was 5.93 (± 3.5), 4.73 (± 3.9), 3.11 (±3.5) 
and 1.85 (± 0.7) respectively.  The non-parametric test showed that values of PG I/II 
in patients with moderate (p<0.05) and severe (p<0.01) atrophy were significantly 
lower than those without atrophy.   
 
4.2.4. Statistical Analyses 
      Relative risks of cancer between groups of H.pylori serostatus, PG I/II and gastrin 
concentrations were estimated as odds ratios (ORs) with associated 95% confidence 
intervals (CIs) using conditional logistic regression 
(24).  By exploiting the algorithmic 
equivalence of proportional hazards regression and conditional logistic regression, 
asymptotic odds ratios were computed using the Cox module of the SPSS statistical 
computer software package with each matched set as a separate stratum 
(25). For 
separate analyses of H.pylori  seropositive and H.pylori  seronegative cases and 
controls, we used unconditional logistic regression with adjustment for the matching 
variables in the original study design. Unconditional logistic regression produced 
estimates very similar to comparable conditional regression analyses. Tests of 
contrasts in odds ratios between subgroups of subjects were performed by including 
an interaction term in the statistical model.  For tests of linear trend, the categorized Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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variable was treated as a continuous variable, and for tests of homogeneity the 
variable was represented with indicator variables. Two-sided p values <0.05 were 
considered statistically significant. 
   
4.3. RESULTS  
          We studied 131 (76%) male and 42 (24%) female cases with 390 and 118 
matched controls, respectively. In the non-cardia subsites, there were 91 male and 38 
female cases. In the cardia, male predominance was much more pronounced with 40 
male vs. 4 female cases. Serum sampling took place between 1972 and 1986 with 
98% of the samples collected between 1972 and 1977. Median age at serum 
sampling was 45.6 (range 23.6-63.4) years and median follow-up time to cancer 
diagnosis was 11.9 (range 0.3-20.3) years in the cases. Median age at cardia cancer 
diagnosis was 57.5 (range 43.6-63.3) years, and median age at non-cardia cancer 
diagnosis was 55.8 (range 34.3-68.2) years.    The time span over which the serum 
samples were obtained preceded the introduction of proton pump inhibitor medication 
to Norway. 
     As previously reported, the association between H.pylori seropositivity and cancer 
was highly dependent upon the gastric subsite
 (14) (Table 4.1). H.pylori seropositivity 
was found in 90% (116/129) of the non-cardia cases and in 43% (19/44) of the cardia 
cases, as compared to 66% (247/376) and 71% (93/132) in the respective control 
groups. There was a negative association between the infection and cancer of the 
cardia (OR 0.27, 95% CI 0.12-0.59). This contrasted with the positive association in 
the non-cardia subsites collectively (OR 4.75, 95% CI 2.56-8.81) (p<0.0005).  The 
odds ratio in the antrum and pylorus combined (OR 7.95, 95% CI 3.07-20.6) was non-
significantly higher (p=0.09) than in the fundus and body combined (OR 2.67, 95% CI 
1.14-6.25).    
 
 
 
 
 
Table 4.1: Risk of gastric adenocarcinoma (estimated by odds ratio with associated 95% confidence interval) for H. pylori serostaus, quintiles of serum 
pepsinogen I/II and quintiles of serum gastrin concentration according to different gastric subsites and adenocarcinoma subtypes. 
 
      Cardia Non-cardia  overall Non-cardia, intestinal  Non-cardia, diffuse  Non-cardia, mixed 
Risk factor  [44 cases, 132 controls]  [129 cases, 376 controls]¤  [59cases, 173 controls]  [35 cases, 100 controls]  [31cases, 91 controls] 
         
H. pylori serostatus            
  Negative   1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference) 
  Positive   0.27 (0.12-0.59)  4.75 (2.56-8.81)  3.96 (1.69-9.27)  3.90 (1.11-13.7)  5.51 (1.52-20.0) 
p-value    0.001 <0.0005 0.002 0.034  0.010 
         
Serum pepsinogen I/II quintiles           
 5
th: 6.060 – 30.973   1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference) 
 4
th: 4.803 – 6.055   0.24 (0.07-0.75)  1.21 (0.48-3.05)  1.07 (0.30-3.74)  0.31 (0.03-3.33)  4.35 (0.44-43.4) 
 3
rd: 3.777 – 4.795   0.68 (0.27-1.74)  2.49 (1.07-5.78)  1.50 (0.47-4.82)  2.02 (0.46-8.86)  13.4 (1.20-150) 
 2
nd: 2.691 – 3.774   0.14 (0.03-0.71)  5.35 (2.35-12.2)  2.96 (0.94-9.29)  7.82 (1.87-32.6)  14.6 (1.35-157) 
 1
st: 0.323 – 2.688   0.78 (0.26-2.39)  11.6 (4.91-27.5)  12.5 (3.57-43.9)  6.29 (1.45-27.3)  24.9 (2.28-272) 
p-value for trend  0.391  <0.0005  <0.0005  <0.0005  0.002 
         
Serum  gastrin quintiles            
 1
st: 2-20 ng/L  1.0 (reference)  1.0 (reference)  1.0 (reference)  1.0 (reference)  1.0 (reference) 
 2
nd: 25-30 ng/L  1.25 (0.44-3.55)  1.99 (0.82-4.83)  1.56 (0.44-5.52)  8.19 (0.80-84.2)  1.75 (0.30-10.2) 
 3
rd: 35-55 ng/L  1.58 (0.58-4.28)  2.45 (1.13-5.35)  1.82 (0.59-5.58)  10.6 (1.13-99.0)  1.66 (0.37-7.41) 
 4
th: 60-90 ng/L  0.71 (0.19-2.66)  3.82 (1.77-8.23)  3.66 (1.23-10.9)  8.42 (0.97-73.2)  3.44 (0.82-14.5) 
 5
th: 95-462ng/L  1.63 (0.48-5.48)  8.99 (3.96-20.4)  12.8 (3.83-42.6)  21.8 (2.29-208)  3.68 (0.77-17.7) 
p-value for trend  0.702  <0.0005  <0.0005  0.007  0.042 
¤ Including four histologically unclassifiable cases and 12 corresponding controls Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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4.3.1. SERUM PEPSINOGEN I / II 
     The individual PG I/II results are presented in Fig. 4.1.  In non-cardia subsites 
collectively, there was a strong association between the PG I/II and subsequent 
development of cancer. The risk of non-cardia cancer increased monotonously with 
decreasing quintiles of PG I/II (Table 4.1).  A PG I/II below 2.69 (lowest quintile) 
conferred an overall 11.6 (95% CI: 4.91-27.5) times higher non-cardia cancer risk than 
a ratio above 6.06 (highest quintile) (p for trend over quintiles <0.0005).  The 
associations were similar for the proximal and distal non-cardia subsites (data not 
shown). With PG I/II values dichotomized, PG I/II <2.5 were associated with a 4.47 
(95% CI: 2.71-7.37) times higher risk of non-cardia cancer than PG I/II >2.5 (Table 
4.2). A statistically significant association between low PG I/II and non-cardia cancer 
was found in both H.pylori positive and negative subjects when analyzed separately 
(Table 4.2).  
     In the cardia, quintiles of PG I/II showed no linear association with cancer risk (p 
for trend=0.391) (Table 4.1).  However, when PG I/II was dichotomized and H.pylori 
seropositive cases and controls were analyzed separately, an association between 
atrophy and cardia cancer appeared. H.pylori positive individuals with a PG I/II <2.5 
had a 3.33 (95% CI: 1.06-10.5) times higher risk of developing cardia cancer relative 
to subjects with PG I/II >2.5 (Table 4.2).   There were no H.pylori negative cases or 
controls with PG I/II < 2.5 precluding an analogous analysis of H.pylori negative 
subjects.      
      
 
 
 
  
 
 
 
Table 4.2: Risk of adenocarcinoma (estimated by odds ratio with associated 95% confidence interval in an unconditional logistic regression model with 
adjustment for the matching variables in the original study design) for serum pepsinogen I/II <2.5 (relative to serum pepsinogen I/II >2.5) and serum gastrin 
concentration ≥60 ng/L (relative to serum gastrin concentration <60 ng/L) according to gastric subsites and H. pylori serostatus. 
 
H. pylori serostatus  Overall  Seropositive  Seronegative 
Gastric subsite       
 Risk  factor      
      
Non-cardia  [129 cases, 376 controls]  [116 cases, 247 controls]  [13 cases, 129 controls] 
      
  Pepsinogen I/II >2.5  1.00 (reference)  1.00 (reference)  1.00 (reference) 
  Pepsinogen I/II <2.5  4.47 (2.71-7.37)  3.45 (2.01-5.91)  12.6 (2.25-70.7)¤ 
 p-value  <0.0005  <0.0005  0.004 
      
  Gastrin <60 ng/L  1.00 (reference)  1.00 (reference)  1.00 (reference) 
 Gastrin  ≥60 ng/L  3.18 (2.03-4.99)  2.77 (1.69-4.54)  3.05 (0.71-13.1) 
 p-value  <0.0005  <0.0005  0.133 
      
Cardia  [44 cases, 132 controls]  [19 cases, 93 controls]  [25 cases, 39 controls] 
      
  Pepsinogen I/II >2.5  1.00 (reference)  1.00 (reference)  1.00 (reference) 
  Pepsinogen I/II <2.5  1.60 (0.62-4.14)  3.33 (1.06-10.5)  a 
 p-value  0.333  0.039   
      
          Gastrin <60 ng/L  1.00 (reference)  1.00 (reference)  1.00 (reference) 
          Gastrin ≥60 ng/L  0.88 (0.37-2.06)  2.23 (0.63-7.87)  0.38 (0.05-3.03) 
               p-value  0.761  0.213  0.362 
a There were no H.  pylori seronegative cardia cases or controls with pepsinogen I/II <2.5 
¤ Unconditional logistic regression analysis without adjustment for the matching variables (only three cases with pepsinogen I/II <2.5 precluded adjustment) Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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4.3.2. SERUM GASTRIN 
            The individual serum gastrin results are presented in Fig. 4.2.  In non-cardia 
subsites collectively, a monotonously increasing risk with increasing serum gastrin 
quintiles was observed, the risk being 8.99 (95% CI: 3.96-20.4) times higher for 
gastrin values ≥95 ng/L than for values ≤20 ng/L (Table 4.1). The pattern was similar 
in proximal and distal non-cardia subsites, with ORs tending to be somewhat higher in 
the distal subsites (data not shown). Length of time between last meal and serum 
sampling was known for 120 (93%) of these the non-cardia cases and 352 (95%) of 
corresponding controls. In this subgroup of subjects the association between serum 
gastrin concentration and cancer was estimated before and after adjustment for time 
since last meal. Overall, the adjustment did not materially alter the point estimates for 
cardia or non-cardia subsites.  However, the adjustment increased the odds ratios in 
the distal non-cardia subsites by approximately 30% within each of the serum gastrin 
concentration quintiles.  In an unconditional logistic regression model with adjustment 
for the variables used for matching in the study design, dichotomizing serum gastrin 
values at  ≥60 ng/L was most discriminating, conferring a 3.18 (95% CI: 2.03-4.99) 
times increased risk of non-cardia cancer relative to gastrin concentrations <60 ng/L. 
This association was apparent and of the same order of magnitude in H.pylori positive 
(OR 2.77, 95% CI: 1.69 – 4.54) and H.pylori negative (OR 3.05, 95% CI: 0.71 – 13.1) 
individuals analyzed separately (Table 4.2).  
      In the cardia, there was no linear association between serum gastrin concentration 
tertiles (p for trend 1.00), quartiles (p for trend 0.41), or quintiles (p for trend 0.70) 
(Table 1) and later development of cancer, nor did gastrin dichotomized at various 
cut-off values show any association with cardia cancer. However, separate analyses 
for H.pylori positive and H.pylori negative cases and controls suggested associations Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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going in opposite directions. In an unconditional logistic regression model, 
hypergastrinaemia (cut-off at 60 ng/L) was positively associated with cardia cancer in 
H.pylori seropositive persons (OR 2.23, 95% CI: 0.63-7.87) but negatively associated 
in H.pylori seronegative persons (OR 0.38, 95% CI (0.05-3.03), a test for homogeneity 
between ORs gave p=0.093). Adjustment for time since last meal did not weaken the 
associations in the subset of subjects for whom this information was available. 
 
4.3.3. HISTOLOGICAL SUBTYPES 
 
          The cardia and non-cardia cancers had different distributions of histological 
subtypes.  Of the 129 non-cardia cancers, 59 (46%) were intestinal, 35 (27%) diffuse 
and 31 (24%) mixed and 4 (3%) of unclassifiable histological subtype.  In contrast, the 
44 cardia cancers comprised 31 (71%) intestinal, 7 (16%) diffuse, 5 (11%) mixed, and 
1 (2%) unclassifiable histological subtypes.  The proportion of intestinal to diffuse 
subtype was significantly higher in the cardia versus non-cardia subsite (p<0.05). 
          In the non-cardia region the risk of each of the three histological subtypes 
increased similarly with decreasing quintiles of PG I/II and increasing quintiles of 
serum gastrin (Table 4.1). 
     In the cardia, however, the different adenocarcinoma subtypes showed different 
associations with both PG I/II and gastrin. For these analyses, the variables were 
dichotomized because of the limited number of cardia cancers and controls. And for 
comparison, analogous analyses based on dichotomized variables were done for the 
non-cardia subsites (Table 4.3).  PG I/II <2.5 (relative to PG I/II >2.5) was associated 
with an increased risk of the diffuse subtype at both non-cardia (OR 3.21, 95% CI: 
1.27-8.13) and cardia subsites (OR 3.46, 95% CI: 0.32-37.5).  Similarly, there was an 
association between serum gastrin ≥60 ng/L (relative to serum gastrin <60 ng/L) and 
the diffuse subtype in both the non-cardia (OR 2.11, 95% CI: 0.92-4.86) and the Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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cardia (OR 5.30, 95% CI: 0.52-54.6). With respect to the intestinal subtype, both low 
PG I/II and high serum gastrin showed disparate effects between the two subsites. 
Low PG I/II was positively associated with the intestinal subtype at non-cardia sites 
(OR=6.68, 95% CI: 2.79-16.0), but not at the cardia (OR=0.72, 95% CI: 0.19-2.79) 
(Table 4.3). The contrast in ORs was statistically highly significant (p=0.007).   
Likewise, hypergastrinaemia was positively associated with the intestinal subtype in 
non-cardia subsites (OR 4.04, 95% CI: 2.05-7.96), but not at the cardia (OR 0.59, 
95% CI 0.22-1.58), (Table 4.3).  This difference in ORs was statistically highly 
significant (p=0.002). 
     The eight cardia cancers occurring in atrophic (PG I/II <2.5) stomachs were all 
H.pylori positive (Table 4.4).  Three of these cancers were of intestinal, three were of 
diffuse and two were of mixed histological subtype, and this distribution of histological 
subtypes was similar to that of the H.pylori positive non-cardia cancers.   The 36 
cardia cancers occurring in non-atrophic (PG I/II >2.5) stomachs were predominantly  
H.pylori  negative (69%) and had a distribution of histological subtypes which was 
different from the non-cardia cancers, the intestinal subtype being more prevalent in 
the cardia (78%) than in the non-cardia (46%). 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 4.3: Risk of adenocarcinoma (estimated by odds ratio with associated 95% confidence interval) for serum pepsinogen I/II <2.5 (relative to serum 
pepsinogen I/II >2.5) and serum gastrin concentration ≥60 ng/L (relative to serum gastrin concentration <60 ng/L) according to gastric subsites and 
adenocarcinoma subtypes. 
 
Histology        Overall¤ Intestinal Diffuse  Mixed
Gastric subsite         
 Risk  factor        
        
Non-cardia  [129 cases, 376 controls]  [59 cases, 173 controls]  [35 cases, 100 controls]  [31 cases, 91 controls] 
         
  Pepsinogen I/II >2.5  1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference) 
  Pepsinogen I/II <2.5  4.32 (2.58-7.24)  6.68 (2.79-16.0)  3.21 (1.27-8.13)  2.32 (0.86-6.25) 
 p-value  <0.0005    <0.0005 0.014  0.097 
        
  Gastrin <60 ng/L  1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference) 
 Gastrin  ≥60 ng/L  2.97 (1.92-4.61)  4.04 (2.05-7.96)  2.11 (0.92-4.86)  2.40 (1.06-5.44) 
 p-value  <0.0005    <0.0005 0.079  0.036 
        
Cardia  [44 cases, 132 controls]  [31 cases, 93 controls]  [7 cases, 21 controls]  [5 cases, 15 controls] 
        
  Pepsinogen I/II >2.5  1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference) 
  Pepsinogen I/II <2.5  1.56 (0.60-4.09)  0.72 (0.19-2.79)  3.46 (0.32-37.5)  - 
 p-value  0.365 0.632  0.307   
        
          Gastrin <60 ng/L  1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference) 
          Gastrin ≥60 ng/L  0.85 (0.38-1.88)  0.59 (0.22-1.58)  5.30 (0.52-54.6)  0.69 (0.06-8.04) 
               p-value  0.689 0.295  0.161  0.764 
¤ Including four histologically unclassifiable cases and 12 corresponding controls  
 
 
 
 
 
 
 
 
 
Table 4.4: Pictorial representation of two main subgroups of cardia cancer based upon premorbid gastric mucosal atrophy and  
                 H. pylori status and histological subtype of tumour (numerals indicate numbers of cases in the respective groups). 
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Fig 4.1: Pepsinogen I/II  in cancer patients and their controls by subsite and H. pylori 
status  
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Fig 4.2: Serum gastrin in cancer patients and their controls by subsite and H. pylori 
status Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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4.4. DISCUSSION 
          This study demonstrates the association between the premorbid state of the 
gastric mucosa and the location and histological subtypes of gastric adenocarcinoma 
presenting over subsequent years.  Cancers of the mid and distal stomach of all 
histological subtypes were positively associated with H.pylori infection, atrophy and 
hypochlorhydria.  Cardia cancer was more complex; it was negatively associated with 
H.pylori infection and the predominant intestinal subtype of cardia cancer was not 
associated with gastric atrophy. However, in subjects with H.pylori infection cardia 
cancer was positively associated with atrophy and hypochlorhydria.  These findings 
can be explained by cardia cancer being of two distinct aetiologies, some cases being 
similar to non-cardia cancer and others having a different aetiology. 
     The findings with non-cardia cancer are consistent with current wisdom that its 
development is a multistage process 
(7).  H.pylori infection induces superficial gastritis 
which progresses to atrophic gastritis with loss of acid secretion and then to dysplasia 
and cancer.  A variety of bacterial, host and environmental factors are known to 
contribute to the progress through these different pre-cancerous stages 
(26).   
     The multistage process of non-cardia cancer development has been traditionally 
more strongly linked to the development of the intestinal histological subtype of cancer 
as the diffuse type may develop in subjects with normal gastric mucosa
  (27). In the 
latter cases, there is often a strong hereditary predisposition with inherited germ-line Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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mutations
 (28).  Our current study, however, along with that of Uemura et al indicates 
that atrophy and hypochlorhydria are associated with increased risk of the diffuse and 
mixed histological subtypes as well as intestinal gastric cancer 
(6).   
       The association between atrophy and non-cardia cancer was apparent in both the 
H.pylori seropositive and seronegative subjects, the association being statistically non 
significantly stronger in the H.pylori seronegative ones.  H.pylori seronegativity may in 
(some of) these individuals be explained by atrophy and hypochlorhydria causing loss 
of  H.pylori  infection and seropositivity 
(29-31).  Previous studies have shown that 
subjects with evidence of atrophy and no evidence of H.pylori have the highest cancer 
risk 
(31).  Some of the non-cardia cancers may have arisen from gastric atrophy due to 
causes other than H.pylori e.g. autoimmune atrophic gastritis.   
       In addition to employing the PG I/II as a marker of atrophy we used serum gastrin 
as a marker of atrophy and hypochlorhydria.  Atrophic gastritis markedly impairs the 
ability of the stomach to secrete acid and the latter stimulates a rise in the circulating 
concentration of the hormone gastrin.  Serum gastrin has been shown to be an 
independent predictor of atrophic gastritis in subgroups with and without H.pylori 
infection 
(32).   Similar to PGI/II, serum gastrin is most sensitive to atrophic gastritis 
affecting the gastric body where the acid secreting parietal cells are located 
(33).  
Serum gastrin increases linearly with an increase in grade of atrophy of the body 
mucosa and exponentially with a decrease in peak acid output from normal 
(>10meq/h) to zero 
(34).  In subjects with achlorhydria or severe hypochlorhydria (peak 
acid output <1.1meq/h), the degree of accompanying hypergastrinaemia decreases 
linearly with increasing grade of antral atrophy 
(34).  This moderating influence of antral 
atrophy is thought to be due to loss of antral G cells and thus inability to produce the 
very high rate of gastrin secretion stimulated by profound hypochlorhydria 
(34).    Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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     There was a particularly strong association between elevation of serum gastrin and 
subsequent risk of non-cardia cancer.  It is possible that the rise in serum gastrin 
associated with atrophy and low acidity may promote the carcinogenic process 
(35).  
The hypergastrinaemic mouse model develops invasive gastric cancer, an effect 
which is markedly accelerated by H.pylori infection and inhibited by gastrin receptor 
antagonism 
(36-38). 
     The state and function of the gastric mucosa associated with cardia cancer is more 
complex than that associated with non-cardia cancer.  In contrast to non-cardia 
cancer, there was a negative association between H.pylori infection and cancer of the 
cardia.   As H.pylori infection causes atrophy and hypochlorhydria, we expected to 
find a lower prevalence of atrophy and hypochlorhydria in the cardia cancers than 
controls due to the lower prevalence of H.pylori in the former (Table 1).   Such a 
finding would be consistent with H.pylori protecting from cardia cancer by the same 
mechanism by which it predisposes to non-cardia cancer, i.e. by reducing gastric 
acidity.  However, despite the significantly lower prevalence of H.pylori infection in the 
cardia cancer patients (43% vs. control 71%) the prevalence of atrophy was at least 
as high in the cases (18%) as in the controls (13%).  The reason for this unexpected 
finding was that the prevalence of atrophy within the H.pylori positive cardia cancer 
patients was significantly higher than the H.pylori  positive controls. Cardia cancer 
patients were thus characterised by having a significantly lower prevalence of H.pylori 
infection but higher prevalence of atrophy in those with the infection as compared to 
the controls. 
     What is the explanation for the complex association between the premorbid state 
of the gastric mucosa and cardia cancer?  The lower prevalence of H.pylori infection 
is consistent with H.pylori  having some protective effect.  However, the high 
prevalence of atrophic gastritis within the H.pylori  infected subjects suggests that Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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atrophic gastritis due to H.pylori predisposes to cardia cancer.  The most plausible 
explanation for our findings is that cancer of the cardia region is of heterogeneous 
aetiology and arising by two different pathways with H.pylori  exerting an opposite 
influence on the two pathways.   
     The positive association with atrophic gastritis in the H.pylori infected cardia cancer 
patients is consistent with a subgroup of cardia cancers having a similar aetiology to 
non-cardia cancer, i.e.  being due to H.pylori infection progressing to atrophic gastritis 
and cancer.   The serological markers of atrophy detect that mostly involving the body 
mucosa 
(33, 39, 40).   Body atrophy induced by H.pylori gastritis causes distal regression 
of the apparent cardia-oxyntic junction due to loss of specialised cells 
(13).  Our finding 
is consistent with a proportion of the cardia cancers having arisen from this process 
and thus being of similar aetiology to non-cardia cancer.  Ye et al recently reported 
that cardia cancer was not associated with H.pylori infection but was associated with 
gastric atrophy and their observation is thus also consistent with atrophy being 
involved in a subgroup of cardia cancers 
(41). 
  
     The lower prevalence of H.pylori infection in the cardia cancer patients supports an 
additional aetiological pathway in which H.pylori  may exert a protective influence.   
Several studies have reported a negative association between H.pylori infection and 
oesophageal adenocarcinoma 
(41-42).  A subgroup of the cardia cancers may have 
similar aetiology to oesophageal adenocarcinoma and be subject to an H.pylori 
protective influence. Proximal expansion of the cardia mucosa can arise by 
metaplasia of oesophageal mucosa which the same process is thought to lead to 
oesophageal adenocarcinoma and to be induced by reflux of gastric acid 
(9-12).  The 
mechanism by which H.pylori infection may protect from this process is unclear but 
may be due to the fact that it causes a fall in acid output with advancing years due to 
development of atrophy 
(43, 44).   Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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     The analyses of the histological subtypes provide further evidence of two distinct 
aetiologies of cardia cancer.  Atrophy increased the risk of the diffuse subtype of 
cardia cancer to a similar extent to which it increased the diffuse subtype of non-
cardia cancer.  This was apparent using either PG I/II or gastrin as the marker of 
atrophy.  However, atrophy did not increase the risk of intestinal-type cardia cancer, 
which was in contrast to the increased risk of the intestinal-type in the non-cardia 
region.  The contrast in associations between atrophy and the intestinal-type in the 
cardia versus non-cardia regions was statistically highly significant using either low 
PG I/II (p=0.007) or high gastrin (p=0.002) as risk indicators.   The diffuse type 
cancers at the cardia thus appear etiologically similar to diffuse non-cardia cancers 
whereas the intestinal-type cancers at the cardia (or at least the majority of them) are 
etiologically distinct from intestinal-type cancers in the non-cardia region (Fig 4.3). 
          The cardia cancers which occurred in the patients with atrophic gastritis (all of 
whom were H.pylori  positive) had similar proportions of intestinal and diffuse 
histological subtypes as occurred in the non-cardia cancers.  This is consistent with 
them being of similar aetiology to non-cardia cancer arising from H.pylori-induced 
atrophic gastritis (Table 4.4). However, the cardia cancers occurring in non-atrophic 
stomachs (69% of which were H.pylori seronegative) had a much higher proportion of 
intestinal versus diffuse histological subtype (7:1).  This predominant intestinal 
histological subtype is similar to that observed in oesophageal adenocarcinoma 
(45) 
and is consistent with this subgroup being of similar aetiology to oesophageal 
adenocarcinoma.
    
     Our observations are relevant to the hypothesis that H.pylori infection may protect 
from oesophageal adenocarcinoma as well as predispose to gastric cancer and that 
both effects are mediated by gastric atrophy.  In order to demonstrate a possible 
protective effect of H.pylori  infection on oesophageal adenocarcinoma via gastric 
atrophy it will be essential to study only oesophageal adenocarcinomas well clear of Intestinal type
Adenocarcinoma
Non-cardia
Diffuse type
Adenocarcinoma
Non-cardia
Chronic Atrophic Gastritis
Intestinal Metaplasia
Dysplasia
Chronic Superficial Gastritis
H.pylori
Diffuse type
Adenocarcinoma
Cardia
Intestinal type
Adenocarcinoma
Cardia
Reflux Oesophagitis
Intestinal Metaplasia
Dysplasia
Gastro-oesophageal Reflux
Fig 4.3: Histological cascade proposed for carcinogenesis of gastric cancer in non-cardia versus cardia locations. Note two types of 
cardia cancer, one group related to GORD, is mainly intestinal subype and other group is mixture of intestinal and diffuse subtypes 
and related to H.pylori induced gastritis.Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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  the gastro-oesophageal junction.  Inclusion of any cardia cancers will obscure a 
possible protective effect of atrophy due to the subgroup of cardia cancers associated 
with gastric atrophy.  
     Our finding may also be relevant to the conflicting reports regarding the association 
between H.pylori infection and cardia cancer 
(1, 46).  In general, the association has 
tended to be negative in studies originating from the West and positive in studies from 
the East 
(1, 46).  Our observation of some cardia cancers aetiologically resembling 
oesophageal adenocarcinoma and others resembling non-cardia adenocarcinoma 
may explain the conflicting associations of cardia cancer with H.pylori .  In parts of the 
world where oesophageal adenocarcinoma is relatively common, most cardia cancers 
will be aetiologically similar to oesophageal adenocarcinoma and a protective effect of 
H.pylori infection and associated atrophy will be apparent.  In contrast, in parts of the 
world such as the East where oesophageal adenocarcinoma is rare and non-cardia 
gastric cancer common, then the predominant aetiological type of cardia cancer will 
resemble non-cardia cancer and show a positive association with H.pylori  and 
atrophic gastritis. 
       One practical implication of our findings is that the state of the gastric mucosa 
may provide a key to determining the origin of cardia cancer.  As already discussed, it 
is usually impossible to determine the origin of such cancers by examining them 
grossly or microscopically.  However, if examination of the stomach well clear of the 
cancerous process reveals atrophic gastritis, then cardia cancer of the intestinal 
histological subtype is likely to be etiologically similar to non-cardia cancer and have 
arisen from original gastric mucosa.  In contrast, if the patient has a healthy non-
atrophic gastric mucosa then cardia cancer of the intestinal histological subtype is 
likely to be of similar aetiology to oesophageal adenocarcinoma and have arisen from 
metaplastic oesophageal mucosa produced by gastroesophageal reflux.  We have Chapter 4: Gastric Phenotype in Gastric Cancer; Cardia Vs. Non-Cardia 
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recently proposed that cardia cancers of the intestinal histological subtype arising in 
patients with evidence of gastric atrophy should be termed type A and those arising in 
patients without gastric atrophy termed type B 
(47)
.   Cardia cancers of the diffuse 
histological subtype are likely to be gastric in origin. 
          In conclusion, our studies indicate that cardia cancers probably comprise two 
distinct aetiological subtypes, one resembling non-cardia gastric cancer and positively 
associated with H.pylori-induced  atrophic gastritis and the other resembling 
oesophageal adenocarcinoma and negatively associated with H.pylori  atrophic 
gastritis.  Further studies with larger numbers of cancers are required to determine 
whether the state of the gastric mucosa will indeed provide the key to differentiate 
between gastric versus oesophageal origin of cardia cancers. 
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5.1. INTRODUCTION 
 
          There has been substantial progress in our understanding of the aetiology of 
adenocarcinoma of the stomach and oesophagus over recent decades.  Most cancers 
of the mid and distal stomach are a long-term complication of H.pylori-induced 
superficial gastritis.  They arise in the subgroup of subjects in whom the superficial 
gastritis progresses to atrophic gastritis and intestinal metaplasia accompanied with 
loss of gastric acid secreting capacity
  (1, 2).  H.pylori-induced atrophic gastritis and 
hypochlorhydria are strong risk factors for both the intestinal and diffuse histological 
subtype of gastric cancer 
(2, 3-6). Another important independent risk factor for gastric 
cancer is smoking
 (7-9). The fall in incidence of adenocarcinoma of the stomach in the 
Western world over recent decades may be attributable in part to a falling incidence of 
both H. pylori infection and smoking
 (6, 10) .
 
      A major risk factor for adenocarcinoma of the oesophagus is gastro-oesophageal 
reflux disease
 (11). The risk of oesophageal adenocarcinoma increases with both the 
frequency and duration of reflux symptoms
  (11-13).
  Frequent reflux of gastric juice 
containing acid, pepsin and bile is thought to induce columnar and intestinal 
metaplasia of the squamous mucosa of the distal oesophagus
 (14, 15). This metaplastic 
or Barrett’s oesophagus has a markedly increased risk of progressing to 
adenocarcinoma of the intestinal histological subtype
  (16). In contrast to 
adenocarcinoma of the mid and distal stomach, that of the oesophagus is negatively 
associated with H.pylori infection
 (17). The mechanism of this negative association is 
unclear but might be related to a healthy acid secreting stomach being required to 
provide a refluxate of sufficient acidity to induce oesophageal damage
 (18).  
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     The aetiology of adenocarcinoma of the cardia and gastro-oesophageal junction is 
unclear and controversial. Understanding its aetiology is important as most 
adenocarcinomas of the upper gastrointestinal tract in the western world and in 
Northwest Iran involve the cardia and GE junction
  (19, 20). The association of cardia 
cancer with H.pylori  infection is confusing with some studies showing a negative 
association, some a positive and some no association
  (21-27). Some studies indicate 
that reflux symptoms are a risk factor for cardia cancer but a weaker risk factor than 
for oesophageal adenocarcinoma
 (28). A number of studies demonstrate smoking to be 
a risk factor for cardia cancer
 (9, 29). 
 
     As discussed in last chapter, we recently studied the association between cancer 
of the cardia and serological evidence of both H.pylori infection and atrophic gastritis
 
(30). This was performed in a nested case control study.  We observed a negative 
association with H.pylori infection but a positive association between atrophic gastritis 
and cardia cancer in those with the infection. We interpreted this as indicating dual 
aetiology of cardia cancer with some cases being due to H.pylori-induced atrophic 
gastritis and aetiologically resembling adenocarcinoma of the mid and distal stomach 
and others being of a different aetiology and associated with a non-atrophic stomach. 
This latter group might be aetiologically similar to oesophageal adenocarcinoma. 
 
     In the current study we extended our investigation of the aetiology of cardia cancer 
by examining the association of both serological evidence of gastric atrophy and reflux 
symptoms with adenocarcinoma of the oesophagus, cardia and non-cardia regions of 
the stomach. This has been performed for the different histological subtypes of the 
cancer. We have also included H.pylori status and smoking history which are other 
well established risk factors for upper GI cancer.  This has been undertaken in a 
population in Northwest Iran with a high incidence of upper gastrointestinal cancer
 (20, Chapter 5: Two Types of Cardia Cancer 
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31). Our studies examining the association with both atrophic gastritis and reflux 
symptoms provide substantial support for cardia cancer being of two distinct 
aetiological subtypes, one similar to non-cardia cancer and the other similar to 
oesophageal adenocarcinoma. 
 
 
5.2. METHOD & MATERIALS 
 5.2.1. Study Setting     
          This was a case-control study, conducted in Aras Clinic in Ardabil province in 
Northwest Iran. The area is a well-known high risk region for gastric cancer in general 
and gastric cardia cancer in particular. Aras Clinic is a referral centre for delivery of 
investigational, therapeutic and preventative services to all patients with upper 
gastrointestinal tract disease throughout the Ardabil province. It is specifically 
equipped and staffed through government funding to conduct research into the 
aetiology of upper GI cancer.  According to the latest estimates from the Ardabil 
Cancer Registry 
(32), approximately half of all incident upper gastrointestinal cancers 
diagnosed in Ardabil province are recorded and evaluated in this Centre. The present 
study has been conducted by collaboration between the University of Glasgow (UK), 
Digestive Disease Research Centre (DDRC) of University of Tehran and Ardabil 
University of Medical Science. 
  
5.2.2. Cancer and Control Groups 
          In total, 157 consecutive eligible patients with gastric or oesophageal 
adenocarcinoma were identified.  We excluded 19 eligible patients for the following 
reasons: very advanced disease that did not allow us to determine exact location of 
tumour (n= 5), poor co-operation of patient due to severity of the illness (n=4), patient Chapter 5: Two Types of Cardia Cancer 
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refusal (n=3) and insufficient or inappropriate serum or histologic samples (n=7).  
Finally, 138 patients with gastric and oesophageal adenocarcinoma were enrolled into 
the study including 66 non-cardia, 53 cardia and 19 oesophageal adenocarcinoma. 
Diagnosis of cancer was made by microscopic verification of multiple endoscopic 
biopsies and all histologic slides were studied by two certified pathologists (N.R and 
R.D) and reviewed by third pathologist (M.S) to ensure meeting the protocol 
requirements in accordance with ICD-O-2 
(33). In controversial cases, diagnosis of 
cancer was made only after joint agreement of all three pathologists
. Cardia cancer 
was defined as tumours whose main bulk was within 2 cm distal to the gastro-
oesophageal junction. Tumours located completely above the gastro-oesophageal 
junction were considered to be oesophageal in origin.  Tumours located anywhere in 
the stomach other than the cardia were called non-cardia gastric cancer.  The 
histological subtypes according to the Lauren classification were also recorded
 (34).   
 
     Prior to endoscopy, each patient had a standardised interview and details recorded 
regarding symptoms of reflux and smoking.  The average frequency of heartburn 
and/or acid regurgitation over the five years prior to presentation excluding those of 
last one year before diagnosis of cancer was recorded.  History of smoking was 
recorded as number of cigarettes per day and duration of smoking in years.  Alcohol 
consumption is extremely rare in this region.  The questionnaire employed was 
validated in a pilot study 
(35).
 A fasting blood sample was collected from each patient 
before endoscopy and serum stored at –70C for later serologic assessment.  
 
     In format of frequency-matched case control design, one control for each case of 
non-cardia and cardia cancer and two controls for oesophageal adenocarcinoma 
patients were selected randomly from dyspeptic patients. They were attending the 
same Centre and their endoscopy had shown no evidence of peptic ulcer or tumours.  Chapter 5: Two Types of Cardia Cancer 
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The controls were sex and age matched within 4 years.  The controls had undergone 
a similar interview to the cases and had also had serum stored prior to their 
endoscopy.  
 
5.2.3. Serologic Studies    
     Serum pepsinogen I (PG I) and pepsinogen II (PG II) were assayed with enzyme 
immuno-sorbant assay (ELISA) methods using monoclonal antibodies to pepsinogen I 
and II (BIOHIT diagnostics, Biohit LTD, UK). All procedures were done according to 
manufacture’s instructions and results of PG I and PG II reported in µg/L. PG I/II ratio 
was calculated and reported in fraction.  We used serum PG I/II less than 2.5 as a 
serologic marker of atrophy as previously reported
 (30).
 
     H.pylori infection was assessed by a serologic test using anti H.pylori Ig G 
antibody, supplied by the same manufacturer. A response titre more than 30 enzyme 
immuno units (EIU) was considered as positive for H.pylori infection. 
 
5.2.4. Statistical Analysis 
     Serum PG I/II as serologic marker of atrophy were presented in quintiles. The PG 
I/II data of each control group were used to make quintiles. Using binary logistic 
regression, relationship of PG I/II quintiles with each cancer was estimated as odds 
ratio (OR) with their 95% confidence interval and related p values. PG I/II quintiles 
were treated as a categorical variable and 5
th quintile was used as referent. Smoking, 
GORD symptoms and H.pylori serology were used as possible risk factors of cancer 
in univariate logistic regression. These variables were also used in multivariate model 
along with PG I/II quintiles. Smoking was presented as a dichotomous variable (1= 
Smoker:  ≥ 10 cigarettes per day for at least 10 years and no more than 5 years 
passed since stopping smoking, and 0=non-smoker including never smokers and 
those who smoked less than limits stated above). GORD symptoms were categorised Chapter 5: Two Types of Cardia Cancer 
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as 0= never or less than one time per week, 1= one to two times per week, and 2= 
more than two times per week. In order to evaluate association of gastric atrophy with 
risk of different histological subtypes of upper GI adenocarcinoma, we used the serum 
PG I/II less than 2.5 as a serologic marker of atrophy.  Two sided p values less than 
0.05 were considered statistically significant. The SPSS statistical software version 
14.0 was used for most analysis
 (36). 
 
5.3. RESULTS 
     5.3.1. Gastric non-cardia cancer 
 
     A total of 66 patients (49 male and 17 female, mean age 65.9 + 6.5) with non-
cardia cancer and similar number of controls were studied (Table 5.1). A monotonous 
decreasing risk of cancer was observed from the lowest to the highest quintiles of PG 
I/II (Fig 5.1a). In univariate analysis, the risk was maximal in patients with PG I/II ≤ 
2.01 with OR=15.76 (3.92 – 63.43).  Smoking also increased the risk of non-cardia 
cancer with OR=2.22 (1.11 - 4.46) (table 5.2).  GORD symptoms in both frequency 
levels showed a negative relationship with non-cardia cancer, but the association was 
only statistically significant in patients with GORD symptoms occurring 1-2 times per 
week. H.pylori seropositivity was detected in 93.9% of cases and 74.2% of controls 
and increased the risk of non-cardia in univariate analysis with OR=2.22 (1.11 - 4.46). 
      In multivariate analysis including smoking, GORD symptoms and H.pylori sero-
status, first and second lowest PG I/II quintiles increased the risk of cancer with ORs 
(95% CI): 21.47 (2.90 – 158.76) and 9.08 (1.10 – 75.29), respectively.  Smoking 
showed a more potent relationship with risk of non-cardia cancer, with OR (95% CI): 
5.83 (2.11 – 16.11), GORD symptoms 1-2 times per week continued to show an 
inverse relationship, with OR (95% CI): 0.31 (0.11 – 0.85), The positive relationship 
between  H.pylori infection and non-cardia cancer no longer reached statistical 
significance OR (95% CI): 1.53 (0.57 -4.14).  
 
 
Table 5.1: Frequency of risk factors of adenocarcinomas of non-cardia, oesophageal and cardia sub-sites, with matched controls 
 
  Non-Cardia      Oesophageal Cardia
  Case (66)  Control (66)  Case (19)  Control (38)  Case (53)  Control (53) 
PG I/II [mean (SD)]  2.01 (1.01)  3.46 (1.73)  4.76 (2.00)  3.43 (1.92)  3.39 (2.23)  4.19 (2.46) 
Smoking          
        
        
        
     Ever smoker  28 (42.4 %)  15 (22.7 %)  10 (52.6%)  9 (23.7 %)  19 (35.8 %)  12 (22.6 %) 
     Non smoker  38 (57.6 %)  51 (77.3 %)  9 (47.4%)  29 (76.3 %)  34 (64.2 %)  41 (77.4 %) 
GORD symptoms 
    <1 time per week  50 (75.8 %)  33 (50.0 %)  2 (10.5 %)  19 (50.0 %)  25 (47.2 %)  32 (60.4 %) 
    1 – 2 times per week  13 (19.7 %)  23 (34.8 %)  6 (31.6 %)  15 (39.5%)  14 (26.4 %)  17 (32.1 %) 
   >2 times per week  3 (4.5 %)  10 (15.2 %)  11 (57.9 %)  4 (10.5 %)  14 (26.4 %)  4 (7.5 %) 
H.pylori Sero-status 
     Positive  62 (93.9 %)  49 (74.2 %)  9 (47.4 %)  28 (73.7%)  44 (83.0 %)  39 (73.6 %) 
     Negative  4 (6.1 %)  17 (25.8 %)  10 (52.6 %)  10 (26.3%)  9 (17.0 %)  14 (26.4 %) 
Histological Subtype 
     Intestinal  36 (54.5 %)  n/a  16 (84.2 %)  n/a  34 (64.2 %)  n/a 
     Diffuse  25 (37.9 %)  n/a  1 (5.3 %)  n/a  16 (30.2 %)  n/a 
     Mixed / Unclassifiable  5 (7.6 %)  n/a  2 (10.5 %)  n/a  3 (5.7 %)  n/a 
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     According to the Lauren histological sub-classification of the non-cardia cancers, 
36 (54.5%) were intestinal subtype, 25 (37.9%) diffuse, and 5 (7.6%) cases mixed or 
unclassifiable. The intestinal subtype adenocarcinoma showed strong positive 
association with gastric atrophy (defined as PGI/II < 2.5) with OR (95% CI): 13.02 
(4.39 – 38.61) in multivariate analysis. The diffuse subtype cancer was also 
associated less strongly with gastric atrophy with OR (95% CI): 3.07 (1.23 – 7.67).   
      
 5.3.2. Oesophageal adenocarcinoma 
 
19 cases of oesophageal adenocarcinoma (12 male and 7 female, mean age 63.9 + 
4.7) were compared with double the number of controls (Table 5.1).  In univariate 
analysis, GORD symptoms, in category of >2 times per week increased the risk of 
cancer with OR (95% CI) of 28.05 (4.74 – 165.91). In multivariate analysis, involving 
PG I/II, smoking and H.pylori sero-status, this relationship showed a decrease as OR 
(95% CI): 12.46 (1.80 – 86.47), (Table 5.3). Smoking also showed a positive 
relationship with the cancer, with OR (95% CI): 4.56 (1.01 – 20.68) which was not 
affected by other risk factors.  There was no association between oesophageal 
adenocarcinoma and atrophy. Frequency of H.pylori infection in patients with 
oesophageal adenocarcinoma was lower than their matched controls (47.4% vs. 
73.7%). While inverse relationship between H.pylori and oesophageal 
adenocarcinoma was evident by univariate analysis (OR; 95% CI: 0.25; 0.08 – 0.75), 
this negative relationship lost its statistical significance in multivariate analysis (OR; 
95% CI: 0.43; 0.10 – 1.91). By the Lauren histologic classification, 16 (84.2%) of the 
19 oesophageal adenocarcinomas were intestinal subtype. 
 
 
 
 
 
  
 
 
Table 5.2: Relationship between risk of non-cardia gastric cancer and pepsinogen I /II, smoking, GORD symptoms and  
                 H.pylori sero-status 
 
  Univariate     Multivariate
  Odds Ratio (95% CI)  P Value    Odds Ratio (95% CI)  P Value 
      PG Ratio quintiles   
5
th: 5.125 – 7.445   1.00    1.00 
4
th: 3.607 – 4.793   3.11 (0.62 - 15.58)  0.168    3.50 (0.45 – 27.37)  0.233 
3
rd: 2.707 – 3.560   4.77 (1.07 - 21.21)  0.040    6.48 (0.78 – 54.01)  0.084 
2
nd: 2.092 – 2.701  7.75 (1.81 - 33.16)  0.006    9.08 (1.10 – 75.29)  0.041 
1
st: 0.189 – 2.011   15.76 (3.92 - 63.43)  0.000    21.47 (2.90 – 158.76)  0.003 
      Smoking   
Non smoker  1.00    1.00 
Ever smoker  2.22 (1.11 - 4.46)  0.025    5.83 (2.11 – 16.11)  0.001 
      GORD symptoms   
<1 time per week  1.00    1.00 
1 – 2 times per week  0.44 (0.20 - 0.96)  0.039    0.31 (0.11 - 0.85)  0.023 
>2 times per week  0.44 (0.17 - 1.10)  0.079    0.91 (0.18 – 4.64)  0.913 
      H.pylori Sero-status          
            Negative 1.00 1.00
Positive  2.22 (1.11 – 4.46)  0.025    1.53 (0.57 – 4.14)  0.401 
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 5.3.3. Gastric cardia cancer 
 
     We studied 53 cases of cardia cancer (37 male and 16 female, mean age 63.8 + 
7.1) and the same number of controls (Table 5.1).   A relationship between lowest 
quintile of PG I/II (≤ 2.37) and cardia cancer was noted in multivariate analysis [OR 
(95% CI): 3.92 (1.77–8.67)], (Table 5.4). However, there was a heterogenic 
relationship between atrophy and risk of cardia cancer with a relatively quadratic trend 
of risk of cardia cancer against different quintiles of PG I/II (Fig. 5.1b).  This contrasted 
with the linear association of non-cardia cancer with atrophy (Fig 5.1a).  There was 
also a positive association between cardia cancer and GORD symptoms at the level 
of >2 times per week having an OR (95% CI): 10.08 (2.29 – 44.36).  No significant 
effect of smoking was detected in our patients [OR (95% CI):1.40 (0.56-3.51)]. While 
serologic  H.pylori infection was more frequent in cases than controls (83.0% vs. 
73.6%), there was no significant relationship between cardia cancer and H.pylori 
infection [(OR (95% CI): 2.42 (0.84–7.02)]. 
 
      We further investigated the nature of the dual association of cardia cancer with 
atrophy and GORD using the dichotomised values.  The association between risk of 
cardia cancer and atrophy based on dichotomised definition PG I/II < 2.5, showed a 
significant relationship with OR (95% CI): 3.05 (1.32–7.06).  GORD symptoms 
dichotomised into >2 times/week versus 0-2 times /week also showed a positive 
relationship with risk of cardia cancer with OR (95% CI): 4.40 (1.34–14.43). In order to 
further evaluate the relationship between atrophy, GORD and risk of cardia cancer, 
we recalculated the association of GORD and cardia cancer risk separately in atrophic 
and non-atrophic subgroups. This showed that the risk of cardia cancer was increased 
by GORD symptoms in non-atrophic patients, OR (95% CI):8.02 (2.25–28.58)], but 
not in atrophic patients (Fisher exact test p value= 1.00).  (Table 5.5, Fig 5.2). 
  
 
 
Table 5.3: Relationship between risk of oesophageal adenocarcinoma and pepsinogen I /II, smoking, GORD  
                  symptoms and H.pylori sero-status 
 
  Univariate     Multivariate
  Odds Ratio (95% CI)  P Value    Odds Ratio (95% CI)  P Value 
      PG Ratio quintiles   
5
th: 4.482 – 9.409   1.00    1.00 
4
th: 3.395 – 4.266   0.35 (0.07 – 1.72)  0.197    0.40 (0.05 – 3.29)  0.397 
3
rd: 2.611 – 3.271  0.35 (0.07 – 1.72)  0.197    0.26 (0.03 – 2.22)  0.217 
2
nd: 1.978 – 2.483  0.29 (0.06 – 1.46)  0.132    0.57 (0.08 – 4.11)  0.573 
1
st: 1.155 – 1.959   0.26 (0.05 – 1.49)  0.131    0.41 (0.05 – 3.69)  0.427 
      Smoking   
Non smoker  1.00    1.00 
Ever smoker  4.70 (1.54 – 14.34)  0.007    4.56 (1.01 – 20.68)  0.049 
      GORD symptoms         
 
         
<1 time per week  1.00    1.00   
1 – 2 times per week  2.60 (0.65 – 10.36)  0.175    1.73 (0.33 – 9.11)  0.520 
>2 more times per week  28.05 (4.74 – 165.91)  0.001    12.46 (1.80 – 86.47)  0.011 
      H.pylori Sero-status 
Negative 1.00   1.00
Positive  0.25 (0.08 – 0.75)  0.014    0.43 (0.10 – 1.91)  0.268 
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  In the cardia, 34 (64.2%) of tumours were classified histologically as intestinal 
subtype, 16 (30.2%) were diffuse subtype and only 3 cases were mixed subtype or 
unclassifiable. Both the intestinal subtype and diffuse subtype were associated with 
gastric atrophy, OR (95% CI):3.64 (1.33–9.97), and OR (95% CI):17.71 (3.66–85.76) 
respectively. 
 
     The association of cardia cancer with GORD symptoms was also related to the 
histological subtype.  The intestinal subtype cardia cancer showed significant 
relationship with presence of GORD symptoms >2 times per week with OR (95% CI): 
5.86 (1.68–20.39).  In contrast, the association between GORD symptoms and diffuse 
subtype statistically was not significant [OR (95% CI): 2.83 (0.56–14.24)].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 5.4: Relationship between risk of gastric cardia cancer and pepsinogen I /II, smoking, GORD symptoms and H.pylori sero-status  
  
  Univariate     Multivariate
  Odds Ratio (95% CI)  P Value    Odds Ratio (95% CI)  P Value 
      PG Ratio quintiles   
5
th: 6.008 – 11.586  1.00    1.00 
4
th: 3.848 – 6.004   1.10 (0.50 – 2.40)  0.817    0.92 (0.37 - 2.26)  0.852 
3
rd: 3.062 – 3.734   0.50 (0.20 – 1.25)  0.138    0.62 (0.23- 1.71)  0.355 
2
nd: 2.378 – 3.017   0.50 (0.20 – 1.25)  0.138    0.49 (0.18 - 1.38)  0.177 
1
st: 0.479 – 2.370   2.77 (1.36 – 5.63)  0.005    3.92 (1.77 – 8.67)  0.001 
      Smoking   
Non smoker  1.00    1.00 
Ever smoker  1.70 (0.79 – 3.67)  0.175    1.40 (0.56 – 3.51)  0.476 
      GORD symptoms   
<1 time per week  1.00    1.00 
1 – 2 times per week  0.95 (0.40 – 2.29)  0.915    1.47 (0.54 – 4.00)  0.451 
>2 more times per week  3.15 (1.17 – 8.49)  0.024    10.08 (2.29 – 44.36)  0.002 
      H.pylori Sero-status 
Negative      1.00   1.00
Positive  1.46 (0.68 – 3.14)  0.332    2.42 (0.84 – 7.02)  0.103 
 
  
 
 
 
Table 5.5: Relationship between GORD symptoms and risk of gastric cardia cancer in atrophic versus non-atrophic subjects 
 
PG I/II  GORD 
symptoms 
Cardia cancer  Fisher’s Exact test  OR 
    Case  Control  P value (two-sided)  (95% CI) 
> 2 / week  1  0 
0-2 / week  24  12  Atrophic
Total   
   
25  12
1.000 NA
> 2 / week  13  4 
0-2 / week  15  37 
Non-
atrophic 
Total    28  41
0.001  8.02 (2.25 – 28.58) 
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Fig 5.1a: Gastric non-cardia cancer Fig 5.1b: Gastric cardia cancer
Fig 5.1: Relationship between severity of atrophic gastritis, expressed by serum PG I/II and risk of gastric cancer at 
non-cardia (A) and cardia subsites (B). The first quintile of PG I/II indicates greatest degree of atrophy and 
5th quintile least atrophy.0.0
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Fig 5.2: This presents the PG I/II values in the individual patients with oesophageal, cardia and non-cardia cancers.
The cardia cancers are grouped according to histological subtype and frequency of GORD symptoms.
Atrophy is indicated by PG I/II values of <2.5 (broken line). Chapter 5: Two Types of Cardia Cancer 
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5.4. DISCUSSION 
          In our subjects with non-cardia gastric cancer, we found a strong association 
between serological evidence of gastric atrophy and risk of cancer and this is 
consistent with many previous studies
 (37, 38). Atrophic gastritis was associated with 
increased risk of both the intestinal and diffuse histological subtypes of non-cardia 
cancer but the association was stronger for the former as previously reported
 (37, 39, 40). 
Whereas, the intestinal subtype is nearly always a consequence of atrophic gastritis 
and intestinal metaplasia, the diffuse histological subtype sometimes develops in a 
non-atrophic stomach with a strong genetic predisposition being an important factor in 
some of these cases
 (41, 42). 
 
     An association between H.pylori infection and non-cardia cancer was present in 
the univariate analysis consistent with previous reports 
(2).  However, this association 
was lost in multivariate analysis when atrophy and lifestyle factors were included.   
This is consistent with H.pylori-induced atrophic gastritis being the pre-cancerous 
lesion rather than H.pylori infection itself. High prevalence of H.pylori infection in the 
background population shown in the current and previous studies can explain its weak 
relationship with gastric cancer risk 
(43).
 
      
          There was no significant association between frequent GORD symptoms (>2 
times/week) and non-cardia cancer in our study. However, the negative association 
between lees frequent GORD and non-cardia cancer can be explained by the atrophic 
gastritis protects against GORD symptoms, but it difficult to understand why this 
would not also protect against more frequent GORD. 
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     We found that smoking was also a risk factor for non-cardia cancer as previously 
reported.  The extent of the association in univariate analysis [OR (95% CI): 2.22 
(1.11-4.46)] is consistent with most previous reports, suggesting smoking as a mild to 
moderate risk factor of non-cardia gastric cancer 
(8, 44, 45). Incorporating atrophy, H. 
pylori status and GORD symptoms into multivariate analysis enhanced the effect of 
smoking [OR (95%): 5.83 (2.11–16.11)]. This indicates that the effect of smoking is 
not mediated through induction of atrophy but acts independent of the atrophic 
process. 
   
          In contrast to non-cardia cancer, oesophageal adenocarcinoma was positively 
associated with reflux symptoms.  This is consistent with previous reports and the 
currently accepted hypothesis that gastro-oesophageal reflux causes columnar and 
intestinal metaplasia which then progresses to intestinal subtype adenocarcinoma
 (11, 
46). Consistent with this, the great majority of oesophageal adenocarcinomas in our 
study were of the intestinal histological subtype.  There was also a positive 
association with smoking as previously reported 
(44, 47).
 There was no association with 
gastric atrophy.  
 
     The main purpose of our study was to investigate the aetiology of cardia cancer 
and its relation to that of non-cardia and oesophageal adenocarcinoma.  Cardia 
cancer showed a complex relationship with gastric atrophy.  Severe gastric atrophy 
indicated by the lowest pepsinogen I/II quintile of <2.37 was associated with an 
increased risk of cardia cancer.  However, unlike non-cardia cancer, there was no 
evidence of a progressive rise in cancer incidence with falling pepsinogen I/II ratio.  
Rather, the relationship between pepsinogen I/II ratio and cancer risk showed a 
quadratic pattern with the risk of cardia cancer being highest for the lowest and 
highest pepsinogen I/II ratios and lowest for the intermediate ratios.  A plausible Chapter 5: Two Types of Cardia Cancer 
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explanation for this complex association between cardia cancer and atrophic gastritis 
is that there are two distinct aetiologies of cardia cancer, one subgroup being 
associated with severe atrophic gastritis and resembling non-cardia cancer and the 
other subgroup unassociated or negatively associated with atrophic gastritis and 
aetiologically resembling oesophageal adenocarcinoma.   
 
      Reflux symptoms were also found to be a risk factor for cardia cancer with GORD 
symptoms of >2 time per week increasing the risk of cardia cancer with OR (95% 
CI):10.08 (2.29–44.36). Reflux symptoms have been reported previously to be a risk 
factor for cardia cancer but not as strong a risk factor as for oesophageal 
adenocarcinoma
 (28). In our study, we were able to investigate the interaction of reflux 
symptoms and atrophy in the aetiology of cardia cancer. This showed that reflux 
symptoms were associated with cardia cancer only in non-atrophic subjects, with a 
powerful OR (95% CI): 8.02 (2.25–28.58).  This is again consistent with two distinct 
aetiologies of cardia cancer, one being associated with atrophic gastritis and 
resembling non-cardia cancer and one associated with reflux and resembling 
oesophageal adenocarcinoma.  
  
          Further evidence of two distinct aetiologies of cardia cancer was apparent on 
examining the atrophy-cancer and GORD-cancer associations separately in the two 
histological subtypes. The association between atrophy and intestinal subtype 
adenocarcinoma was weaker in the cardia than in the non-cardia region of the 
stomach. This is consistent with the intestinal subtype cardia cancer being a mixture 
of tumours positively associated with atrophy (similar to non-cardia intestinal subtype 
adenocarcinomas) and tumours unassociated or negatively associated with atrophy 
(similar to oesophageal intestinal subtype adenocarcinoma). 
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     The association of atrophy with diffuse cancer was stronger in the cardia than in 
the non-cardia region of the stomach. This difference may be related to the different 
topographic distribution and extent of atrophy required to produce cancer at those two 
sites and the ability of PGI/II to detect the atrophy associated with cancer at these two 
sites.  Atrophy tends to start in the distal stomach at the junction between the antrum 
and body mucosa and progress proximally
 (48, 49). Cancers tend to develop within 
atrophic mucosa and thus cancers of the distal stomach may develop in subjects with 
less extensive atrophy than would be required to produce cancer up at the cardia 
region.  Furthermore, PGI/II is a reliable marker for detecting extensive atrophy 
involving the body mucosa but a poor marker for detecting early atrophy or that 
confined to the antral mucosa
 (50, 51).
 
 
     The association between GORD symptoms and cardia adenocarcinoma was also 
related to the histological subtype. GORD symptoms were strongly associated with 
the intestinal subtype cancers at the cardia and this relationship was similar to that for 
oesophageal adenocarcinoma. This association with GORD symptoms and intestinal 
subtype adenocarcinoma at the cardia is consistent with some of these cancers 
occurring by the same mechanism as oesophageal adenocarcinoma which is also of 
the intestinal subtype; the reflux of gastric juice leading to columnar intestinal 
metaplasia, dysplasia and adenocarcinoma. In contrast, there was no relationship 
between GORD symptoms and diffuse subtype adenocarcinomas at the cardia. 
 
     Our findings thus support two distinct aetiologies of cardia cancer.  One subtype is 
associated with atrophic gastritis and may be of the intestinal, diffuse or mixed 
histological subtype.  It resembles non-cardia cancer and is likely to have arisen by 
the same process  i.e. H. pylori-induced atrophic gastritis.  The other subtype is 
associated with GORD and is of the intestinal histological subtype.  It is likely to have Chapter 5: Two Types of Cardia Cancer 
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a similar aetiology to oesophageal adenocarcinoma and to have arisen from acid 
reflux induced columnar intestinal metaplasia of original oesophageal squamous 
epithelium.  
  
     The above observations imply that there are not only two distinct aetiologies of 
cardia cancers but that the structural and functional state of the stomach associated 
with them is profoundly different.   One type is associated with a non-atrophic healthy 
gastric mucosa producing sufficient acid and pepsin to damage the mucosa of the 
gastro-oesophageal junction and lead to columnar intestinal metaplasia and intestinal 
subtype cancer.  The other is associated with atrophic gastritis of sufficient severity 
and extent to involve the proximal stomach leading to the development of intestinal or 
diffuse subtype cancer from the atrophic gastric mucosa.  
 
          It is very difficult pre-operatively, during surgery or even at post-mortem 
examination to determine whether cancer of the cardia has arisen from original gastric 
or oesophageal mucosa.  Our study points to three factors likely to be useful in 
determining the origin of the cancer: (i) the histological subtype of the tumours, (ii) the 
state of the gastric mucosa distant from the tumour and (iii) the frequency of GORD 
symptoms (Fig. 2).  Diffuse histological tumour subtype strongly indicates gastric 
origin.  Intestinal subtype tumours with non-atrophic gastric mucosa and frequent 
GORD symptoms are highly likely to be of oesophageal origin.  Intestinal subtype 
tumours with atrophic gastric mucosa and less frequent GORD symptoms are likely to 
be gastric in origin.  It is difficult to classify a proportion of the intestinal type cardia 
cancer.  This might be improved by more precise means of assessment of GORD and 
more accurate determination of the presence/absence of gastric atrophy, i.e. by 
histology of gastric mucosal biopsies.   Chapter 5: Two Types of Cardia Cancer 
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          One of the limitations of this study is the relatively small numbers of recruited 
patients (which predominantly refers to patients with oesophageal adenocarcinoma). 
Application of strict eligibility criteria in general and a low actual incidence of 
oesophageal adenocarcinoma in the population in particular were the main problems 
in the performance of the study. The other point to be considered in interpretation of 
our results is the high proportion of gastric cardia to non-cardia cancer in the target 
population. Although the results of the current study have been supported by the 
findings of the previous work of ourselves, further large-scale investigations should be 
carried out in other populations with different proportions of cardia to non-cardia 
cancer, i.e. South East Asian countries to further validate the present results.  
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6.1. Cancer and Gender 
 
     In humans, the incidence of most cancers is higher in males than in females. A 
review of medical literature of the current and last centuries shows a marked male 
predominance of overall cancer incidence worldwide 
(1-4). According to historical 
evidence, excess incidence and mortality of cancer in males could be a phenomenon 
of the current and last centuries. William Roger Williams, a late-19
th-century writer, 
wrote; ”want of proper exercise and excess of food”  leaving men subject to “women’s 
diseases” 
(5). The perception that cancer was a “female” disease was based on the 
observation that females were especially liable to cancer of the breast and uterus, 
therefore overall cancer mortality due to cancer in females was remarkably greater 
than that of males 
(6, 7).  
     The influence of gender on cancer incidence varies by location and histological 
types of tumours. Although the overall male to female ratio (M/F) of cancer occurrence 
of all sites is approximately 1.30, this ratio shows great variation (Table 6.1). 
Regardless of histological type, cancer of the larynx with a M/F ratio of 8.5 and those 
located in the bladder with M/F over 4 are strongly male-predominant. Malignant 
tumours of the thyroid and cancer of the gall bladder occur unusually frequently in 
females 
(8). Almost all other cancers are male-predominant and show a M/F ratio 
between 1 to 3. Cancers confined to the lungs, oesophagus, stomach, liver, pancreas 
and kidneys all are major examples of this group.  
     The gender disparity in cancer incidence may vary by histological type (or subtype) 
of the tumour in every site. Hepatocellular cell carcinoma shows a remarkable male-
predominance compared to other histological types of liver cancers 
(9). Lung 
adenocarcinoma has the least tendency to male gender than other histological types 
of lung cancer 
(10-12). The most common histological type of bladder cancer, Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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transitional cell carcinoma, also expresses the largest M/F ratio compared to any 
other types 
(4).  
Table 6.1: Male to female ratios of cancer  incidence in different sites worldwide, 
estimates of 2002, modified from Parkin et al (1) 
 Males    Females     
Site Cases  ASR 
(World) 
 Cases  ASR 
(World) 
 M/F 
Ratio 
Oral cavity  175,916 6.3   98,373 3.2    1.97
Nasopharynx 55,796 1.9   24,247 0.8    2.38
Other pharynx  106,219 3.8   24,077 0.8    4.75
Oesophagus 315,394 11.5   146,723 4.7    2.45
Stomach 603,419 22.0   330,518 10.3    2.14
Colon, Rectum  550,465 20.1   472,687 14.6    1.38
Liver 442,119 15.7   184,043 5.8    2.71
Pancreas 124,841 4.6   107,465 3.3    1.39
Larynx 139,230 5.1   20,011 0.6    8.50
Lung 965,241 35.5   386,891 12.1    2.93
Melanoma of skin  79,043 2.8   81,134 2.6    1.08
Kidney 129,223 4.7   79,257 2.5    1.88
Bladder 273,858 10.1   82,699 2.5    4.04
Brain & CNS  108,221 3.7   81,264 2.6    1.42
Thyroid 37,424 1.3   103,589 3.3    0.39
N.H. lymphoma  175,123 6.1   125,448 3.9    1.56
Hodgkin disease  38,218 1.2   24,111 0.8    1.50
Multiple myeloma  46,512 1.7   39,192 1.2    1.42
Leukemia 171,037 5.9   129,485 4.1    1.44
All sites but skin  5,801,839 209.6  5,060,657 161.5    1.30
 
          Upper gastroesophageal cancers are common malignancies worldwide. Male 
predominance in this group of cancers varies by histological types and location of 
tumour. While oesophageal squamous cell carcinoma shows a relatively mild male 
predominance, adenocarcinoma of the oesophagus has a strong tendency to male 
gender 
(4, 13). Indeed male gender is an important risk factor for oesophageal 
adenocarcinoma 
(14). Adenocarcinoma of stomach, as the main histological form of 
gastric cancer, is also a male-predominant cancer. It has been shown that influence of Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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gender on gastric adenocarcinoma varies by location of tumour, i.e. tumours located 
in the cardia have a greater M/F ration compared to those in the non-cardia region 
(15). 
Also, the intestinal subtype of the Lauren classification of gastric adenocarcinoma has 
been shown to express more M/F ratio in comparison to diffuse subtype 
(16). In spite of 
great and invaluable studies regarding the association of tumour location and 
histological types of upper gastroesophageal cancers, there are many unanswered 
questions regarding the role of the mentioned factors and the nature of male-
predominance in adenocarcinoma of the oesophagus and the stomach. 
          In this chapter, after a brief introduction to cancers with a prominent gender 
disparity, including hepatocellular cell carcinoma of the liver, lung cancer and bladder 
cancer, I will present the results of our study of factors of male predominance of upper 
gastroesophageal adenocarcinoma. In this study we have investigated the role of 
histological subtype and location of tumour in the male tendency of adenocarcinoma 
of the oesophagus, gastric cardia and gastric non-cardia subsites. In addition, we 
have modelled the age-specific incidence curves of intestinal and diffuse subtypes of 
upper gastroesophageal adenocarcinoma to compare the lag of cancer development 
between males and females. In order to produce reliable, unbiased and accurate data, 
we have studied a randomly-selected sample of all incidences of oesophageal and 
gastric adenocarcinoma recorded in the West of Scotland Cancer Registry, 1998-
2002. In a further complementary study we have tried to answer a new question; in 
the multistage carcinogenesis cascade of intestinal subtype gastric cancer, where is 
gender acting? Again, a population-based study of gastric inflammatory and 
precancerous lesions was performed by randomly selecting adult residents of Ardabil, 
a high risk area for gastric cancer in Northwest Iran. Prevalence of each inflammatory 
and precancerous lesion was determined in males and females separately. I will 
discuss all findings at the end of the chapter. 
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6.2. Major Cancers with Marked Male Predominance 
 
6.2.1. Hepatocellular Carcinoma 
 
     Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and 
accounts for approximately 60-90% of primary liver cancer 
(9). Global data suggest 
that more than 500,000 new cases of primary liver cancer develop each year, 
equating to an age-adjusted worldwide incidence of 14.97 per 100,000 men and 5.51 
per 100,000 women per year 
(17). The incidence of HCC shows a huge geographical 
variation. The age standardised rate of HCC is highest in East Asian countries, i.e. 
South Korea, Japan and China with approximately 30 per 100,000 and 8 per 100,000 
in men and women, respectively. Low incidence area are regions with less than three  
per 100,000 annually: the United Kingdom, Netherlands, Norway, Sweden and 
Finland. Most populations fall in the intermediate risk group and have an incidence 
rate of between three and 30 per 100,000. This cancer obviously involves men rather 
than women and there is an un-ignorable variation on M/F ratios, from 5: 1 in high risk 
areas to 2: 1 in low risk areas 
(9). HCC usually occurs in individuals with chronic liver 
disease: in fact, the risk of developing HCC per year in cirrhotics ranges from 2 to 8%, 
depending on the different aetiologies of the underlying cirrhosis 
(18, 19).  
     Chronic hepatitis, caused by the hepatitis B virus or an hepatitis C virus infection, 
is the major risk factor for the development of HCC. There is considerable evidence 
for the involvement of various chemical carcinogens such as aflatoxin, cigarette 
smoking or heavy alcohol consumption. Also, it is well known that HCC develops 
more frequently in male cirrhotic patients than in females, and this striking male 
predominance led to the introduction of male gender as a risk factor. Not only do 
males develop HCC more  
 Fig 6.1: Gender difference in age specific incidence curves of hepatocellular 
carcinoma in populations with different risk of cancer 
(Plotted from Parkin et al: Cancer in five continents Vol. VIII 2002)Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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often than females, but once they develop the cancer, it is also more likely that the 
disease recurs, and the survival period is shorter 
(20). 
     Many investigators have focused on the possible importance of sex hormones in 
determining such preference for the male gender. In fact, HCC occurs more often in 
males with chronic liver disease. Males are under the constant influence of androgens 
throughout their life, but due to the presence of the underlying liver disease they also 
present a characteristic ‘feminization’ of their phenotype due to a relative hyper-
estrogenic state. As a result, both the presence of male sex hormones and the effect 
of the cirrhosis-induced feminization have been blamed as responsible, at least in 
part, for the development of HCC 
(21). On the other side, all these hormonal effects on 
the carcinogenic pathway interact with the host immune system, which play a critical 
role in response to viral (or even non-viral) infection.  
 
6.2.1.1. The role of Androgens     
            Association of androgens with an increased risk of liver neoplasm has been 
known for a long time. Agnew et al in 1952 reported an increased development of liver 
tumours in different strains of mice after chronic exposure to androgens 
(22). This 
finding was supported by later studies which showed excess susceptibility of rodents 
to chemical and viral induced carcinogenesis 
(23-26). In in vitro studies, the growth and 
proliferation of a hepatic normal or tumour cell line has been shown to be increased 
by dehydrotestosterone (DHT) and testosterone. In clinical practice, the use of 
androgenic steroids is associated with an increased risk of liver neoplasm including 
HCC 
(27-30). In a study on H-ras12V transgenic mice by Wang et al, orchidectomy 
significantly reduced the incidence of hepatotumorigenesis in males. However, no 
significant difference was detected in the incidence of tumorigenesis between 
ovariectomized and non-ovariectomized females. Molecular biochemical experiments Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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showed that the sex organ-related factors significantly influenced transgene 
expression, which contributed to activation of the MAPK signaling pathway 
(31). 
Velazquez and Alter reviewed the reported associations between anabolic androgenic 
steroids and liver tumours in patients with Fanconi's anemia. They concluded that all 
patients on anabolic androgenic steroids are at risk of liver tumours, regardless of the 
underlying diagnosis 
(17). 
     Androgen receptors (AR) are present in the normal liver tissue from both male and 
female mammalians, but their expression and activation is reported to be increased in 
the tumour tissue and in the surrounding liver tissue of individuals with HCC 
(33-37). 
Nagasue et al. showed that individuals with AR negative tumours had a survival rate 
of 55% five years after surgery, while those with AR positive tumours had a survival 
rate of 0% 
(37). The influence of high serum testosterone levels on the risk of tumour 
recurrence and long-term prognosis in male patients undergoing hepatectomy for 
early stage HCC has been studied by Lin et al. They showed patients with high serum 
testosterone to have significantly higher 5-year tumour recurrence rates and an 
inferior long-term prognosis than patients with low testosterone levels 
(38). 
     The hepatic effect of androgens is clearly receptor mediated, since their effect on 
tumour growth is inhibited by the concomitant presence of anti-androgen products that 
specifically block the AR. Orchidectomy or the use of anti-androgen treatment protects 
male rodents from tumour development 
(39-41). Moreover, ovariectomized female 
rodents receiving testosterone have a susceptibility to tumour development similar to 
that of intact males 
(42). 
The results of a follow-up study of 46 males with HCV related cirrhosis by Tanaka et 
al showed that elevated serum testosterone levels together with decreased estrogens 
may promote the development of HCC in cirrhosis 
(43). The male predominance in 
HBV-related HCC is much higher than that of HCV-related HCC with a ratio of 5-7: 1 
vs. 2-3: 1 
(44, 45). In addition, among male HBV carriers, those with a higher level of Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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serum androgen and more active AR gene alleles have a significantly increased risk 
of HCC 
(46, 47). This finding prompted investigators to examine whether specific HBV 
viral factors might also participate in male hepatocarcinogenesis by targeting the AR 
signalling pathway. Chiu et al showed that HBx, a HBV non-structural gene, increased 
the anchorage-independent colony forming potency of AR in a mouse hepatocyte cell 
line 
(48). 
          Despite strong evidence of involvement of androgen compounds in the 
hepatocarcinogenesis, the results of anti-androgenic trials in the treatment of HCC 
have been quite disappointing, as most of the published studies show a complete lack 
of effect of this therapeutic approach. Three large studies have been published 
recently: in the first study, Chao et al. assessed the clinical activity and toxicity of 
Flutamide, an anti-androgenic compound, in 32 patients with un-resectable HCC 
(49). 
The patients received Flutamide for 8 weeks; at the end of treatment, no complete or 
partial responses were observed. The authors concluded that HCC may not be an 
androgen-responsive tumour. In the second study, Grimaldi et al reported a multi 
centric double blind trial with 244 patients with un-resectable HCC randomized to 
receive different regimens of anti-androgens or placebo 
(50). No significant difference 
among the groups was reported at the end of the study. In the third study, male 
patients with advanced HCC were randomized into 2 groups treated with (a) 
leuprorelin, flutamide and tamoxifen or (b) tamoxifen alone administered until death. 
376 male patients were included. At the end of study, no benefit in survival was found 
with antiandrogenic treatment in male patients with advanced HCC 
(51). 
 
6.2.1.2. The role of Oestrogens 
          The normal liver tissue of male and female mammalians has high-affinity, low-
capacity, saturable and specific oestrogen receptors 
(52, 53). It has been shown that 
estrogens play an important role in the control of liver cell proliferation 
(54). The hepatic Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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ERs increase and are actively translocated to the nucleus after partial hepatectomy in 
humans and rats 
(55). Anti-oestrogens, like Tamoxifen, reduce the levels of both 
cytosolic and nuclear ER and inhibit hepatocyte proliferation following partial 
hepatectomy. 
     Cirrhotic patients have a unique hormone imbalance with an absolute or relative 
hyper-oestrogenic state manifested clinically by the occurrence of a ‘feminized’ 
phenotypic appearance 
(56-58). This feminization is the result of a direct effect on 
gonads of toxic agents (i.e. alcohol), altered hormone metabolism due to chronic liver 
disease, and failure of the hypothalamus- pituitary-gonadal axis. The activity of 
cytosolic ERs is also increased in liver diseases in males, enhancing the responsitivity 
of male liver to oestrogens 
(56-59). Moreover, the serum estradiol to testosterone ratio is 
higher in individuals with HCC and cirrhosis than in normal individuals or individuals 
with cirrhosis alone 
(56). Castagnetta and colleagues investigated the activity and 
expression of the aromatase enzyme in non-tumoural, cirrhotic, and malignant human 
liver tissues and cells. Human hepatocellular carcinoma (HCC) tissues and HepG2 
hepatoma cells showed elevated aromatase activity, compared to non-tumoural 
hepatic tissues where no aromatase activity could be detected. Cirrhotic samples 
exhibited intermediate enzyme activity. This implies that locally elevated oestrogen 
formation in malignant human liver tissues and cells may have a role in the 
development and/or maintenance of human HCC, eventually leading to develop 
alternative strategies for treatment of HCC patients using anti-aromatase agents 
(60). It 
is not clear if this could be a pathogenic factor in HCC or just an epiphenomenon. 
     In animal experiments it has been shown that oestrogens may induce also the 
formation of free radical-mediated DNA and RNA adducts potentially mutagenic 
(61). In 
humans, the chronic use of oestrogens is associated with increased risk of developing 
liver neoplasms such as benign nodular hyperplasia and hepatic adenoma 
(62-64). 
Oestrogens have also been described as a putative agent of HCC in humans, and the Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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level of nuclear ERs in the neoplastic liver is higher than in normal tissue 
(64). It has 
also been shown that intrahepatic transplantation of ovarian fragments in 
ovariectomized rats results in morphological abnormalities. Dombrowski and 
colleagues investigated the long-term development of these oestrogen-induced foci of 
altered hepatocytes in a large group of rats. They divided 451 Lewis rats into one test 
group and 11 control groups and observed them for up to 30 months. Test group 
animals were ovariectomized and received ovarian transplants into the right lobe of 
their liver. Different combinations of castration, transplantation of ovarian or testicular 
fragments, and administration of anti-oestrogenic Toremifene were used in controls. 
Hepatocellular carcinoma (HCC) appeared only in the test group. At 24 and 30 
months, 78% of test group showed at least one carcinoma. Administration of 
Toremifene in ovariectomized and transplanted animals completely prevented 
carcinogenesis. They concluded that initially adaptive but preneoplastic alterations in 
hepatocytes downstream of intrahepatically transplanted ovarian fragments may 
transform into HCC, indicating a strong hepatocarcinogenic potential of high local 
levels of endogenous estrogens in the rat liver 
(65).  
          In contrast to literature supporting carcinogenic effects of oestrogens, there is 
some evidence for oestrogen and oestrogen-like compounds to have a beneficial 
effect on the pathogenesis of hepatocellular carcinoma. The findings of Huang et al 
suggest that oestrogen and oestrogen-like compounds may induce anti-proliferative 
and apoptotic effects in Hep3B cells, and the E2 and the E2-like compounds’ 
mediated apoptotic effect was oestrogen receptor dependent 
(66).  
     HCC represents a classic case of inflammation-linked cancer 
(67), and chemically or 
genetically induced HCC depends on inflammatory signaling 
(68, 69). These 
inflammatory signals have some interactions with sex hormones during HCC 
carcinogenesis. Recently, Naugler et al in an animal study 
(70) used the chemical 
carcinogen diethylnitrosamine (DEN) to induce HCC in mice, which causes HCC in Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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100% of male mice but only in 10 to 30% of female littermates 
(71, 72). The DEN 
administration caused greater increases in serum interleukin-6 (IL-6) concentration in 
males than it did in females. DEN exposure promoted production of IL-6 in Kupffer 
cells in a manner dependent on the Toll-like receptor adaptor protein MyD88, ablation 
of which also protected male mice from DEN-induced hepatocarcinogenesis. The 
study that oestrogen inhibited secretion of IL-6 from Kupffer cells exposed to necrotic 
hepatocytes and reduced circulating concentrations of IL-6 in DEN-treated male mice 
(70). As its authors believe, the pathogenesis of HCC in this mouse model differs from 
that in humans and thus the protective effect of oestrogen may not be directly 
comparable to human HCC. 
     Several studies have used Tamoxifen for the treatment of HCC and the results 
appeared to be initially encouraging. Tamoxifen (TMX) is an anti-oestrogen drug used 
for the treatment of breast cancer. TMX has several other biologic activities that may 
have relevance in cancer treatment: inhibition of PKC, calmodulin, TGF-α and TGF-b1 
induction; antagonism of oestrogen binding to the erbB-2 oncogene; and activation of 
NK mediated cytotoxicity. Some of these may be responsible for the reported effects 
of TMX on various cancers. Most of the studies published in the early 90s reported a 
reduced tumour growth with prolonged survival in individuals treated with Tamoxifen 
as compared with untreated controls. The results were consistent with a meta-
analysis on the palliative treatment for HCC which indicated Tamoxifen as one of the 
few therapeutic approaches with a clear and significant beneficial effect 
(73). Di 
Bisceglie et al induced liver tumours by injecting ethyl-nitrosourea in a type of male 
mice. Two chemopreventive agents were administered over a period of 60 weeks: 
Tamoxifen and a retinoid, 13-cis-retinoic acid. Animals were killed at 60 weeks and 
their livers examined for HCC and premalignant lesions. All liver lesions occurred 
significantly less frequently in the Tamoxifen-treated group than the group given only 
ethylnitrosourea (HCC developed in 4% vs. 25%). Tamoxifen significantly decreased Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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the incidence of chemical carcinogenesis in this model, suggesting an important role 
for estrogens in the pathogenesis of HCC 
(74). 
     The positive conclusions about Tamoxifen were later contradicted by the results of 
two large trials utilizing Tamoxifen. In a multi centric trial, 496 patients with HCC at 
any stage were randomized into two matched group to receive Tamoxifen or a 
placebo 
(75). The median survival was 15 and 16 months, respectively, and the 
conclusion was that Tamoxifen is not effective in HCC treatment. The same results 
were observed by Liu et al: 119 patients with un-resectable HCC were randomized in 
two matched groups to receive Tamoxifen or a placebo 
(76). The median survival was 
44 and 41 days, respectively, and no relation between better survival and presence of 
ER receptors was found. 
 
6.2.1.3. Conclusion 
     Hepatocellular  cell  carcinoma  shows a distinctive male predominance in both 
incidence and mortality rates. Except to exposure with aflatoxine, alcohol, and 
chemical carcinogens, the majority of HCCs are developed in a background of 
cirrhosis due to viral hepatitis. While the reported prevalence of viral hepatitis is more 
noticeable in males than in females in some western European populations, this 
difference is unlikely to be able to explain profound male predominance of HCC 
worldwide. Experimental and clinical data have shown that both estrogens and 
androgens have important effects in controlling the replication rate of hepatic cells. 
Both estrogens and androgens may also have an effect on inducing or at least 
promoting the growth of liver tumours, including HCC. However, the disappointing 
results obtained by anti oestrogen and anti-androgen treatments may suggest that 
either the suppression of their effect, once the tumour has developed, has probably no 
clinical relevance on the progression of the disease or that ‘clinically’ HCC is not a sex Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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hormones responsive tumour. The controversial findings of the protective effects of 
oestrogen may open a different way for the interpretation of these data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2.2. Lung Cancer 
     Lung cancer has been the most common cancer in the world since 1985 
(2), and by 
2002, there were 1.35 million new cases, representing 12.4% of all new cancers. It 
was also the most common cause of death from cancer, with 1.18 million deaths, or 
17.6% of the world total. Worldwide, it is the most common cancer of men, with the 
highest rates observed in North America and Europe (Fig 6.2). Moderately high rates 
of men are also seen in Australia/New Zealand and East Asia i.e. China and Japan. 
Globally, the incidence rate is 35.5 per 100,000 men versus 12.1 per 100,000 women.  
This yields an M/F estimate of 3:1 
(1). Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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Fig 6.2: Age standardized incidence rate of lung cancer by geographical region 
(1)
 
     Lung cancer remains a highly lethal disease. Survival at 5 years measured by the 
SEER program in the United States is 15%, the best recorded at the population level. 
The average survival rate in Europe is 10%, not much better than the 8.9% observed 
in developing countries. The survival rate varies by stage of disease 
(1). The 
corresponding 5-year relative survival rates are 51.3% for localized, 17.1% for 
regional, and 2.1% for metastatic disease 
(77). Women have a better relative survival Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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rate compared to men for each stage of the disease, 
(10) and male sex is a 
consistently unfavourable prognostic indicator in advanced disease 
(78-80).  
 
6.2.2.1. Male predominance of lung cancer 
     Lung cancer historically has been more prevalent in men than women; however, 
the male/female incidence ratio has narrowed dramatically, as the incidence rate in 
men declines while the rate in women continues to rise slowly 
(10). This rising 
incidence of lung cancer in women is primarily due to an increase in tobacco use 
which started in the 1940s. The lung cancer death rate in women has subsequently 
increased rapidly since the 1960s, from about 5 cases per 100,000 women to an 
estimated 40 per 100,000 in 2000. Today, lung cancer is the most common cause of 
cancer death in women (27%) in USA, claiming more lives than breast and colorectal 
cancer combined (15 and 10%, respectively) 
(81). The estimated number of lung 
cancer cases worldwide has increased by 51% since 1985, but the rate of increase is 
significantly different in male and females, 44% in the former and 76% in the latter. In 
males, this increase is due solely to population growth and aging; there has actually 
been a small (3.3%) decrease in the actual age-standardized incidence. However, the 
ASRs have increased by 22% in females 
(1).  
   
6.2.2.2. Smoking and gender difference of lung cancer 
          Smoking is the overwhelming cause of lung cancer in both male and females. 
Although females diagnosed with lung cancer are more likely to be non-smokers than 
males, 
(11, 12, 82, 83) overall (both sexes) 85 to 90% of patients with lung cancer are 
current or former smokers. Smokers are 22 times more likely to die from lung cancer 
than non smokers 
(84).The proportion of smoking–related lung cancer can be 
estimated by comparing observed incidence in different areas with that expected 
based on rates in non smokers from several large cohort studies 
(85, 86). For the year Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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2000, an estimated 85% of lung cancer in men and 47% of lung cancer in women is 
the consequence of tobacco smoking. The fractions are lower for women, and several 
areas, including south-central Asia, have no smoking attributable cases. The highest 
fractions are in North America (85%), northern Europe (74%), and Australia/New 
Zealand (72%), where women have been smoking the longest 
(1).  
 
     Primary lung cancer represents different histological types including squamous cell 
carcinoma, adenocarcinoma, small cell carcinoma, and large cell carcinoma. Non-
small cell lung cancers (NSCLC) account for approximately 85% of lung cancer, and 
include the histological types of squamous cell carcinoma and large cell carcinoma, 
which arise from epithelial cells, and adenocarcinoma, which develops from glandular 
tissue in the peripheral regions of the lung. The proportional occurrence of these 
histological subtypes differs significantly between males and females 
(10). 
Adenocarcinoma is currently the most common histological subtype in both males and 
females, and females have proportionally less squamous cell carcinoma compared to 
males (Table 6.2). Cigarette smoking has been linked to all four histological subtypes; 
however, the proportion of non-smokers is highest in those who develop 
adenocarcinoma 
(87).  
 
     The incidence rates for the various histological subtypes have changed over time 
and reflect changes in smoking habits. For example, incidence rates for squamous 
cell carcinoma decreased in men between 1975 and 1999 while increasing slightly in 
women. On the other hand, the incidence rate of adenocarcinoma increased both in 
men and in women during that same time period, with a greater increase observed in 
women 
(10, 91). The increase in adenocarcinoma has been associated with the 
introduction of low-tar cigarettes that enhance delivery of smoke to peripheral regions 
of the lungs 
(92).  Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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Table 6.2: Frequency of patients diagnosed with different histological types of  
lung cancer by gender  
Squamous Cell 
Carcinoma 
 Adenocarcinoma   Other  histologies    Refs 
M (%)  F (%)    M (%)  F (%)    M (%)  F (%)     
36 21    33  45    31 34    10 
32 22    48  60    20 18    11 
38 24    38  47    24 29    12 
31 20    42  50    27 30    88 
41 17    42  74    17 9    89 
30 21    32  40    38 39    90 
 
     Approximately 10–15% of patients with lung cancer are non-smokers. The ratio of 
women to men in patients with lung cancer who have never smoked is approximately 
3:1 
(11, 93). The risk for developing lung cancer in both smokers and non-smokers is 
modulated by determinants that may vary between individuals. The development of 
lung cancer despite the low level of exposure to tobacco suggests that a subset of the 
general population may be more susceptible to the carcinogenic effects of tobacco 
smoke. Susceptibility is likely to be determined by each individual's capacity to 
activate and detoxify carcinogens in tobacco smoke. A positive family history also has 
been defined as a risk factor in non-smokers; particularly in the development of 
adenocarcinoma, in females, and in cases with an earlier age at onset 
(94-97).  
 
6.2.2.3. Sex differences in lung tumour biology 
     The current epidemiological evidence clearly shows sex-specific differences in lung 
cancer susceptibility and prognosis. Female patients with lung cancer appear to have 
a better survival rate. In a large population-based study, elderly women with early lung 
cancer had better risk adjusted survival regardless of the type of treatment compared Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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to men 
(98). On the other hand, women appear to have an increased susceptibility to 
tobacco carcinogens.  Smoking-related lung cancer is induced by the formation of 
DNA adducts in lung epithelial cells 
(99). The formation of DNA adducts is dependent 
on the enzymatic activation of several tobacco-related pro-carcinogens, including 
polycyclic aromatic hydrocarbon (PAH), 
(100). PAH activation is catalyzed by the 
cytochrome P450 enzymes CYP1A1 and CYP1B1, and inactivated by glutathione S-
transferases (GSTs). Levels of lung DNA adducts correlate with the level of CYP1A1 
expression. Among smokers, female patients had a 3.9-fold higher median level of 
CYP1A1 compared to males. Independent of smoking history, the combined variant 
genotype of CYP1A1 and GSTM1 contributes to an increased risk of lung cancer in 
women compared to men with the odds ratio 6.54 versus 2.36, respectively 
(101). 
Moreover, the carcinogens of tobacco smoke are associated with specific mutations of 
a relatively small number of codons of tumour suppressor p53 
(102). Analysis by gender 
shows that the tobacco-related p53 mutations are more common in females than 
males, evidence that females may be more susceptible to the carcinogenic effects of 
tobacco smoke 
(103-105).  
 
6.2.2.4. Sex hormones and Lung Cancer 
     Gender differences in the histological distribution of lung cancer and a possibly 
greater susceptibility of females than males to smoking–related carcinogenesis 
suggest a possible effect of sex specific hormones. Oestrogen plays a role in both 
normal pulmonary physiology and in the biology of non-small cell lung carcinoma 
(NSCLC) 
(106-108). In vitro studies confirm that NSCLC cells respond to oestrogens and 
anti-oestrogens by altering endogenous gene expression 
(109). ER-beta, and to a 
lesser extent ER-alpha, are expressed in lung tumours from both men and women. 
Expression of ER-beta is associated with improved survival, while expression of ER-
alpha is a poor prognostic factor 
(108, 110-112). In a case control study, a reduction in lung Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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cancer risk was observed with the use of oral contraceptives, and history of hormonal 
replacement therapy was also associated with lower risk of lung cancer, particularly 
after long term usage 
(113).  
          The chemopreventive role of phytoestrogens in lung cancer as an exogenous 
source of sex hormones has been evaluated in few studies. In a large scale 
population-based case-control study, the highest quartiles of total phytoesterols, 
isoflavones, lignans, and phytoestrogens were associated with reductions of the risk 
of lung cancer ranging from 21% to 46%. While there are limitations regarding case-
control studies of diet and cancer, this study provided a support for the growing 
evidence that phytoestrogens are associated with a decrease in the risk of lung 
cancer 
(114). 
     The greater survival rate of female patients with lung cancer has partly been linked 
to increased expression of the parathyroid hormone-related protein (PTHrP). This 
protein is commonly expressed in non-small cell lung cancer and could have 
implications for progression of the disease because it regulates cancer cell growth, 
apoptosis, and angiogenesis 
(115). A recent study showed that lung carcinoma in 
female mice expressed more PTHrP than in males possibly because of negative 
regulation by androgens in males 
(116). This finding is unique evidence implying a 
promotional effect of androgens on lung cancer. 
 
6.2.2.5. Conclusion 
Male predominance in lung cancer is a universal phenomenon throughout the world. 
Smoking is the most important risk factor for lung cancer and it explains a major part 
of gender difference. While the number of cases and incidence rate of lung cancer is 
more in men than in women, the latter shows more susceptibility to the effects of 
smoking which in turn modifies large expected M/F ratios. Most histologic types of 
lung cancer except adenocarcinoma demonstrate significant male predominance and Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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also a greater relationship with smoking. Sex hormones and genetic susceptibility are 
among the risk factors associated with the development of lung cancer in either 
smokers or non-smokers, but their role in male predominance is not clear 
 
 
 
 
 
6.2.3. Bladder Cancer 
          Bladder cancer with an estimated 357,000 cases in 2002 is the ninth most 
common cause of cancer for both sexes combined worldwide. It is relatively common 
in developed countries, where 63% of all incident cases occur (Figure 6.3). Rates are 
high in many southern and eastern European countries where smoking has been 
prevalent 
(1), and in parts of Africa and the Middle East where bladder cancer, 
particularly of the squamous cell type, is linked to chronic infection with Schistosoma 
hematobium 
(117). Some occupational exposures contribute to the high risk of 
developed countries. The highest recorded incidence rate is that found in Egypt, 
where the estimated world-standardized rate in men is 37 per 100,000. In the United 
States, the incidence in Whites is higher than in Blacks; about double among men and 
50% greater among women. It is unlikely that this is due to differences in exposure to 
environmental carcinogens, and explanations based on differential susceptibility have 
been proposed, including, for example, genetic polymorphisms of metabolic enzymes 
such as N-Acetyltransferase (NAT) and Glutathione S-transferase 1 (GSTM1) 
(118, 119). Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
 
141
 
Fig 6.3: Age standardized incidence rate of bladder cancer by geographical region 
(1)
 
6.2.3.1. Male predominance of bladder cancer 
     The majority (77%) of bladder tumours occur in men 
(1). The M/F ratio varies from 
8.2: 1 to 2.5: 1. The maximum M/F ratio has been reported from high incidence areas, 
i.e. Southern Europe. In most western countries, M/F ratio of bladder cancer is 2.5 to 
5 
(1, 120-127). Between 1985 and 2000 the number of bladder cancers diagnosed 
annually in the United States increased by 33%, at roughly the same rate in both 
genders 
(128, 129). Bladder cancer is virtually never recognized incidentally at autopsy Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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(130, 131). This coupled with the consistent method by which bladder cancer has been 
diagnosed (cystoscopy and biopsy) over the last six decades, indicates that the 
increase in bladder cancer cannot be attributed to technological innovations or major 
changes in the delivery of medical care. As a result, the reported differences in 
incidence rates between the genders cannot be simply explained by a failure to 
diagnose the disease in particular groups 
(132).  
     Cigarette smoking is a well established risk factor of urinary bladder cancer 
(127, 133-
137). It has been estimated that 65% of bladder cancer in men and 20% to 30% in 
women is attributable to cigarette smoking 
(127). Bladder cancer risk tends to increase 
with both increasing duration and increasing intensity of smoking 
(135, 138-145). As 
mentioned earlier, there is a huge male predominance in incidence of bladder cancer. 
Some have speculated that the high sex ratios observed in some countries may be 
due to the large differences in smoking prevalence between men and women 
(146). In 
support of this hypothesis, Samanic and colleagues removed the number of incident 
cases due to smoking in men and women from the incidence rates in their study. The 
M/F ratio fell from 8.2 to 1.7, suggesting that the high M/F ratio may be largely due to 
smoking, although the contribution of additional factors cannot be ruled out. They 
proposed two factors to explain the higher population attributable risk (PAR) for 
smoking in men than in women. These are first, the higher prevalence of smoking 
among men (37%) compared with women (8.7%), and second, the higher point 
estimates for smoking in men (OR, 7.4 current; OR, 3.8 former) than women (OR, 5.1 
current; OR, 1.8 former). The findings of this study overall suggest that smoking 
explains almost the entire male excess of bladder cancer in Spain 
(127). Only one study 
contrasts with that of Hartge et al 
(147), who found that cigarette smoking and 
occupational exposures explained only a part of the male excess of bladder cancer in 
the United States. 
 Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
 
143
 
Section 3 
 
 
Male predominance in incidence of gastric and oesophageal 
adenocarcinoma 
 
 
 
 
 
 
 
 
 
6.3.1. INTRODUCTION 
 
          A remarkable and unexplained characteristic of upper gastrointestinal 
adenocarcinoma is its male predominance.   This male predominance of gastric 
cancer is related to the histological subtype of the tumour.  Gastric adenocarcinoma 
may be of the intestinal or diffuse histological subtype as described by Lauren.
(148)  
The intestinal subtype is strongly linked to chronic H. pylori superficial gastritis.   
According to Correa, the latter may induce intestinal metaplasia of the gastric mucosa 
from which the intestinal subtype cancer is thought to develop.
(149)  The diffuse 
histological subtype of gastric cancer is less strongly associated with H.pylori infection 
and genetic predisposition is thought to be more important.
(150-152)  The gender 
phenomenon is more marked in gastric cancer of the intestinal versus diffuse 
histological subtype and this has been described well by Sipponen and colleagues.
(16)  
However, few, if any, cancer registries have reliable records of the histological 
subtype of gastric and oesophageal cancer and therefore true population-based 
incidence studies of the influence of gender on intestinal versus diffuse gastric cancer 
are lacking. 
     Interest in the role of gender in upper gastrointestinal cancer has been rekindled by 
the rapidly rising incidence of adenocarcinoma of the oesophagus in the western Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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world.
(153)  These cancers also demonstrate a marked male predominance and tend to 
present at a younger age in males.
(154)  Adenocarcinoma of the oesophagus is 
considered to be a consequence of chronic damage to the squamous mucosa of the 
distal oesophagus by acid, pepsin and probably bile refluxing from the stomach and 
small intestine.
(155, 156)  In response to this chronic damage, the oesophageal 
squamous epithelium undergoes metaplasia to become columnar in type and 
eventually resembling that of the small or large intestine.
(157, 158)  Oesophageal 
adenocarcinoma is thought to arise from this intestinal metaplasia and histologically 
resembles the intestinal subtype of gastric adenocarcinoma.   
     Global data from cancer registries suggests that the male predominance of upper 
gastrointestinal cancer is related to the anatomical location, being higher for 
adenocarcinoma of the oesophagus and lower for adenocarcinoma of the distal 
stomach.
(159)  The male to female ratio of age-standardised incidence rates for 
oesophageal adenocarcinoma in Scotland is of the order of 4.5:1, for adenocarcinoma 
of the proximal cardia region of the stomach or gastro-oesophageal junction it is 3.5:1 
and for more distal gastric cancer it is 2.0:1. 
(160)  However, the proportion of the 
intestinal histological subtype differs according to anatomical site and it is unclear 
whether it is the anatomical site or the histological subtype which is associated with 
the gender phenomenon. 
     Understanding the point at which the gender phenomenon is acting will facilitate 
unravelling its mechanism.  We have therefore conducted a population-based study to 
determine whether the gender phenomenon is primarily related to the anatomical site 
or to the histological subtype of adenocarcinoma of the upper gastrointestinal tract.  
This has been conducted in the West of Scotland, a region with a moderately high 
incidence of gastric cancer and with the highest recorded incidence of oesophageal 
adenocarcinoma in the world 
(160).  Our findings indicate that the intestinal subtype has 
the greatest impact on the gender ratio and this is unrelated to whether the carcinoma Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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has developed in the oesophagus or distal stomach.  Our study also indicates that the 
gender phenomenon is due to the development of the intestinal subtype of cancer 
being delayed by 17.3 years in females.  
 
 
6.3.2. METHODS & MATERIALS 
6.3.2.1. Setting 
     The study was based on patients with a diagnosis of gastric or oesophageal cancer 
recorded in the West of Scotland Cancer Registry between 1998 and 2002.  The 
Cancer Registry was covering more than a half of the Scottish population at this time.  
The registry constantly monitors data quality to evaluate reliability of recorded 
diagnosis. According to a recent reliability report in 1997, there was a 97% agreement 
in coding the major tumour site category based on ICD-10 and only 2% discrepancy in 
microscopic verifications of tumours.  Registration of cancers based on death 
certificate only (DCO) criteria for all malignant neoplasms, excluding non-melanoma 
skin cancer was only 0.4% in 1997 
(161).  For the time period included in our study, the 
estimated completeness of cancer registration was >96% 
(162). 
 
 
6.3.2.2. Selection Process 
We collected the tumour identification number of all cases of gastric and oesophageal 
adenocarcinoma recorded in the West of Scotland during the five year period 1998-
2002.  The study was conducted on histology slides and records of 812 randomly 
selected patients from a total of 3270 cases of gastric and oesophageal cancers 
recorded in the database. The number of samples was stratified by tumour site to 
ensure that the sites are present in the sample in the same proportion as in the 
population.  A random sample of pre-defined size was selected from each group of Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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cancers (approximately 25% for each site). Randomisation was performed with a 
computerised random number generator (SPSS Inc, Chicago, IL, USA). To be 
included in the study, all cases were required to have histologic samples available for 
microscopic verification. 
 
6.3.2.3. Histologic Study 
     All pathology records of sampled subjects were reviewed for microscopic diagnosis 
and anatomical site of tumour using ICD-10 and ICD O-2. The histologic subtype of 
adenocarcinoma was determined by the Lauren classification 
(148). By definition, 
intestinal subtype tumours have a glandular pattern usually accompanied by papillary 
formations or solid components. The glandular epithelium consists of large 
pleomorphic cells with large hyperchromatic nuclei often with numerous mitoses. They 
are usually fairly well polarized columnar cells, sometimes with a prominent brush 
border and goblet cells. Diffuse subtype was defined as tumour predominantly 
composed of poorly cohesive or completely un-cohesive infiltrating small tumour cells. 
Gland formation is inconspicuous, except sometimes in the superficial part of the 
tumour. Signet ring cells are common and there may be extracellular mucin in stroma. 
          When the information on the pathology reports was inadequate, the original 
microscopy slides were re-evaluated by the study pathologists using the Lauren 
classification. In order to ensure compatibility of reported classifications with our study 
definitions, at least 10% of all specimens with complete histologic records were 
selected randomly for re-examination using the same protocol.    
 
6.3.2.4. Statistical Analysis 
Binary logistic regression models were used to estimate the relationship between the 
odds of male gender (dependent variable) and histological subtype, tumour location Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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and age (independent variables). The histological subtype included intestinal and 
diffuse subtypes but not mixed subgroup due to a very small percentage of this type in 
the population sample. All gastric and oesophageal tumours of histology other than 
adenocarcinoma were excluded from analysis. Tumour location was defined as 
oesophageal, gastric cardia and gastric non-cardia as defined in the cancer registry 
database. Patients were categorised into 5 age-groups: <50, 50-59, 60-69, 70-79 and 
>80.   The 10 year groupings were arbitrarily chosen on common-sense grounds; the 
top and bottom groups extend beyond a decade to ensure all groups have an 
adequate number of patients.  Grouping age in this way for the logistic regression 
means that no assumptions have to be made about the form of the relationship (e.g, 
linear) between age and the odds of male gender.  The logistic regression models 
were used to estimate the odds of male gender for the categories of the independent 
variables, the associated 95% confidence intervals and the associated p-values.   
Logistic regression models were fitted initially for each independent variable 
separately.  A multiple logistic regression model was finally fitted including all the 
independent variables. All 2-way interactions between the independent variables were 
initially considered in this multivariable model, but as none were statistically significant 
at 10% they were omitted from the final analysis. 
 
6.3.2.5. Supplementary studies 
 
     As the above analysis indicated that male predominance was associated with the 
intestinal histological subtype and not tumour location, we proceeded to investigate 
characteristics of the male predominance affecting the intestinal versus diffuse 
subtype of tumours.  This included modelling the age specific incidence in males 
versus females in the intestinal and diffuse tumours and also of other tumours in our 
cancer registry.   Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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6.3.2.5.1. Curve fitting age-specific cancer incidence data  
     A curve fitting approach was taken to quantitatively describe the age-specific 
incidence of cancer using non-linear regression analysis. Equation 1 was fitted to the 
age-specific incidence data using the SOLVER function of Excel 
(163).
 The difference 
between the data and the model (sum of the square differences (SS)) was computed 
and the target function which was minimised by non-linear regression analysis using 
Generalized Reduced Gradient (GRG2) non-linear optimization was the root mean 
square of SS. Curve fits were obtained using similar starting estimates for all age-
specific incidence data. 
Equation 1                                          
b
t d t a I ) ( ) ( − × =
where,  
It is the age-specific incidence of cancer (per 100,000 person-year) at age t 
t is the mean age of the group 
a, b and d are regression constants where a is a scaling factor, b is a power 
term that reflects the rate of incidence with age and d is a delay term for the 
time between birth and age of increased incidence above zero. A logic IF 
function was used in Excel such that when t < d (t – d <0), I (t) = 0. Thus only 
when d > t was I (t) > 0.  
 
 
6.3.2.5.2. Comparison of gender related, age-specific incidence with other cancers 
     The 1998-2002 average age-group-specific incidence (per 100,000 person-years) 
were extracted from the ISD Scottish Cancer Registry for: cancer of the oesophagus, 
adenocarcinoma (ICD-10: C15, ICD-O-2 various); cancer of the oesophagus, 
squamous cell (ICD-10: C15, ICD-O-2: 8050-8076); cancer of the lung, squamous cell 
carcinoma (ICD-10: C33-34; ICD-O-2: 8050-8076), cancer of the lung, Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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adenocarcinoma (ICD-10: C33-34; ICD-O-2: various); cancer of the lung, small cell 
carcinoma (ICD-10: C33-34; ICD-O-2: 8040-8045); cancer of the bladder, squamous 
cell carcinoma (ICD-10: C67; ICD-O-2: 8051-8076); cancer of the bladder, transitional 
cell carcinoma (ICD-10: C67; ICD-O-2: 8050, 8120-8122, 8130); cancer of the colon 
(ICD-10: C18; ICD-O-2: various); and cancer of the pancreas (ICD-10: C25; ICD-O-2: 
various). These cancers were recorded for West of Scotland Cancer Registry 
matching the population for gastric and oesophageal cancer. The age-specific 
incidence of these cancers were also analysed by curve fitting, as described 
previously,  to examine gender differences in the incidence rate and the age at which 
incidence increased above zero.  
 
6.3.2.6. Ethical Considerations 
     The study protocol was reviewed and approved firstly by the Multi Centre Research 
Ethics Committee (MREC) which is acting nationally and subsequently by local NHS 
Ethics Committees. 
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6.3.3. RESULTS 
 
          In total 812 incident cancers with histologic diagnosis of oesophageal 
adenocarcinoma (C15), gastric cardia cancer (C16.0) and gastric non-cardia cancer 
(C16.1-16.9) were reviewed. Of these, 25 records (3.1 %) were excluded because 
both original reports and materials were missing (n=9) or they were recorded in 
duplicate (n=16). After the first round of document review, 3241 slides from 463 
cancer cases were reviewed because their original records had inadequate 
information regarding the Lauren histological subtypes. Among 349 reports with 
adequate information, 42 reports were selected randomly and related slides were re-
evaluated.  Classification of only 2 cases (<5%) required to be changed (from diffuse 
subtype to mixed subtype).  The distribution of cancers by sex and anatomical site in 
the sample studied showed no statistical difference from the correspondent entire 
cancer registry data.  
     Regardless of anatomical subsite, the upper GI cancers were more common in 
males (502, 63.8%) than females (285, 36.2%).  Four hundred and five (51.5%) of the 
cancers originated from the non-cardia region of the stomach, 173 (22.0%) from the 
gastric cardia and 209 (26.6%) from the oesophagus.   
     Histologically, 63.8 % of all tumours were of intestinal and 21.3% of diffuse subtype 
(Table 6.3). Of the remaining 117, 25.6% were mixed type of Lauren classification, 
30.8% undifferentiated carcinoma, and 43.6% of other histological diagnosis. The last 
group included adenosquamous carcinoma (n=1), large cell carcinoma (n=1), 
leiomyosarcoma (n=1), lymphoma (n=1), carcinoid tumour (n=7), carcinoma in situ 
(n=7), squamous cell carcinoma (n=10) and metastatic tumours of unknown origin Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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(n=23). For the purpose of this study, we only analysed the data of patients with either 
intestinal or diffuse type carcinoma which included more than 85 % of incident 
cancers. 
     The proportion of histological subtypes varied with tumour location. Intestinal 
/diffuse subtype ratio was 163/17 (9.6: 1) for oesophageal adenocarcinomas, 102/32 
(3.2: 1) for cardia and 227/119 (1.9: 1) for non-cardia adenocarcinomas (Fig 6.4). 
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Fig 6.4: Crude incidence rates of intestinal versus diffuse subtypes of 
adenocarcinoma in different tumour location 
 
 
 
  
 
 
 
 
 
Table 6.3: Crude incidence rates of upper GI cancer of the random sample of West of Scotland by histology and tumour location 
 
Tumour 
Location  Gastric Non-Cardia  Gastric Cardia  Oesophageal adenocarcinoma 
Histology  Number  Incidence Rate* Number  Incidence Rate* Number  Incidence Rate*
                          M F M F M F M F M F M F
Intestinal  151                        76 10.14 4.66 76 36 5.10 2.20 128 35 8.60 2.14
Diffuse  57                        62 3.82 3.79 17 15 1.14 0.91 9 8 0.60 0.49
Mixed  9                        6 0.60 0.37 4 3 0.27 0.18 6 2 0.40 0.12
Undifferentiated 7                        8 0.47 0.49 6 4 0.40 0.24 9 2 0.60 0.12
Other  10                        19 0.67 1.16 5 7 0.34 0.43 8 2 0.54 0.12
All types  234                      171 15.73  10.48 108 65 7.26 3.98 160 49 10.75 3.00
 
* Crude annual incidence rate, per 100,000 person-years 
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6.3.3.1. Association of male predominance with tumour location versus 
histological subtype 
 
     6.3.3.1.1. Gender and histological subtypes: Regardless of anatomical site, the 
crude incidence rate of intestinal subtype upper GI adenocarcinoma was higher in 
males at 23.86 per 100,000 person-years versus females at 9.00 per 100,000 person-
years, resulting in a M/F ratio of 2.65.  In contrast, the crude incidence rate of diffuse 
subtype adenocarcinoma was similar in males and females (5.58 vs 5.20 per 100,000 
person-years) yielding M/F ratio of 1.07 (Table 6.4, and Fig 6.5).  Gender effect 
expressed as M/F incidence ratio varied with age and histological subtype.  As shown 
in Fig 6.6, M/F ratio of intestinal subtype cancer was 3.41 at age less than 50, 
reached a peak of 7.86 at age 50-59, and then showed a progressive decrease with a 
minimum of 2.29 at age group 80 years and over. In contrast, M/F ratio of diffuse 
subtype cancer was 0.89 at age less than 50 and did not show any significant 
changes with increasing age. 
 
     6.3.3.1.2. Gender and tumour location: Regardless of histological subtype, the 
male predominance of adenocarcinoma incidence varied with anatomical location 
(Table 6.5).  Male predominance was greatest in the oesophagus with crude 
incidence rates of 9.21 and 2.63 in males versus females, respectively (M/F = 3.50). 
For cardia cancer the crude incidence rates were 6.25 and 3.12 for males and 
females (M/F= 2.00) and for non-cardia cancer 13.98 and 8.46 (M/F= 1.65). (Fig 6.7)  
 
 
 
 
  
 
 
 
Table 6.4: Distribution of upper gastrointestinal adenocarcinoma in different age groups by gender and histological subtypes 
 
Age groups 
<50  50-59  60-69  70-79  ≥ 80  All ages 
 Histology    
n  Rate
* n  Rate
* n  Rate
* n  Rate
* n  Rate
* n  Rate
**
Male  20 2.51 60 32.56 94 65.38 124 134.74 57 177.11 355 23.86
Female  6 0.57 8 4.14 21 12.50 52 38.94 60 77.44 147 9.00
Total  26 68 115 176 117 502
Intestinal 
subtype 
M/F  3.41 7.86 5.23 3.46 2.29 2.65
Male  7 0.68 14 7.56 25 17.38 27 29.34 10 31.07 83 5.58
Female  8 0.75 11 5.69 17 10.11 24 17.98 25 32.26 85 5.20
Total  15 25 42 51 35 168
Diffuse 
subtype 
M/F  0.89 1.33 1.72 1.63 0.96 1.07
Male  27 2.60 74 40.16 119 82.77 151 164.07 67 208.18 438 29.44
Female  14 1.32 19 9.83 38 22.62 76 56.93 85 109.71 232 14.21
Total  41 93 157 227 152 670
Both 
subtypes 
M/F  1.97 4.09 3.66 2.90 1.90 2.07
 
Rate
*:
 Age-specific incidence rate per 100,000 person-years 
Rate**: Crude incidence rate per 100,000 person-years 
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Figure 6.5: Age specific incidence rate of upper GI adenocarcinoma by gender, (top) combined 
intestinal and diffuse subtype, (middle) intestinal subtype and (bottom) diffuse subtype 
 
Table 6.5: Distribution of upper gastrointestinal adenocarcinoma in different age groups by gender and tumour location 
 
Age groups 
<50  50-59  60-69  70-79  >= 80  All ages 
Tumour 
location 
  
n  Rate
* n  Rate
* n  Rate
* n   Rate
* n  Rate
* n      Rate
**
Male  9 0.86 28 15.20 54 37.56 69 74.97 48 149.15 208 13.98
Female  11 1.04 10 5.17 25 14.88 41 30.71 51 65.73 138 8.46
Total  20 38 79 110 99 346
Gastric  
non-cardia 
M/F  0.83 2.94 2.52 2.44 2.27 1.65
Male  9 0.86 15 8.14 24 16.69 36 39.12 9 27.97 93 6.25
Female  2 0.18 5 2.59 5 2.98 18 13.48 21 27.11 51 3.12
Total  11 20 29 54 30 144
Gastric cardia
M/F  4.78 3.14 5.69 2.90 1.03 2.00
Male  9 0.86 31 16.82 41 28.52 46 49.98 10 31.07 137 9.21
Female  1 0.09 4 2.07 8 4.76 17 12.73 13 16.78 43 2.63
Total  10 35 49 63 23 180
Distal 
oesophagus 
M/F  9.56 8.13 5.99 3.93 1.85 3.50
Male  27 2.60 74 40.16 119 82.77 151 164.07 67 208.18 438 29.44
Female  14 1.32 19 9.83 38 22.62 76 56.93 85 109.71 232 14.21
Total  41 93 157 227 152 670
All sites 
M/F  1.97 4.09 3.66 2.90 1.90 2.07
 
Rate
*:
 Age-specific incidence rate per 100,000 person-years 
Rate**: Crude incidence rate per 100,000 person-years 
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Figure 6.6: Male to female ratios of age-specific incidence rate of upper GI adeno-
carcinoma by histological subtype.  Note that the ratio of the intestinal subtype
increases to a maximum at age group 50-59 followed by a progressive decrease.
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     6.3.3.1.3. Multivariable analysis of male predominance risk factors: 
Multivariable logistic regression including histological subtype, tumour location and 
age indicated that the odds of male gender was mainly related to the histological 
subtype and age rather than anatomical location. Although the odds of male gender 
was higher for oesophageal versus non-cardia adenocarcinoma when anatomical 
location was considered alone in a logistic regression model [Odds ratio (OR)= 2.11;  
95% confidence interval (CI): 1.41 - 3.17],  this relationship with anatomical location 
lost statistical significance in the multivariable analysis when histological subtype and 
age were  added [OR=1.37; 95% CI: 0.88 - 2.12]. In addition the overall significance 
level in the logistic regression model for anatomical location diminished from p<.001 
when it was considered alone to p=.333 when considered together with age and 
histological subtype. This suggests that male predominance in upper GI 
adenocarcinomas was not primarily a function of tumour location but rather related to 
histological subtype and age (Table 6.6). Intestinal subtype adenocarcinoma was 
associated with increased odds of male gender irrespective of anatomical location or 
age [OR=2.64; 95% CI: 1.78 – 3.90). Increasing age showed an overall inverse 
relationship with the odds of male gender excluding those aged < 50 years; again this 
relationship persisted when anatomical location and histological subtype were 
considered in the same logistic regression model. 
 
 
 
 
 
  
 
Table 6.6: Logistic regression analysis of association between gender (in favour of male) and histological subtype, tumour location and 
age 
 
 
Independent Variable Considered 
Individually  Multivariable Model 
    95 % C.I. for OR  95 % C.I. for OR 
  
P value 
  
Odds Ratio
(OR)  Lower  Upper 
 
P value 
  
Odds Ratio
(OR)   Lower  Upper 
Histological subtype                 
   Diffuse                     (Referent)    1.000        1.000     
   Intestinal  0.000  2.473  1.728  3.539  0.000  2.637  1.784  3.896 
Tumour Site                 
   Gastric non-cardia  (Referent)    1.000        1.000     
   Gastric Cardia  0.355  1.210  0.808  1.811  0.983  0.995  0.648  1.529 
   Distal Oesophagus  0.000  2.114  1.410  3.168  0.161  1.368  0.883  2.121 
      P value for overall effect  0.000        0.333       
Age band                 
   Age < 50                 (Referent)    1.000        1.000     
   Age 50-59  0.093  2.019  0.890  4.581  0.165  1.821  0.782  4.240 
   Age 60-69  0.200  1.624  0.773  3.409  0.328  1.466  0.681  3.155 
   Age 70-79  0.934  1.030  0.511  2.079  0.721  0.876  0.423  1.813 
   Age >=80  0.015  0.409  0.199  0.840  0.006  0.347  0.164  0.736 
      P value for overall effect    0.000     
 
  0.000     
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6.3.3.2. Characteristics of male predominance of upper GI adenocarcinoma 
 
     The rise in incidence with increasing age was much more marked in the intestinal 
versus diffuse subtype (Fig 6.8).  For the diffuse histological subtype the crude and 
age-specific incidence rates were similar for males and females. Curve fitting of the 
age-specific incidence data for diffuse subtypes resulted in similar equations, y = 
0.016 x mean age 
2.007, R
2 = 0.999 and y = 0.016 x mean age 
1.954, R
2 = 0.989, for 
male and females respectively.  The age at which the age-specific incidence curve 
rose above zero was similar in males (33.0 years) and females (35.8 years).  For the 
intestinal histological subtype, the age-specific incidence data were different for males 
and females. Curve fitting indicated a similar incidence rate in males (y = 0.016 x 
mean age 
2.315, R
2 = 0.990) and in females (y = 0.016 x mean age 
2.316, R
2 = 0.998). 
However, the age-specific incidence curve for females did not appear to deviate from 
zero until an older age compared with male intestinal subtype. The age at which the 
age-specific incidence curve rose above zero was 28.8 years in males versus 46.1 
years in females indicates a delay of 17.3 years in the appearance of intestinal 
subtype cancer in females.  
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6.3.3.3. Characteristics of male predominance in other cancers:       
          Analysis of all recorded cases of oesophageal adenocarcinoma in the Scottish 
Cancer Registry between 1998 and 2002 produced similar age-specific incidence 
curves to that observed in our random sample of oesophageal adenorcarcinoma with 
an age delay in the appearance of intestinal subtype cancer in females of 15.6 years 
(Table 6.7).  Analysis of age-specific incidence curves of squamous cell carcinoma of 
oesophagus, lung cancer (three common histologic types), bladder cancer (two 
common histologic types), colon cancer (all histologies) and pancreatic cancer (all 
histologies) showed no evidence of a gender related delay in the incidence of these 
cancers.  This analysis included squamous cell carcinoma of lung and transitional cell 
carcinoma of bladder, which have a M/F ratio of 2.1 and 2.6 respectively.  In the latter 
cancers, the higher male incidence was due to a higher rate of increase rate rather 
than any gender specific delay in the rise of incidence (Table 6.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 6.7:  Parameters from fit of equation 1 to age-specific incidence rates of upper GI adenocarcinomas compared with other cancers 
from West of Scotland 1998-2002. 
 
M / F ratio 
 
Male 
 
     
Female  Gender Bias 
 
 
(of crude 
incidence) 
 
a 
 
b 
 
d 
     
a 
 
b 
 
d  ∆a 
 
∆b 
 
∆d 
                      
Upper GI adenocarcinoma,  
Intestinal subtype 
 
2.65  0.02               
                    
              
                    
               
                    
              
                    
              
                    
                    
                    
                
                    
              
                    
                    
2.32 28.8    0.02 2.32 46.1   0.0 0.0 17.3
Upper GI adenocarcinoma,  
Diffuse subtype 
 
1.07  0.02 2.01 33.0    0.01 1.95 35.8   0.0 -0.1 2.8
Oesophageal  
adenocarcinoma 
 
2.96  0.02 2.21 33.1    0.01 2.09 48.7   0.0 -0.1 15.6
Oesophageal squamous  
cell carcinoma 
 
1.07  0.02 2.16 34.7    0.01 2.15 37.0   -0.1 -0.1 2.3
Squamous cell  
carcinoma of lung 
 
2.10  0.02 2.64 38.2    0.02 2.47 38.7   0.0 -0.2 0.5
Adenocarcinoma of lung 
 
1.32  0.03  2.24  34.5    0.02  2.18  32.5    0.0  -0.1  -2.0 
Small cell carcinoma of lung 
 
1.14  0.02  2.38  34.4    0.04  2.16  37.3    0.0  -0.2  2.9 
Squamous cell carcinoma  
of bladder 
 
0.88  0.001 2.22 38.2    0.001 2.31 38.8 0.0 0.1 0.6
Transitional cell carcinoma  
of bladder  
 
2.57  0.01 2.63 40.0    0.01 2.20 36.0   0.0 -0.4 -4.0
Cancer of the colon  
 
1.06  0.02  2.49  34.8    0.06  2.21  36.7    0.0  -0.1  1.9 
Cancer of the pancreas  1.07  0.09  1.84  39.4    0.04  1.90  36.2    -0.1  0.1  -3.2 
 
Note: Equation1:    where,  I is the incidence rate of cancer at age t, which is the mean age of the age group, a is a scaling factor, b 
is a power term that reflect the rate of increasing incidence with age and d is a delay term for the time between birth and age of rise of age-specific 
incidence curve above zero.  
b
t d t a I ) ( ) ( − × =
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Section 4 
 
 
 
Evaluation of gender difference in prevalence of gastric 
precancerous lesions 
 
 
 
 
 
6.4.1. INTRODUCTION 
     As we showed in the previous section, the incidence of Intestinal subtype gastric 
adenocarcinoma in males is higher than in females and almost all male predominance 
of upper gastroesophageal cancer can be explained by a remarkable 17 years’ delay 
in the development of the intestinal subtype in females compared to males. The 
intestinal subtype of gastric adenocarcinoma arises due to progression of a H.pylori-
induced chronic inflammation to atrophic gastritis to intestinal metaplasia and finally to 
adenocarcinoma. The histological stage in this pathway in which gender acts is 
unclear.  
     As mentioned earlier, the Ardabil province in Northwest of Iran is an area with high 
incidence of gastric cancers, particularly those located at gastric cardia. Due to 
excellent collaboration of local health and academic authorities with national and 
international research teams, this area has been considered for many population-
based projects on upper gastrointestinal tract cancers. The current study on gender 
and gastric precancerous lesions is part of a large cross-sectional study on gastric 
and oesophageal cancer in this region, and we have investigated the influence of Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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gender on the frequency of different histological inflammatory and precancerous 
lesions.  
 
 
 
 
6.4.2. METHOD & MATERIALS 
 
6.4.2.1. Subjects  
     Participants in the study were selected in collaboration with Ardabil University of 
Medical Sciences. A list of all the families resident in the Meshkinshahr district was 
prepared and the rural/urban distribution of the population was computed. The 
sampling framework included all the families with at least one member aged ≥40 
based on the 2001 census. By using stratified random sampling, 650 families were 
selected from rural and urban areas in proportion to the population size of each area. 
In families with more than one eligible member, one only was selected randomly and 
invited by trained native interviewers to participate in the study. Five-hundred and 
thirty-seven individuals (82.7%) agreed to participate. Before endoscopy, all 
participants were interviewed and a brief physical examination was performed. 
Twenty-five individuals were excluded from the study for three reasons: presence of 
cardiac, respiratory, or other problems which were expected to increase the risk of 
complications of endoscopy and biopsy for the patients (eighteen cases), pregnancy 
(one case), and recently taking medications for H.pylori eradication (six cases). Four 
cases were excluded because of poor cooperation during endoscopy. Finally, 508 
participants were recruited to the study after signing an informed consent agreement.  
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6.4.2.2. Endoscopic evaluation and mucosal biopsy  
     The procedure for endoscopy and tissue sampling was designed by the Digestive 
Diseases Research Centre (DDRC) and approved by the medical ethics committee of 
Tehran University of Medical Sciences. All the endoscopy procedures were performed 
by four experienced gastroenterologists after local anaesthesia by oral administration 
of 10% Lidocaine spray and intravenous infusion of 5–7.5 mg Midazolam. Before the 
study the gastroenterologists were informed of the objectives and details of the 
procedures. The nomenclature and visual diagnostic criteria of the lesions of the 
upper GI tract were reviewed by the members of the team to minimize inter-observer 
diagnostic variations. Pentax EG2940 video endoscopes were used for the procedure. 
All notable lesions were recorded and reported in minimal standard terminology 
(164). 
Biopsy specimens were obtained using conventional disposable biopsy forceps. The 
first biopsy from the incisura angularis was used for a rapid urease test (RUT). Biopsy 
sites for histological examination were chosen in accordance with a modified format of 
the updated Sidney classification recommendations 
(165). In this format six different 
biopsies were performed and oriented on filter paper before fixation. The biopsies 
included three samples from different parts of the antrum, two from the corpus, and 
one from the cardia. Samples were placed in six pre-labeled containers with 10% 
neutral buffered formalin as fixative. Additional separate biopsy samples were taken 
from any lesions observed endoscopically and treated in the same way as the other 
samples.  
 
 
6.4.2.3. Histopathological examination of samples 
     All the specimens were processed, sectioned, and stained with the hematoxyline– 
eosin method in routine procedures and studied by a team of three pathologists well 
experienced in upper GI biopsies. All samples with abnormal findings were studied by Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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the second pathologist of the team. In the event of diagnostic discrepancy the 
controversial case was agreed to be reviewed by both pathologists in joint sessions to 
reach a diagnostic consensus. 
 
     One out of ten slides was also randomly and blindly re-examined by the second 
pathologist for diagnostic quality assurance. The histological criteria used for 
evaluation of gastritis were based on the updated Sydney system for classification of 
gastritis 
(165). PMN and MN cell infiltrations of the mucosa were scored from zero to 
three on the basis of morphological scales but we used the results as dichotomous 
data in most of the calculations. The sum of PMN and MN infiltrations was expressed 
as combined inflammatory score (CIS) for each biopsy site. For evaluation of H.pylori 
infection the presence of the bacteria in at least one biopsy site or a positive RUT was 
regarded as indicative of global infection of the stomach. 
 
     6.4.2.4. Statistical methods 
Relationships between the two components of gastritis (PMN and MN infiltrations) and 
male gender were indicated by the odds ratio (OR) and the 95% confidence interval 
(CI) for each subsite.  
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6.4.3. RESULTS 
6.4.3.1. Chronic Gastritis and Gender 
     In the general population, the frequency of active inflammation in all biopsy sites 
between both genders was similar (Table 6.8). Our data also did not show any 
difference in chronic inflammation between males and females (Table 6.9). The rate of 
H.pylori infection, based on histology and rapid urease test was similar among both 
genders (82.1 % and 82.5 % in males and females, respectively), [OR=1.0 (0.6 – 1.7).  
 
Table 6.8: Relationship between gender and Active inflammation (PMN infiltration) 
                  In different locations of the gastric mucosa 
Male Female  Biopsy site 
N % N % 
Male Vs. Female 
OR (95% CI) 
Cardia  Cardia 122  54.2  136  50.9  1.1 (0.8 – 1.6) 
Greater Curvature  94   40.7  124  45.8  0.8 (0.6 – 1.2)  Corpus 
Lesser Curvature  123  53.7  141  52.6  1.0 (0.7 – 1.5) 
Prepyloric   149  64.2  177  66.0  0.9 (0.6 – 1.3) 
Incisura Angularis  148  63.8  190   70.1  0.8 (0.5 – 1.1) 
Antrum 
Greater Curvature  127  55.7  161  59.4  0.9 (0.6 – 1.2) 
 
Table 6.9: Relationship between gender and chronic inflammation (MN infiltration) 
                  in different locations of the gastric mucosa 
Male Female  Biopsy Site 
N % N % 
Male Vs. Female 
OR (95% CI) 
Cardia  Cardia 158  70.2  185  69.3  1.0 (0.7 – 1.5) 
Greater Curvature  159  68.8  193  71.2  0.9 (0.6 – 1.3)  Corpus 
  Lesser Curvature  186  81.2  208  77.6  1.2 (0.8 – 1.9) 
Prepyloric   198  85.3  219  81.7  1.3 (0.8 – 2.1) 
Incisura Angularis  211  90.9  238  87.8  1.4 (0.8 – 2.5) 
Antrum 
 
Greater Curvature  185  81.1  214  79.0  1.1 (0.7 – 1.8) 
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6.4.3.2. Precancerous changes and Gender  
 
    The frequency of non-metaplastic atrophy at the all biopsy sites was similar in both 
genders (Table 6.10). Intestinal metaplasia of antrum was more prevalent in males 
than in females (11.6 % vs. 5.9 %) and showed a significant relationship with gender 
[OR= 2.1 (1.1 – 4.0)]. A similar relationship was evident in cardia and corpus subsites 
[OR= 3.1 (1.2 – 8.1) and OR= 7.4 (1.6 – 33.3), respectively]. Considering the 
presence of intestinal metaplasia in at least one subsite of gastric mucosa, males had 
more metaplastic changes than females (24.4 % vs. 16.8%) and the subsequent 
relationship with gender had narrower confidence interval [OR=1.6 (1.1 – 2.5)]. (Table 
6.11) 
 
 
Table 6.10: Relationship between gender and mucosal atrophy in different 
                    locations of the stomach 
 
Male Female  Biopsy Site 
N % N % 
Male Vs. Female 
OR (95% CI) 
Cardia  Cardia 63  28.0  79  29.6  0.9 (0.6 – 1.4) 
Greater Curvature  70  30.3  104  38.4  0.7 (0.5 – 1.0)  Corpus 
  Lesser Curvature  86  37.6  105  39.2  0.9 (0.7 – 1.4) 
Prepyloric   83  35.8  104  38.8  0.9 (0.6 – 1.3) 
Incisura Angularis  89  38.4  121  44.6  0.8 (0.5 – 1.1) 
Antrum 
 
Greater Curvature  91  39.9  110  40.1  1.0 (0.7 – 1.4) 
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Table 6.11: Relationship between gender and intestinal metaplasia in different  
                    locations  of the gastric mucosa 
 
Male Female  Biopsy Site 
N % N % 
Male Vs. Female 
OR (95% CI) 
Cardia  Cardia 15  6.7  6  2.2  3.1 (1.2 – 8.1) 
Greater Curvature  12  5.2  2  0.7  7.4 (1.6 – 33.3)  Corpus 
  Lesser Curvature  18  7.9  15  5.6  1.5 (0.7 – 3.0) 
Prepyloric   19  8.2  19  7.1  1.2 (0.6 – 2.3) 
Incisura Angularis  27  11.6  16  5.9  2.1 (1.1 – 4.0) 
Antrum 
 
Greater Curvature  12  5.3  21  7.7  0.7 (0.3 – 1.4) 
All Sites (IM in at least one site)  57  24.4  46  16.8  1.6 (1.1 – 2.5) 
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6.5. DISCUSSION 
 
   This study confirms the long-recognised male predominance of adenocarcinoma of 
the upper gastrointestinal tract, the crude incidence rates being 29.44 in males and 
14.21 in females. It also confirms that the degree of male predominance varies by 
anatomical site of the adenocarcinoma, being greatest in the oesophagus (M/F ratio = 
3.50), less at the cardia (M/F ratio =2.00), and least in the more distal non-cardia 
region of the stomach (M/F ratio = 1.65). This relationship between anatomical site 
and male predominance has been observed in several previous studies from different 
regions of the world.
(154, 166)
          The proportion of the intestinal to diffuse histological subtypes varied with 
anatomical locations, being 9.6: 1 in the oesophagus, 3.2: 1 at the cardia and 1.9: 1 in 
the distal stomach (Table 6.3). A high ratio of the intestinal /diffuse histological 
subtypes has been reported in the cardia and non-cardia region of the stomach in 
previous studies 
(151, 167-170). 
     A strong association was observed between male predominance and histological 
subtype. Regardless of anatomical subtype, the crude incidence rate of intestinal type 
upper gastrointestinal tract adenocarcinoma was higher in males with a M/F ratio of 
2.65: 1.  In contrast, the crude incidence rates of the diffuse subtype were similar in 
male and females with a M/F ratio of 1.07: 1.  
              Applying multivariable analysis to our population-based data allowed us to 
investigate for the first time whether the gender phenomenon was related to the 
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indicated that it was the intestinal subtype that was associated with male 
predominance rather than anatomical location. The higher male predominance in 
oesophageal versus gastric adenocarcinoma is explained by the higher incidence of 
intestinal subtype in the former.  
          The Lauren histological classification was originally devised to classify gastric 
adenocarcinoma and has proved to be of aetiopathogenic value 
(148). The intestinal 
histological subtype of gastric cancer develops against a background of chronic H. 
pylori induced gastritis.
(149, 171)  The chronic inflammation causes atrophy of 
specialized gastric glands that are replaced by intestinal metaplasia from which the 
intestinal type of gastric adenocarcinoma is believed to originate. Oesophageal 
adenocarcinoma is nearly always intestinal in subtype and histologically 
indistinguishable from the intestinal subtype of adenocarcinoma of the stomach. 
Oesophageal adenocarcinoma also resembles intestinal subtype gastric cancer in its 
pathogenesis in that it develops against a background of chronic mucosal damage. 
Exposure of the squamous epithelium of the distal oesophagus to refluxing gastric 
juice causes it to undergo metaplasia to columnar type epithelium resembling the 
stomach and then to the intestinal type of epithelium 
(172, 173) from which the 
oesophageal adenocarcinoma of intestinal phenotype develops. The finding in our 
current study, that the intestinal type of adenocarcinoma of the oesophagus and 
stomach show the same male predominance, provides further evidence of similarity of 
pathogenesis and supports applying the Lauren classification to oesophageal 
cancers. 
          We further investigated the male predominance of intestinal type upper 
gastrointestinal adenocarcinoma by comparing the age-specific incidence rates of the 
two sexes. Curve fitting indicated that the male and female were described by similar 
power terms in the functions describing the curves.  The only difference between the 
curves was that the rise in the incidence of female cancer lagged behind that of the Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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male by 17.3 years. The male predominance of this cancer is due to the rise of cancer 
incidence with age in males commencing at 28.8 years of age compared to 46.1 years 
of age for females.  Sipponen and Correa have previously reported a delay in the 
development of the intestinal subtype of gastric cancer in females in the Finnish 
population.
(174)    A delay in development of oesophageal carcinoma in females has 
not been reported previously but there are reports of a delay in development of 
Barrett’s oesophagus in females versus males. 
(175, 176). 
     The fact that the rise in age-specific incidence of intestinal subtype is occurring 
17.3 years later in females than males, but has the same slope, indicates that there is 
temporary delay in development of the cancer in females which then disappears 
around age 46.  If the protection against of cancer development persisted throughout 
life the power term in the function describing the incidence rate would be expected to 
be different in females compared with males.  The maximum difference in the gender 
incidence ratio will occur at whatever age the process differentially influencing the 
carcinogenic process in males versus females disappears.  The difference in M/F ratio 
increased to a maximum at 50-59 years of age (7.9: 1) and then showed a marked 
progressive decrease (Figure 6.6).  This indicates the difference in the age-specific 
incidence of cancer between males and females is limited to <55 years of age.  
          In contrast to intestinal type adenocarcinoma, the diffuse subtype showed no 
difference in age-specific incidence between males and females. In addition, the 
power term in the function describing the incidence rate for diffuse subtype was lower 
than that for the intestinal subtype. This is consistent with a stronger genetic 
predisposition being involved in the development of the diffuse subtype of cancer and 
thus fewer mutations are required to complete the carcinogenic process 
(177).  
     Applying similar curve-fitting analysis to a range of other types of cancers in the 
same population over the same time period revealed no evidence of a gender based 
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transitional cell carcinoma of bladder which have a strong male predominance related 
to smoking 
(178, 179) showed differences in power term in the function describing the 
incidence rate between the genders but no evidence of a delay in onset.  
     In summary, our study indicates (I) that the male predominance of gastrointestinal 
adenocarcinoma is related to the intestinal subtype and is independent of whether the 
cancer arises in the oesophagus or proximal or distal stomach; (II) that the male 
predominance of the intestinal subtype is due to a delay of 17.3 years in its rise in 
incidence in females; (III) that this delay is due to differences between males and 
females of less than 55 years of age.   
     The reason for the difference in the development of the intestinal subtype of upper 
gastrointestinal cancer in females versus males is unclear and deserves further 
consideration and investigation.  The fact that the delay is occurring at age less than 
55 years makes it likely to be related to an endogenous protective effect associated 
with the reproductive years in the female. Fox et al reported gender specific H.pylori–
related carcinogenesis in INS-GAS mice which was explained by a protective effect of 
17β-estradiol 
(180-182). In humans, delayed menopause and hormone replacement 
therapy may protect against gastric cancer
 (183-185).  The intestinal subtype of cancer 
arises against a background of chronic inflammation and tissue damage. The female 
sex hormone, oestrogen, is known to suppress the inflammatory response and 
cytokine production in certain tissues and might be exerting similar effects in the 
upper GI tract 
(186, 187). In addition, females have lower body iron stores during their 
reproductive years and this might modify the degree of DNA damage arising from 
chronic inflammation 
(188 -191).   
     Several observations indicate that the delayed development in females is unlikely 
to be explained by different lifestyle factors such as smoking.  Firstly, in cancers with 
male predominance due to exogenous lifestyle factors (i.e. lung, bladder), the age 
specific incidence data demonstrate differences in the power terms for the function Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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describing the data rather than a delay in appearance of the cancer.  Secondly, recent 
studies have reported male predominance of gastric cancer in never-smokers
 (192, 193).  
Thirdly, male predominance is observed in animal models of gastric cancer raised in 
an identical environment
 (194).  Fourthly, smoking rates in the U.K. available from 1978-
1998 are similar for males and females under 50 years of age.
(195)
          The intestinal subtype of gastric adenocarcinoma arises due to progression of 
chronic superficial gastritis to atrophic gastritis to intestinal metaplasia to dysplasia 
and finally cancer 
(149).  Where the gender acts in the carcinogenesis cascade was 
one of the questions we tried to investigate. We were able to analyse data of our 
population-based cross sectional study of gastric precancerous lesion in Ardabil, 
Northwest of Iran 
(196). The results of histologic examination of gastric biopsies from 
different pre-determined sites revealed similar rates of chronic gastritis (including both 
PMN and MN infiltrations) among men and women. The frequency of atrophic gastritis 
in men and women also showed no difference. These results were consistent with the 
results of Watabe et al who showed a similar rate of serologic atrophic gastritis among 
Japanese men and women 
(197). 
     In contrast to inflammatory and atrophic lesions, intestinal metaplasia of the gastric 
mucosa was more prevalent in men. This was evident in all three subsites. This 
finding is consistent with the results of You et al who showed a higher prevalence of 
intestinal metaplasia and glandular dysplasia in men in a Chinese population 
(198). This 
suggests that the gender phenomenon is acting at or after the metaplastic stage.   
With respect to the oesophagus, columnar epithelial metaplasia is more common in 
males than females (M/F = 1.7:1) and specialised intestinal epithelial more markedly 
so (M/F = 2.1:1).  This again indicates the gender phenomenon is evident at and after 
the metaplastic stage.
(199) 
     In conclusion, this study indicates that the marked male predominance of upper 
gastrointestinal adenocarcinoma is due to a more than 17 years delay in the Chapter 6: Male Predominance in Upper Gastrointestinal Cancer 
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development of the intestinal subtype of the cancer. The basis of this phenomenon 
requires investigation as it accounts for a substantial proportion of upper 
gastrointestinal cancers and of such cancers occurring at a younger age when the 
personal, social and economical implications are greatest. It is likely also to give 
valuable new insights into the control of the carcinogenic process. 
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             Conclusion 
 
 
 
     Gastric and oesophageal cancers were responsible for more than one million 
deaths in 2002 
(1, 2). Although the global incidence of gastric cancer is decreasing, this 
malignancy is still the fourth most common cause of cancer worldwide 
(3). The 
incidence of oesophageal adenocarcinoma is rising rapidly, three-fold in the last two 
decades 
(4-7). The incidence of adenocarcinoma of gastric cardia is stable.   
     In the pathogenesis of both gastric and oesophageal adenocarcinomas, the state 
of the gastric mucosa and its secretory function plays a central role. Non-cardia 
adenocarcinoma develops in subjects with H.pylori associated atrophic gastritis and 
hypochlorhydria. Little is known about the gastric phenotype in patients with 
adenocarcinoma of the cardia and gastroesophageal junction.   
     In the first study we aimed to investigate the association between the pattern of 
H.pylori gastritis and gastric secretory function in 255 H.pylori-infected patients with 
dyspepsia who had a normal endoscopy. Our findings demonstrate the strong 
correlation between H.pylori  body gastritis and reduced gastric acid secretion. Both 
inflammation and atrophy of the body mucosa were strongly associated with reduced 
gastric acid secretion.  The effect of the atrophy is clearly explained by the loss of acid 
secreting parietal cells.  The inflammation of the body mucosa is thought to produce 
functional inhibition of acid secretion.  We, and others, have shown that eradicating Chapter 7: Conclusion 
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H.pylori  in patients with low acid secretion produces recovery of secretion, which is 
associated with resolution of the body gastritis without any change in atrophy 
(8, 9). The 
mechanism by which H.pylori-induced inflammation impairs the function of the oxyntic 
mucosa is not clear.  However, the infection is known to stimulate production of 
interleukin-1 beta, which is a powerful inhibitor of acid secretion, blocking the release of 
histamine from the ECL cells and also inhibiting the function of the parietal cells 
(10, 11). The 
current study clearly showed that atrophy and inflammation are both independently 
associated with low acid secretion.  
    In the next study, we compared cancers at the cardia and non-cardia subsites with 
respect to pre-morbid gastric mucosal atrophy and acid secretion. This study 
demonstrates the association between the pre-morbid state of the gastric mucosa and 
the location and histological subtypes of gastric adenocarcinoma presenting over 
subsequent years.  Cancers of the mid and distal stomach of all histological subtypes 
were positively associated with H.pylori infection, atrophy and hypochlorhydria.   
Cardia cancer was more complex; it was negatively associated with H.pylori infection 
and the predominant intestinal subtype of cardia cancer was not associated with 
gastric atrophy. However, in subjects with H.pylori infection cardia cancer was 
positively associated with atrophy and hypochlorhydria.  These findings can be 
explained by cardia cancer being of two distinct aetiologies, some cases being similar 
to non-cardia cancer and others having a different aetiology. 
     The multistage process of non-cardia cancer development has been traditionally 
more strongly linked to the development of the intestinal histological subtype of cancer 
as the diffuse type may develop in subjects with normal gastric mucosa
  (12). In the 
latter cases, there is often a strong hereditary predisposition with inherited germ-line 
mutations
  (13).  Our study, however, along with that of Uemura et al indicates that 
atrophy and hypochlorhydria are associated with increased risk of the both diffuse and 
intestinal subtypes of gastric cancer 
(14).   Chapter 7: Conclusion 
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     The state and function of the gastric mucosa associated with cardia cancer is more 
complex than that associated with non-cardia cancer.  In contrast to non-cardia 
cancer, there was a negative association between H.pylori infection and cancer of the 
cardia.   As H.pylori infection causes atrophy and hypochlorhydria, we expected to 
find a lower prevalence of atrophy and hypochlorhydria in the cardia cancers than 
controls due to the lower prevalence of H.pylori in the former, as shown by Kamangar 
et al 
(15). Such a finding would be consistent with H.pylori  protecting from cardia 
cancer by the same mechanism by which it predisposes to non-cardia cancer, i.e. by 
reducing gastric acidity.  However, despite the significantly lower prevalence of 
H.pylori infection in the cardia cancer patients (43% vs. control 71%) the prevalence 
of atrophy was at least as high in the cases (18%) as in the controls (13%).  The 
reason for this unexpected finding was that the prevalence of atrophy within the 
H.pylori  positive cardia cancer patients was significantly higher than the H.pylori 
positive controls. Cardia cancer patients were thus characterised by having a 
significantly lower prevalence of H.pylori infection but higher prevalence of atrophy in 
those with the infection as compared to the controls. 
     The lower prevalence of H.pylori infection is consistent with H.pylori having some 
protective effect.  However, the high prevalence of atrophic gastritis within the H.pylori 
infected subjects suggests that atrophic gastritis due to H.pylori predisposes to cardia 
cancer.  The most plausible explanation for our findings is that cancer of the cardia 
region is of heterogeneous aetiology and arising by two different pathways with 
H.pylori exerting an opposite influence on the two pathways.   
     The positive association with atrophic gastritis in the H.pylori infected cardia cancer 
patients is consistent with a subgroup of cardia cancers having a similar aetiology to 
non-cardia cancer. The serological markers of atrophy detect that mostly involving the 
body mucosa 
(16-18).   Body atrophy induced by H.pylori  gastritis causes distal 
regression of the apparent cardia-oxyntic junction due to loss of specialised cells 
(13).  Chapter 7: Conclusion 
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Our finding is consistent with a proportion of the cardia cancers having arisen from 
this process and thus being of similar aetiology to non-cardia cancer.  Ye et al recently 
reported that cardia cancer was not associated with H.pylori  infection but was 
associated with gastric atrophy and their observation is thus also consistent with 
atrophy being involved in a subgroup of cardia cancers 
(19). 
  
     On the other hand, several studies have reported a negative association between 
H.pylori infection and oesophageal adenocarcinoma 
(19, 20).  A subgroup of the cardia 
cancers may have similar aetiology to oesophageal adenocarcinoma and be subject 
to an H.pylori protective influence. Proximal expansion of the cardia mucosa can arise 
by metaplasia of oesophageal mucosa which the same process is thought to lead to 
oesophageal adenocarcinoma and to be induced by reflux of gastric acid 
(21-23).  The 
mechanism by which H.pylori infection may protect from this process is unclear but 
may be due to the fact that it causes a fall in acid output with advancing years due to 
development of atrophy 
(24, 25).  Other possible mechanisms such as mucosal changes 
of the cardia and highly alkaline ammonia produced by locally-colonising H.pylori 
might protect the cardia and adjacent distal oesophageal mucosa against cancer 
(26). 
     The analysis of the histological subtypes provided further evidence of two distinct 
aetiologies of cardia cancer.  Atrophy increased the risk of the diffuse subtype of 
cardia cancer to a similar extent to which it increased the diffuse subtype of non-
cardia cancer. However, atrophy did not increase the risk of intestinal-type cardia 
cancer, which was in contrast to the increased risk of the intestinal-type in the non-
cardia region.  The contrast in associations between atrophy and the intestinal-type in 
the cardia versus non-cardia regions was statistically highly significant using either 
low PG I/II or high gastrin as risk indicators.   The diffuse type cancers at the cardia 
thus appear aetiologically similar to diffuse non-cardia cancers, whereas the intestinal-
type cancers at the cardia (or at least the majority of them) are aetiologically distinct 
from intestinal-type cancers in the non-cardia region. Chapter 7: Conclusion 
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     These findings indicate two aetiologies of cardia cancer, one associated with 
H.pylori-related  atrophic gastritis, resembling non-cardia cancer, and the other 
associated with non-atrophic gastric mucosa, resembling oesophageal 
adenocarcinoma.  Serological markers of gastric atrophy may provide the key to 
determining gastric versus oesophageal origin of cardia cancer. 
     In the next study, we extended our investigation of the aetiology of cardia cancer 
by examining the association of both serological evidences of gastric atrophy and 
gastroesophageal reflux disease (GORD) symptoms with adenocarcinoma of the 
oesophagus, cardia and non-cardia regions of the stomach. This has been performed 
for the different histological subtypes of the cancer. We have also included H.pylori 
status and smoking history which are other well-established risk factors for upper GI 
cancer.  This has been undertaken in a population in Northwest Iran with a high 
incidence of upper gastrointestinal cancer
.  Serum pepsinogen I/II was used as a 
marker of atrophic gastritis and categorised to five quintiles. History of GORD 
symptoms, smoking and H.pylori infection was incorporated in logistic regression 
analysis. Lauren classification was used to subtype gastric and oesophageal 
adenocarcinoma. 
          Atrophic gastritis was associated with increased risk of both the intestinal and 
diffuse histological subtypes of non-cardia cancer but the association was stronger for 
the former as previously reported
  (27-29). Whereas, the intestinal subtype is nearly 
always a consequence of atrophic gastritis and intestinal metaplasia, the diffuse 
histological subtype sometimes develops in a non-atrophic stomach with a strong 
genetic predisposition being an important factor in some of these cases
 (30, 31). 
     An association between H.pylori infection and non-cardia cancer was present in 
the univariate analysis consistent with previous reports 
(14).  However, this association 
was lost in multivariate analysis when atrophy and lifestyle factors were included.   
This is consistent with H.pylori-induced atrophic gastritis being the pre-cancerous Chapter 7: Conclusion 
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lesion rather than H.pylori infection itself. High prevalence of H.pylori infection in the 
background population shown in the current and previous studies may explain its 
weak relationship with gastric cancer risk 
(32).
            In contrast to non-cardia cancer, oesophageal adenocarcinoma was positively 
associated with reflux symptoms.  This is consistent with previous reports and the 
currently accepted hypothesis that gastro-oesophageal reflux causes columnar and 
intestinal metaplasia which then progresses to intestinal subtype adenocarcinoma
 (33, 
34). Consistent with this, the great majority of oesophageal adenocarcinomas in our 
study were of the intestinal histological subtype.  There was also a positive 
association with smoking as previously reported 
(35, 36).
 There was no association with 
gastric atrophy.  
     As shown in the previous part of the study which was conducted on a Norwegian 
population, cardia cancer in an Iranian population also showed a complex relationship 
with gastric atrophy.  Severe gastric atrophy indicated by the lowest pepsinogen I/II 
quintile of <2.37 was associated with an increased risk of cardia cancer.  However, 
unlike non-cardia cancer, there was no evidence of a progressive rise in cancer 
incidence with falling pepsinogen I/II ratio.  Rather, the relationship between 
pepsinogen I/II ratio and cancer risk showed a quadratic pattern with the risk of cardia 
cancer being highest for the lowest and highest pepsinogen I/II ratios and lowest for 
the intermediate ratios.  A plausible explanation for this complex association between 
cardia cancer and atrophic gastritis is that there are two distinct aetiologies of cardia 
cancer.  
      Reflux symptoms were also found to be a risk factor for cardia cancer with GORD 
symptoms of >2 time per week increasing the risk of cardia cancer with OR (95% 
CI):10.08 (2.29–44.36). Reflux symptoms have been reported previously to be a risk 
factor for cardia cancer but not as strong a risk factor as for oesophageal 
adenocarcinoma
 (37). In our study, we were able to investigate the interaction of reflux Chapter 7: Conclusion 
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symptoms and atrophy in the aetiology of cardia cancer. This showed that reflux 
symptoms were associated with cardia cancer only in non-atrophic subjects, with a 
powerful OR (95% CI): 8.02 (2.25 – 28.58).  This is again consistent with two distinct 
aetiologies of cardia cancer, one being associated with atrophic gastritis and 
resembling non-cardia cancer and one associated with reflux and resembling 
oesophageal adenocarcinoma.  
          Further evidence of two distinct aetiologies of cardia cancer was apparent on 
examining the atrophy-cancer and GORD-cancer associations separately in the two 
histological subtypes. The association between atrophy and intestinal subtype 
adenocarcinoma was weaker in the cardia than in the non-cardia region of the 
stomach. This is consistent with the intestinal subtype cardia cancer being a mixture 
of tumours positively associated with atrophy and tumours un-associated or negatively 
associated with atrophy (similar to oesophageal intestinal subtype adenocarcinoma). 
     The association of atrophy with diffuse cancer was stronger in the cardia than in 
the non-cardia region of the stomach. This difference may be related to the different 
topographic distribution and extent of atrophy required to produce cancer at those two 
sites and the ability of PGI/II to detect the atrophy associated with cancer at these two 
sites.  Atrophy tends to start in the distal stomach at the junction between the antrum 
and body mucosa and progress proximally
  (38, 39). Cancers tend to develop within 
atrophic mucosa and thus cancers of the distal stomach may develop in subjects with 
less extensive atrophy than would be required to produce cancer up at the cardia 
region.  Furthermore, PGI/II is a reliable marker for detecting extensive atrophy 
involving the body mucosa but a poor marker for detecting early atrophy or that 
confined to the antral mucosa
 (40, 41).
     The association between GORD symptoms and cardia adenocarcinoma was also 
related to the histological subtype. GORD symptoms were strongly associated with 
the intestinal subtype cancers at the cardia and this relationship was similar to that for Chapter 7: Conclusion 
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oesophageal adenocarcinoma. This association with GORD symptoms and intestinal 
subtype adenocarcinoma at the cardia is consistent with some of these cancers 
occurring by the same mechanism as oesophageal adenocarcinoma which is also of 
the intestinal subtype; the reflux of gastric juice leading to columnar intestinal 
metaplasia, dysplasia and adenocarcinoma. In contrast, there was no relationship 
between GORD symptoms and diffuse subtype adenocarcinomas at the cardia. 
     The above observations imply that there are not only two distinct aetiologies of 
cardia cancers but that the structural and functional state of the stomach associated 
with them is profoundly different.   One type is associated with a non-atrophic healthy 
gastric mucosa producing sufficient acid and pepsin to damage the mucosa of the 
gastro-oesophageal junction and lead to columnar intestinal metaplasia and intestinal 
subtype cancer.  The other is associated with atrophic gastritis of sufficient severity 
and extent to involve the proximal stomach leading to the development of intestinal or 
diffuse subtype cancer from the atrophic gastric mucosa.  
     Another important but poorly understood risk factor for upper GI adenocarcinoma 
is male gender. In our last study, we investigated the relationship between gender and 
upper gastrointestinal adenocarcinoma.  Male gender is a well-established risk factor 
for oesophageal adenocarcinoma 
(42, 43). Male predominance of gastric cancer is 
related to the histological subtype of the tumour being more marked in the intestinal 
versus diffuse histological subtype. In addition, global data suggests that the male 
predominance of upper gastrointestinal cancer is related to the anatomical location, 
being higher for proximal and lower for distal tumours 
(44). However, the proportion of 
the intestinal histological subtype differs according to anatomical site and it was 
unclear whether it is the anatomical site or the histological subtype which is 
associated with the gender phenomenon.  We conducted a population-based study to 
investigate this.   Chapter 7: Conclusion 
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     The study was based upon 3270 gastric and oesophageal cancers recorded in 
West of Scotland Cancer Registry between 1998 and 2002.  The Lauren subtype of 
adenocarcinoma was determined by reviewing 1204 reports and 3241 slides in a 
sample of 812 cases. Logistic regression models were used to estimate relationship 
between male predominance and histological subtype, tumour location and age. 
     We found that the crude incidence rate of intestinal subtype was higher in males 
versus females, giving M/F of 2.65.  M/F ratio of intestinal subtype cancer was 3.41 at 
age <50, reached a peak of 7.86 at age 50-59, and then showed a progressive 
decrease throughout the life. In contrast, the incidence rate of diffuse subtype 
adenocarcinoma was similar in both sexes, yielding M/F of 1.07. Multivariable 
analyses including histological subtype, tumour location and age indicated that the 
male predominance was related to the histological type rather than anatomical 
location. Intestinal subtype tumour showed similar male predominance of incidence 
irrespective of its anatomical location (OR, 95% CI: 2.64, 1.78 – 3.90).  Further 
analysis of the age-specific incidence curves indicated that the male predominance of 
intestinal subtype was due to a 17.3-year delay of development of this cancer in 
females. 
     The reason for the difference in the development of the intestinal subtype of upper 
gastrointestinal cancer in females versus males is unclear and deserves further 
consideration and investigation.  The fact that the delay is occurring at an age of less 
than 55 years old makes it likely to be related to an endogenous protective effect 
associated with the reproductive years in the female. Fox et al reported gender 
specific H.pylori–related carcinogenesis in INS-GAS mice which was explained by a 
protective effect of 17β-estradiol 
(45-47). In humans, delayed menopause and hormone 
replacement therapy may protect against gastric cancer
 (48-50).  The intestinal subtype 
of cancer arises against a background of chronic inflammation and tissue damage. 
The female sex hormone, oestrogen, is known to suppress the inflammatory response Chapter 7: Conclusion 
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and cytokine production in certain tissues and might be exerting similar effects in the 
upper GI tract 
(51, 52). In addition, females have lower body iron stores during their 
reproductive years and this might modify the degree of DNA damage arising from 
chronic inflammation 
(53-56).   
     Several observations indicate that the delayed development in females is unlikely 
to be explained by different lifestyle factors such as smoking.  Firstly, in cancers with 
male predominance due to exogenous lifestyle factors (i.e. lung and bladder), the age 
specific incidence data demonstrate differences in the power terms for the function 
describing the data rather than a delay in appearance of the cancer.  Secondly, recent 
studies have reported male predominance of gastric cancer in never-smokers
 (57, 58).  
Thirdly, male predominance is observed in animal models of gastric cancer raised in 
an identical environment
 (59).  Fourthly, smoking rates in the U.K. available from 1978-
1998 are similar for males and females under 50 years of age 
(60). 
     Where gender acts in the gastric carcinogenesis cascade was one of the questions 
we tried to investigate. We were able to analyse data of our population-based cross 
sectional study of gastric precancerous lesion in Ardabil, Northwest of Iran 
(61). The 
results of histologic examination of gastric biopsies from different pre-determined sites 
revealed similar rates of chronic gastritis (including both PMN and MN infiltrations) 
among males and females. The frequency of atrophic gastritis in males and female 
also showed no difference. These results were consistent with the results of Watabe 
et al who showed similar rate of serologic atrophic gastritis among Japanese males 
and females 
(62). 
     In contrast to inflammatory and atrophic lesions, intestinal metaplasia of gastric 
mucosa was more prevalent in males, which was evident in all three subsites. This 
finding is consistent with results of You et al who showed a higher prevalence of 
intestinal metaplasia and glandular dysplasia in a Chinese population 
(63). This 
suggests that the gender phenomenon is acting at or after the metaplastic stage.   Chapter 7: Conclusion 
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With respect to the oesophagus, columnar epithelial metaplasia is more common in 
males than females (M/F = 1.7:1) and specialised intestinal epithelial more markedly 
so (M/F = 2.1:1).  This again indicates that the gender phenomenon is evident at and 
after the metaplastic stage 
(64).
     We believe our consecutive studies presented in this thesis have provided new 
insights to major risk factors of upper gastrointestinal adenocarcinomas. The critical 
significance of the gastric mucosal state (including its pathological pathways) leading 
to altered acid secretion has been emphasized. In particular, application of gastric 
mucosal and secretory state data to distinguish two types of cardia cancer is one of 
the advances that should be replicated in other studies using different populations.  
     Introduction of gender as a risk factor for upper gastrointestinal cancers was one of 
the main targets of our study. This is a relatively dark side of the upper GI cancer 
research and we tried our best to provide a simple, but robust evidence of male 
predominance of gastric and oesophageal adenocarcinoma. The marked delay 
phenomenon in development of intestinal subtype adenocarcinoma in females and 
lack of similar delay pattern in other cancers with prominent male predominance make 
this group of cancers very special to cancer research. Many endogenous factors 
including long- term exposure to feminine hormones, a different pattern of cell-
mediated immunologic response to long-term H.pylori infection, differences in aging 
and immunosenescence phenomena, and different systemic and mucosal iron 
kinetics are attractive factors to be considered for future investigations. Environmental 
factors are less likely to be justified for investigations on gender effect. References (Chapter 1) 
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